Operation, characterisation & physical modelling of unflattened medical linear accelerator beams and their application to radiotherapy treatment planning by Cashmore, Jason
  
 
 
 
 
 
 
Operation, characterisation & physical 
modelling of unflattened medical linear 
accelerator beams and their application to 
radiotherapy treatment planning. 
 
 
by 
 
 
Jason Cashmore 
 
 
 
A thesis submitted to the 
University of Birmingham 
for the degree of 
DOCTOR OF PHILOSOPHY 
 
 
School of Physics and Astronomy 
University of Birmingham 
July 2013 
 
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
  
ii 
 
ABSTRACT 
The flattening filter is a conical shaped piece of metal sitting within the treatment 
head of a linear accelerator, used to produce a flat, uniform beam of X-rays from the 
forward-peaked distribution exiting the target. Despite their routine use since the 
introduction of the linac in the 1950’s, however, there are still several unresolved 
issues surrounding their use. The photon scatter and electron contamination 
introduced by modifying the fluence are difficult to model, as is the variation in 
energy spectrum caused by differential absorption across the field. Leakage radiation 
also causes increased whole body doses to the patient, and the filter itself causes acts 
as an amplifier for beam bending and steering issues. 
With advances in tumour imaging, dose optimisation and in-room image-
guidance it is now possible to locate a tumour accurately in space and to design 
radiation fields to conform to its shape, avoiding adjacent normal and critical tissues. 
This active production of non-flat fields means that the prerequisite for flat fields no 
longer exists, and the filter is potentially no longer a necessary component. 
This thesis reports on research to produce a filter-free linear accelerator, from 
basic operation and optimisation, dosimetric characterisation and beam modelling, 
through to treatment planning and dose delivery. FFF beams have been shown 
reduce many of the problems seen with the current generation of linear accelerators, 
producing beams that are inherently more stable, simple to model and with reduced 
patient leakage (leading to reduced secondary cancers). The increase in dose rate also 
translates into shorter treatment times for many treatments, aiding patient comfort 
and reducing problems associated with intra-fraction motion. 
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CHAPTER 1 
 
AN INTRODUCTION TO CANCER 
AND RADIOTHERAPY 
 
 
This chapter introduces the basics of cancer biology, the causes of cancer and its 
subsequent treatment, focussing specifically on radiotherapy treatments. The 
concepts of linear accelerator function and treatment planning are also introduced, as 
is the rationale for flattening filter removal and its consequences. 
 
1.1 Cancer 
1.1.1 Cancer biology 
Cell multiplication (proliferation) is a normal physiological process that occurs in 
almost all tissues. Normally the balance between proliferation and cell death is tightly 
regulated to ensure the integrity of organs and tissues, but mutations in DNA can 
disrupt these processes leading to cancer. Cancer therefore refers to a group of 
  
2 
diseases characterized by uncontrolled cell division leading to growth of abnormal 
tissue. 
The uncontrolled and often rapid proliferation of cells can lead to either a benign 
tumour or a malignant tumour (cancer). Benign tumours do not spread to other 
parts of the body or invade other tissues, and they are rarely life threatening. 
Malignant tumours, on the other hand, can invade other organs, spreading to distant 
locations in the body via the lymphatic system or the bloodstream and becoming life 
threatening. 
 
1.1.2 Cancer incidence & causes of cancer 
There are more than 200 types of human cancer, each with different causes, 
symptoms and treatments. In 2009 there were 264,700 newly diagnosed cases of 
malignant cancer registered in England. Of this total, 134,700 cancers were in males 
and 130,000 for females, with four types of cancer accounting for over half of all new 
cases (figure 1.1a). 
Cancers are predominantly an environmental disease with 90-95% of cases being 
attributed to lifestyle factors, and 5-10% due to genetics (Anand et al 2008). Common 
environmental factors leading to cancer death are shown in the figure 1.1b. 
Some slow-growing cancers are particularly common with post-mortem studies 
in Europe and Asia showing that up to 36% of people have undiagnosed thyroid 
cancer at the time of their deaths, and that 80% of men develop prostate cancer by 
age 80 (Fraumeni et al 2006, Bostwick et al 2007). These cancers are often very 
small and tend to be diseases people die with rather than of. 
While cancer can affect people of all ages the overall risk of developing cancer 
generally increases with age, at least up to age 80-85 yr. In 2007, cancer caused about 
  
3 
13% of all human deaths worldwide (7.9 million). These rates are rising as more 
people live to an old age and as lifestyle changes occur in the developing world. 
 
 
 
Figure 1.1. (a) Cancer incidence figures in the UK for 2010 (accessed May 2013 at 
http://www.cancerresearchuk.org), (b) Causes of cancer, modified from Anand (2008) 
 
1.1.3 Types of cancer 
Cancers originate from a single cell; hence cancers can be classified by the type of cell 
in which it originates and by the location of the cell.  
Carcinoma: Cancers originating from epithelial cells. This group includes many 
of the most common cancers and include nearly all those developing in the breast, 
prostate, lung, pancreas and colon. Adult cancers usually form in epithelial tissues. 
Sarcoma: Cancers arising from connective tissue (i.e. bone and muscle).  
Lymphoma and leukemia: These two classes of cancer arise from 
haematopoietic (blood-forming) cells that leave the marrow and tend to mature in the 
lymph nodes (lymphatic tissue) and blood (bone marrow stem cells), respectively.  
Diet
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Teratoma/Germ cell tumour: Begins within germ cells most often in the 
testicles or the ovaries (seminoma and dysgerminoma) respectively 
Blastoma: Cancers derived from immature "precursor" cells or embryonic 
tissue, these are most common in children. 
Melanoma arises in melanocytes, normally those in the skin. 
 
1.1.4 Cancer staging and treatment 
The stage of a cancer is a description of how far a cancer has spread within a patient’s 
body, taking into account the size of a tumour, how deeply it has penetrated, how 
many lymph nodes it has spread to (if any), and whether it has spread to distant 
organs (metastasis). 
The TNM staging system is used for solid tumours, and is an acronym for the 
words "Tumour", "Nodes", and "Metastases". For example, a T1N2M0 cancer would 
be a cancer with a T1 tumour, N2 involvement of the lymph nodes, and no 
metastases. 
Staging of cancer is critical because the stage at diagnosis is the most powerful 
predictor of survival, and treatments are often changed based on the stage. Thus, 
incorrect staging can lead to improper treatment. Staging can also be used to identify 
any clinical trials that may be suitable for a particular patient. 
Cancer staging can be subdivided into a clinical stage and a pathologic stage, 
denoted by a small "c" or "p" before the stage (e.g. cT1N1M0 or pT2N0). The c-prefix 
is implicit in absence of the p-prefix. Clinical stage is based on all of the available 
information obtained before a surgery to remove the tumour, therefore it may include 
information about the tumour obtained by physical examination or radiological 
examination. Pathologic stage adds in additional information gained by microscopic 
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examination of the tumour by a pathologist. Since they use different information, 
clinical stage and pathologic stage are often different.  
Metastatic tumours are very common in the late stages of cancer and may spread 
via the blood, the lymphatic system, or both. The most common places for metastases 
to occur are the lungs, liver, brain, and the bones. 
When tumour cells metastasize, the new tumour is called a secondary or 
metastatic tumour, and its cells are like those in the original tumour. This means, for 
example, that, if breast cancer metastasizes to the lungs, the secondary tumour is 
made up of abnormal breast cells, not of abnormal lung cells. 
Tumour grading is different to staging in that it describes how abnormal the 
tumour cells look under microscopic examination. Tumours are usually graded from 1 
to 4 depending on the amount of abnormality, with grade 1 being ‘well-differentiated’ 
i.e. the tumour cells are organised in a similar way to normal cells, and grade 4 being 
‘undifferentiated’, i.e. cells are abnormal in nature, lacking normal tissue structures. 
Higher grades of tumour tend to grow and spread more rapidly than lower grades, so 
generally indicate a worse prognosis. 
When given, treatment can involve surgery, chemotherapy, radiotherapy and 
targeted therapies (using hormonal and biological agents). Conventional surgery is 
the treatment of first choice for most solid tumours but in practice most patients will 
receive a combination of treatments, the exact nature of which depends on the type of 
cancer, its location and grade, and also on the stage of the disease, as well as the 
general state of a person's health. 
Most cancers are suspected by initial signs or symptoms (or through screening) 
but the definitive diagnosis of most malignancies must be confirmed by histological 
examination of the cancerous cells by a pathologist. 
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The tissue diagnosis indicates the type of cell that is proliferating, its histological 
grade, genetic abnormalities, and other features of the tumour. Together, this 
information is useful to evaluate the prognosis of the patient and to choose the best 
course of treatment. 
 
1.2 Radiotherapy 
1.2.1 Background 
High energy radiation from X-rays and particles (electrons, protons and heavy ions) 
damage living cells and can be used to target tumours. Radiotherapy is simply the use 
of radiation to treat illness and is one of the most effective ways of treating cancer. 
Shortly after their discovery in 1895 by Roentgen, X-rays were being used to treat 
breast cancer patients. Since then they have taken on a routine role in the 
investigation, diagnosis and treatment of disease and 40-50% of people with cancer 
will now have radiotherapy as part of their treatment.  
It has been estimated that the addition of radiotherapy to cancer treatment 
improves 5 year survival by 16% (Barton et al 1995). In comparison the 5 year 
survival contribution from chemotherapy drugs is estimated at 2% (Morgan et al 
2004), making radiotherapy second only to surgery in its effectiveness. 
Radiotherapy can be given by:- 
 
1 External beam radiotherapy (teletherapy):  radiation is delivered from an 
external source outside of the patient using x-rays, gamma rays or high energy 
particles (tele = Greek for far away) 
2 Brachytherapy: dose is delivered from radioactive sources implanted in the 
patient close to or inside the target (brachys = Greek for short distance) 
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3 Unsealed source therapy: a radioactive substance is swallowed or injected 
to irradiate internally 
 
Here we are concerned with external beam radiotherapy which currently 
constitutes approx. 90% of radiotherapy treatments. 
 
1.2.2 Rationale for radiotherapy and the need for accuracy 
Radiotherapy relies on the delivery of therapeutic doses of radiation to the tumour 
volume whilst minimising the dose to surrounding normal tissues. In order to 
maintain a high ‘tumour control probability’ (TCP) we must deliver as much dose as 
possible to the target in order to kill all of the viable cancer cells. 
In doing this we also damage surrounding normal tissues and this dose must be 
minimised to give a low ‘normal tissue complication probability’ (NTCP) [see figure 
1.2]. As with most treatments, radiotherapy therefore treads a fine line between cure 
and complication. 
 
Figure 1.2. Generalised dose-response curve for tumour and normal tissues. In this case a small 
change in dose has a much greater effect on the normal tissue than on the tumour itself. 
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In practice a dose must be chosen that gives acceptable complication levels, 
accepting the level of cure possible. 
Due to the gradient of the respective curves at the prescription dose level, any 
uncertainty in dose means that the response can be greater in the normal tissues than 
for the tumour (see figure 1.2), highlighting the need for greater accuracy in the 
delivery and reporting of radiotherapy doses. In practice a dose must be chosen that 
gives acceptable complication rates for a given level of cure. 
The radiation dose delivered to the target and surrounding tissues is one of the 
major predictors of radiotherapy treatment outcome. It is generally assumed that the 
dose must be delivered within an uncertainty of less than ± 3.5% of the prescribed 
dose to ensure the treatment aims are met (IAEA TecDoc 734, 1994). In clinical 
situations this is realistically 5-8% (Svensson H, 1984), with ‘best practice’ currently 
being around 5% (table 1.1). 
 
Table 1.1. Uncertainties in ‘best practice’ radiotherapy dose delivery (95% 2SD). (Knoos and 
McClean, 2007). 
1 Dose at calibration point 1.5% 
2 Dose at other points 1.1% 
3 Patient data 1.5% 
4 Dose-calculation 3.0% 
5 Set-up 2.5% 
6 Beam monitor stability 1.0% 
7 Beam flatness/symmetry 1.5% 
 Total 5.0% 
 
Normal tissues usually have superior repair mechanisms than tumour cells for 
low doses, therefore to further reduce toxicity the total dose is split into small 
fractions of typically ~2Gy. Delivery of dose over a long period in this way 
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(fractionation) rather than in a single dose requires the patient to be repeatedly 
irradiated in the same position and it is vital that each fraction is delivered according 
to plan each day, so the treatment positioning must be stable and reproducible. 
 
1.2.3 The treatment planning process 
The patient pathway through the treatment process (figure 
1.3) generally begins with the patient either presenting to a 
GP with non-specific symptoms, or though a screening 
process (e.g. mammography). Since there are no symptoms 
unique to cancer further tests are required, and if cancer is 
suspected then referral is made to an oncologist. Once a 
definitive diagnosis of cancer is confirmed (by tumour 
biopsy) the patient will then go on to the staging process. 
Treatment outcomes are very closely related to the disease 
stage, and categorising patients in this way leads to a good 
estimation of prognosis and to an appropriate course of 
treatment. At this stage the performance status of the 
patient and individual wishes are also an important factor in 
any decision to treat. 
Depending on these assessments the first choice to be 
made is whether the treatment will be radical (of curative 
intent) or palliative (for symptom relief). Decisions can then 
be made regarding the treatment mode (e.g. surgery, 
radiotherapy). 
 
Figure 1.3. Basic stages in the radiotherapy treatment process. 
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Once a decision is made to deliver radiotherapy a series of further imaging 
studies (such as MRI, SPECT, ultrasound etc.) may be undertaken to localise the 
tumour within the body, and to define a target volume and shape. To allow accurate 
and reproducible delivery on a daily basis it is usually necessary to immobilise the 
patient in some way and this should be achieved before any further imaging is 
performed. Depending on the complexity of the plan a simple outline of the patient 
may be sufficient, but generally a CT scan of the region is obtained to allow accurate 
delineation of the target region(s) and any surrounding critical structures. 
Historically, beam placement was often carried out using a dedicated unit known 
as a simulator, a low-energy unit designed to accurately mimic the mechanical 
movements of the treatment machine. Treatment areas are targeted using diagnostic 
energy X-rays, with borders being marked according to anatomical boundaries. 
It is now more usual for the patient to receive a CT scan before treatment and to 
use virtual simulation. A virtual simulator is a software package designed to allow the 
reconstruction of imaging data to aid visualisation and allow the creation of 3D 
treatment volumes and delineation of organs at risk (figure 1.4). 
Treatment planning is performed using specialised software capable of 
calculating dose within a specified volume. The complexity of the dose calculations 
has increased over time, from simple 2D calculations using lookup tables to 
sophisticated 3D algorithms and Monte Carlo. Most planning systems now use beam 
algorithms based on splitting the dose into primary and scatter components which 
utilise machine- and energy-specific beam models. These algorithms in turn require 
CT information for accurate dose calculation, as these images provide accurate 
electron density (and hence attenuation) information. 
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(a) (b) 
(c) (d) 
Figure 1.4. Virtual simulation of an oropharangeal carcinoma. (a) Coronal CT slice with target and 
normal structures outlined, (b) 3D reconstruction of the CT data showing the internal position of 
target and critical structures, (c) custom shielding using an MLC and (d) 3D representation of the 
treatment machine. 
 
When CT information is available it is usual to outline the treatment area and 
normal structures. As not all of the tumour may be visible on a CT image it often 
beneficial to include further imaging (e.g. PET and MRI) to aid this process. To 
account for microscopic spread of the cancer, and any movement (e.g. due to 
respiration or rectum/bladder filling) further volumes must also be added. These are 
discussed in further detail in chapter 5 and Appendix B. 
Patient specific planning is usually based on a ‘class solution’ for the site in 
question. This usually specifies a standard initial setup including the number of 
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beams, their arrangement around the patient, and any particular weighting 
parameters. By changing each these parameters the planner will attempt to deliver 
the prescribed dose to the tumour (within -5% and +7% [ICRU 50, 1993 and ICRU 
62, 1999]) whilst minimising the dose to surrounding normal tissues and critical 
structures. This equates to aiming for a high TCP and low NTCP. Treatment planning 
is always limited by normal tissue tolerance, and if a level of normal tissue sparing 
cannot be achieved then target coverage may be sacrificed. To help shape the high 
dose region and to shield critical structures, beam shaping devices such as wedges 
and customised shielding blocks may be used. 
An alternative to the physical manufacture of custom shaped blocks is the use 
multi-leaf collimators (MLCs), which are individual leaves of tungsten that can be 
moved into the beam under computer control (figure 1.4c). 
Once a plan is ready it must be evaluated by an oncologist and receive further 
checks by dosimetry staff before it can be transferred electronically to the patient 
management system. This software acts as a booking system and a ‘record and verify’ 
system, controlling the treatment machine and logging radiation delivery. Before 
treatment can begin the beam positioning must be verified relative to internal patient 
anatomy either by 2D transmission (portal) imaging or by use of 3D cone-beam (CT) 
imaging. Any discrepancies in position are evaluated and can result in a positional 
correction or, if the difference is too large, repeat imaging/planning. Imaging will also 
occur at additional points as the treatment progresses to ensure consistency, and to 
monitor any changes in patient anatomy (e.g. due to weight loss or tumour 
shrinkage). If changes occur that are likely to affect the delivery of the intended plan 
then action must be taken to modify the treatment to compensate. These are the basic 
concepts of image-guided radiotherapy (IGRT) and adaptive radiotherapy (ART). 
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1.3 Radiotherapy treatment machines 
Figure 1.5 shows the depth dose characteristics for several x-ray beam energies. To 
treat deep seated tumours without exceeding tolerance doses to the skin multiple 
(converging) high energy beams are required and it can be seen that the relative dose 
at depth increases with increasing beam energy. High energy beams also allow a 
certain amount of ‘skin-sparing’ due to the dose build-up effect which is clinically 
important since all of the beams in external radiotherapy enter through the skin. 
Initial experiences with radiotherapy were hampered by the limited energy of x-
ray generators. These were useful for treating skin lesions, but for deep seated 
tumours they were of insufficient energy to deliver high enough doses to the tumour 
without exceeding tolerance doses to the skin. Advances in radiotherapy technology 
were therefore initially centred on producing ever increasing beam energies to 
maximise dose at depth and improve skin-sparing. The first sources used for external 
beam radiotherapy were gas filled x-ray tubes, but these were quickly followed by the 
vacuum tube in 1913, operating at up to 140kVp. Subsequent designs allowed x-ray 
generation at up to 400kV but were still ‘soft’ with the maximum dose being delivered 
at the skin surface, limiting the dose that could be safely applied to the tumour. 
Emphasis then shifted to gamma emitting radionuclides with the introduction of the 
‘radium cannon’ in 1912, but due to the high costs and limited availability of 226Ra, 
production was soon stopped. In the early 1930s work began on the use of resonant 
transformers which could obtain peak voltages of 1-2MV but, again, this technology 
was soon superseded by the introduction of the Van de Graff machine (the first of 
which treated patients in Boston in 1937). By 1946 commercial production of these 
units had started, with 40 accelerators being built before 1959 (12 of which were still 
operating in 1983). However, these units tended to be large, un-manoeuvrable and 
very expensive. 
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Figure 1.5. Depth dose characteristics of x-ray beams. Increasing the energy of the photon beam 
raises dose at depth relative to the surface and also allows some skin-sparing due to the buildup 
effect. 
 
For these reasons the emphasis shifted back to radionuclide units, but now 
concentrating on 60Co sources, the first three of which were produced in 1952 and 
installed in Canada and the USA. Each source contained several kilocuries of 60Co, 
emitting gamma rays with energies of 1.17 and 1.33MeV (mean 1.25MeV). The depth 
dose curve for 60Co has its peak at 5mm below the skin surface allowing some skin-
sparing (figure 1.5). 
At the same time further increases in photon energy were made possible by the 
introduction of the betatron, with the first patient treatment in 1949 with x-rays 
generated from 20MeV electrons (USA). Betatrons played a significant role in the 
development of radiation therapy since the increased energy provided greater skin-
sparing, higher depth doses and produced less side scatter than beams from 
radioisotope sources or x-ray tubes. The major disadvantages were their weight, low 
beam intensity (approx. 40cGy/min) and small field size (12.5 x 12.5cm2). 
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Table 1.2. Summary of external beam radiotherapy (EBT) treatment approaches. 
 
Superficial X-Rays 40 to 120kVp 
Orthovoltage X-Rays 150 to 400kVp 
Telecurie units 137Cs and 60Co 
Megavoltage X-Rays Linear accelerators (MV) 
Electrons Linear accelerators (MeV) 
Heavy charged particles Protons, C, Ar, ... (MeV to GeV) 
Others Neutrons, pions 
 
RF linear accelerators were made possible by the advances made during World 
War II in the construction of magnetrons for radar. In England the first travelling-
wave linear accelerator (using microwave generators for electron acceleration) was 
demonstrated in 1946 by DW Fry. In contrast to betatrons the RF accelerator can 
deliver dose-rates of 400cGy/min with field sizes of 40x40cm. The first of these was 
installed at the Hammersmith Hospital in 1952. The first patient was treated in 1953 
(figure 1.6) and the last in 1969. Table 1.2 summarises the different treatment 
approaches and energies associated with external beam radiotherapy. 
 
 
Figure 1.6.Historical image showing Gordon Isaacs, the first patient treated on the Stanford linear accelerator 
(1956). (http://news.stanford.edu/news/2007/april18/med-accelerator-041807.html) 
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1.3.1 The linear accelerator 
The modern medical linear accelerator (linac) is a machine used to treat cancer in 
patients by irradiating the tumour with high energy X-rays or electrons. Although 
many types of linear accelerator are available for medical use they generally all 
consist of a standard subset of components as illustrated in the block diagram of 
figure 1.7 below. 
The main beam forming components of a modern linac can be grouped into six 
categories (Podgorsak 2005): 
 
1 Injection system 
2 RF power generation 
3 Accelerating waveguide 
4 Beam transport 
5 Beam collimation and monitoring 
6 Auxiliary systems (e.g. cooling, vacuum) 
 
1.3.1.1 Accelerating structure 
Electromagnetic waves travel at the speed of light in free air, but when confined 
within a suitably designed waveguide this speed can be reduced. An RF field can 
therefore be used to accelerate electrons provided that the waveguide is designed so 
that at each point along its length the propagation speed matches that of the 
electrons. 
The waveguide itself is a cylindrical tube with a series of circular cavities 
designed so that the speed of propagation of the microwaves used for acceleration 
increases in the first part of the structure and reaches almost the speed of light for the 
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remainder. Bunches of electrons from the gun are injected into the waveguide to 
coincide with pulses from the microwave source, and are accelerated down the tube 
by riding the wave as it increases in speed. 
 
 
Figure 1.7. Block diagram of an Elekta linac. 
 
The RF power source for microwave generation is either a magnetron (an RF 
oscillator) or klystron (an RF amplifier) operating in the 2-10MW range, with the 
power of the source defining the maximum energy of the accelerator. 
Power is supplied to the microwave source by high voltage pulses from a 
modulator. Microwaves are then transported to the accelerator through rectangular 
waveguides pressurised with SF6 to prevent electrical breakdowns. 
The automatic frequency control (AFC) system constantly monitors the 
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frequency within the accelerator, tuning the magnetron for optimum output. 
There are two distinct types of accelerator waveguides: the travelling wave (wave 
is propagated along the accelerator axis, used by Elekta) and standing wave (where 
the wave is stationary, used by Varian, Siemens). Both systems inject electrons into 
the accelerator waveguide in phase with the RF power. Electrons enter an initial 
buncher section (typically 30cm long) where they increase in speed until close to 
the speed of light. After this section the irises have a constant spacing and energy 
gains result in a relativistic mass increase. 
The pulsed electron beam is provided by a heated tungsten wire, the electron 
gun, the temperature of which can be used to control the energy and dose rate of the 
accelerator. 
The vacuum system provides the low pressures needed for the electron gun, 
accelerator waveguide and bending system. Without this the gun would quickly burn 
out, and the electrons would quickly disperse due to collisions with air molecules. 
Since mutual repulsion of electrons in the guide causes the beam to diverge, a 
system of focussing and steering coils are used along the waveguide to focus and 
centre the beam. Most of these currents are set during installation, but a set of coils 
mounted near the end of the structure (2R and 2T) are under servo control to adjust 
beam steering during operation. 
Accelerating structures tend to be too long to mount vertically on the accelerator 
gantry, so it is necessary to bend the beam through approx. 90° towards the patient. 
This is achieved using a bending magnet. For a usable clinical beam it is necessary 
for the electron beam to enter the treatment head at the correct angle and energy and 
to provide a small focal spot, a fairly simple task if the beam is mono-energetic. Since 
it is difficult to control the energy spread, an achromatic bending system is generally 
used, which will ensure that electrons of different energies exit the bending system at 
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the same point and in the same direction regardless of their initial energy. In an 
Elekta linac this is achieved with a slalom bending system. 
 
1.3.1.2 Treatment head 
MV X-rays are generated by high energy electrons striking a high Z metal target 
(figure 1.8). These electrons undergo rapid deceleration resulting in x-ray formation. 
X-ray production at high energies tends to be along the direction of travel of the 
incident electrons so the x-rays pass through the target. Megavoltage accelerators 
therefore use transmission targets. 
Since the efficiency of bremsstrahlung production is low the target needs to be 
water cooled. The cooling system acts to both remove heat from the accelerator 
components, and to maintain an even operating temperature to maintain stability for 
any components sensitive to temperature change (such as the accelerator waveguide). 
The photon beam then passes through a primary collimator which has a 
circular aperture and sets an initial limitation on the beam size and shape. 
The problem with high-energy x-ray production by bremsstrahlung processes is 
that photons are emitted within a relatively narrow cone, and this cone becomes 
narrower with increasing energy. The ‘ideal’ x-ray distribution on leaving the target is 
an even intensity spread across the width of the beam, resulting in the uniform 
irradiation of a target volume in a patient. Since x-ray production is predominantly in 
the forward direction this results in an x-ray intensity lobe that is peaked in this 
direction so to avoid delivering a higher dose on the central axis a beam ‘flattening 
filter’ is used. 
The flattening filter itself is an energy specific, conical shaped piece of metal. This 
preferentially absorbs x-rays on the central axis (CAX) providing a more uniform 
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intensity across the beam.  
 
 
Figure 1.8. The flattening filter acts to produce a ‘flat’ radiation beam from the forward-peaked 
bremsstrahlung dose produced by the target. 
 
As the beam passes through there is an inevitable change in the energy spectrum. 
The materials used to manufacture the flattening filter vary, but in general high 
atomic number such as lead are avoided and metals like aluminium, copper and steel 
are used. Since the shape of the peak is energy dependant a different flattening filter 
(or combination of filters) is required for each photon energy used. 
Modern accelerators are generally capable of operating at several x-ray and 
electron energies so various filters are necessary, and are located on a rotating 
carriage (the carousel) in the treatment head (figure 1.9). 
Flattened beam 
Forward-
peaked profile 
Electron beam 
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Figure 1.9. Simplified view of the linac head (Elekta design). 
 
Below the flattening filter is a system of ionisation chambers to measure 
radiation dose and to maintain beam stability. A set of secondary collimators 
(jaws) then exists to shape the radiation to the desired (rectangular) field size. 
Further collimation can be provided either by lead blocks or by multi-leaf 
collimators (MLC) or lead blocks mounted on a shadow tray (figure 1,9). 
 
1.3.1.3 Beam monitoring and control 
A transmission ionisation chamber is mounted in the treatment head just below the 
flattening filter to monitor and control dose delivery. The unit consists of a series of 
Flattening filter 
Primary collimator 
Target 
Ion Chamber 
Carousel 
Wedge 
MLC bank 
Collimating 
jaws 
Lead blocks 
Shadow tray 
Bending magnet 
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parallel plate chambers sandwiched together, each divided in separate zones (figure 
1.10). The use of two chambers ensures dual dosimetry in case of a failure in one of 
the units. 
 
Figure 1.10. Exploded diagram of a transmission ionisation chamber, as used by Elekta. 
 
The currents in the steering coils at the gun end of the waveguide, the focussing 
coils, and the bending magnet are run from stabilised power supplies at 
predetermined values depending on the beam energy. 
Currents in the target end steering coils are under servo control by signals from 
the monitor chamber. With the beam on information from the chamber is used to 
regulate the position of the focal spot which must be closely monitored to maintain a 
flat, uniform beam. The chambers monitor the beam energy, dose rate and beam 
uniformity, symmetry and flatness. An imbalance in any of the signals from paired 
chambers can be used to actively servo the electron gun and beam steering magnets 
(2R and 2T) to maintain correct running conditions. 
The treatment head and gantry itself are capable of 360° rotation around a single 
reference point. The intercept of the beam central axis with the gantry, collimator and 
couch rotation axes is known as the isocentre (figure 1.11). This is ideally a single 
point in space, but due to the weight of the gantry arm and the torque exerted by the 
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treatment head, the isocentre is realistically confined to a sphere with a diameter of 
approx. 1mm (see section 8.3.4). The idea then is to place the tumour at the isocentre 
position so that beams can be directed into the patient from various angles without 
having to enter the room or move the patient between fields. As the gantry rotates the 
accelerator waveguide and bending system move through the Earth’s magnetic field 
which, while small in strength, is strong enough to move the beam away from its 
correct trajectory.  The currents in the steering magnets 2R and 2T therefore need to 
vary with gantry angle, and are controlled by look-up tables. The ‘aim’ value is 
updated with gantry angle, and the servos will operate around this value to maintain 
beam steering. 
The linac is constantly monitored by a digital control system to ensure correct 
performance and the safe, accurate delivery of the radiation dose to the patient. Any 
deviations from intended performance can give rise to a series of fault warnings 
which can halt or terminate the beam depending on severity. 
 
Figure 1.11. Diagram to illustrate the concept of the treatment isocentre. 
Axis of 
gantry 
rotation 
Axis of collimator 
and couch rotation 
Isocentre 
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These interlocks are in place to ensure the performance and safety of the linac in 
delivering the correct dose to the patient. 
 
 
1.4 Rationale for flattening filter free 
Beam flatteners have been regarded as an essential component since the introduction 
of linear accelerators in the 1950’s. However, despite their longstanding use there are 
still a number of unresolved issues regarding their use. 
In order to produce this flat radiation beam it is necessary to remove a large 
proportion of the beam intensity (see figure 1.12), and this radiation is converted to 
scatter with the flattening filter acting as a secondary source of radiation (for both 
photons and electrons). The photon head scatter and electron contamination 
produced by the flattening filter are still the subject of much research and are still not 
modelled accurately within most radiotherapy treatment planning systems. 
Monte Carlo studies have shown that the flattening filter is responsible for the 
majority of scatter produced in the treatment head (Petti et al 1983, Zhu and 
Bjarngard 1995). 
 
Figure 1.12. The flattening filter removes a large proportion of the beam shown, reducing the central 
axis dose to approx. 50% of its initial value (at 6MV). 
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It is estimated that extra-focal radiation contributes 11-16% of the photon fluence 
at the isocentre and that roughly 70% of this comes from the flattening filter (Liu et al 
1997, Petti et al 1983); exact figures are energy and vendor specific. The filter also 
acts as the main source of electron contamination (which is also very difficult to 
model) (Nilsson and Brahme 1986, Hounsell and Wilkinson 1999, Klein and 
Esthappan 2003). Leakage radiation from the head also delivers a whole-body dose 
to the patient necessitating the use of considerable amounts of shielding around the 
head of the machine to reduce this. 
The primary function of the flattening filter is to provide a flat radiation beam. 
However, due to the effects of scatter within the patient and changing beam spectrum 
it is not possible to create a beam with a ‘flat’ profile at all tissue depths, and 
flattening filters are generally designed to produce a flat profile at only one given 
depth (usually 10cm). Nearer the surface the beam will have ‘ears’, and at greater 
depth will be more curved (figure 1.13). The flattening filter therefore only produces a 
beam of ‘nominal’ flatness. 
 
Figure 1.13. Change in beams profile with depth. Normalised to 100% on the central axis and scaled 
to remove divergence. Note the change in beam profile towards the edge of the beam with increasing 
depth. 
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In producing a flat beam the filter therefore causes a series of problems, such as:- 
 
 Decreased primary beam intensity, leading to reduced dose rate 
 Differential absorption across the field (changes in beam spectrum) 
causing problems for dose calculation and beam modelling 
 The need for the introduction of “horns” in the particle fluence to 
compensate for this angular variation of the spectrum 
 The creation of a significant source of extra-focal scattered radiation within 
the beam 
 Electron contamination in the primary beam 
 Increased leakage radiation from the treatment head 
 Amplification of beam steering errors necessitating active beam monitoring 
and servo control 
 
The problem with unflattened beams of course has always been utilising the 
forward peak in the dose distribution. Historically, radiotherapy has been based on 
the delivery of flat (or wedged) beams to treat ‘box-like’ volumes to a uniform dose. 
Modern imaging techniques and advances in computer hardware/software now allow 
a much more detailed view of the patient anatomy necessitating the use of intensity 
modulation within each field. Modern radiotherapy therefore relies less and less on 
flat radiation fields and more on the routine use of fluence modifying devices and 
techniques. At the extreme end of this is intensity-modulated radiotherapy (IMRT) 
(Appendix A). In these circumstances it is likely that the flattener isn’t actually 
necessary as all modulation could be performed by the MLC (see figure 1.14). If the 
initial field shape can be taken into account in the segmentation process the filter 
might not be necessary at all. 
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Figure 1.14. The IMRT process relies on the MLC leaves to modulate the ‘flat’ beam to produce the 
photon fluence necessary. It is possible that an initially flat beam is not required (a) and that all 
modulation necessary can be performed by the MLCs (b). 
 
The study of unflattened beams has come to be known by the acronym FFF, for 
flattening-filter-free. FFF beams were first studied by O’Brien et al (1991) who 
studied their use on a Therac-6 linear accelerator with the intention of increasing the 
dose rate to reduce treatment times for intracranial stereotactic treatments. At this 
time there was already an accelerator operating without a flattening filter, the 
Racetrack Mictrotron MM50 (Brahme et al 1980, Karlsson et al 1993) which utilised 
a scanning electron beam incident on the target to buildup dose in the patient in a 
similar manner to spot-scanning proton beams. 
In recent years the flattening filter free linac has gained popularity, with a 
significant number of articles on the subject appearing in the literature, and reference 
is made to these throughout this work. At the beginning of this research project a 
small number of research articles had been published on the dosimetric properties of 
FFF beams from Varian accelerators, but as yet nothing regarding the Elekta linac 
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(Fu et al 2004, Titt et al 2006a & b, Vassiliev et al 2006a & b, Mesbahi 2007, Ponisch 
et al (2006) and Zhu et al (2006)). 
 
 
1.5 Scope of work 
Flattening filter removal could aid treatment accuracy by reducing some of the 
sources of uncertainty in beam modelling and dose calculation, helping to reduce 
variations in beam symmetry and uncertainties in relative dose calculation (2, 4 and 6 
in table 1.1). In reality some of these uncertainties are linked (2&7, 1&6). 
Specifically, removal of the flattening filter from the beam line should lead to:- 
 
 Increased dose rate 
 Greatly reduced head scatter 
→ More accurate dosimetry 
→ Less leakage (whole-body) radiation 
→ Tighter beam penumbra 
 Greater beam stability 
 Reduced range of output and wedge factors 
 Simplified beam spectrum variations 
 More consistent profile with depth 
 Better imaging due to increased low energy x-ray component 
 
This thesis explores the factors which affect radiotherapy treatments when the 
flattening filter is removed, following the chain of events necessary to bring the FFF 
linac to clinical use, from dosimetric characterisation and machine operation through 
to beam modelling, treatment planning and quality assurance. 
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Efforts have been concentrated on the use of a 6 MV X-ray FFF beam from an 
Elekta Precise linear accelerator as this now seems to be the standard beam energy 
used by most radiotherapy departments for modulated techniques, but some 10MV 
data is also presented. 
A significant proportion of results reported in the work are based on relative, 
rather than absolute measurements. Where appropriate, uncertainties have been 
included in text, tables and figures. Where uncertainties have not been specified in 
figures it can be assumed that error bars are within the bounds indicated by the 
marker points. 
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CHAPTER 2 
 
LINAC SETUP AND DOSIMETRIC 
CHARACTERISATION 
 
 
In this chapter the technical details of machine setup and characterisation will be 
discussed. This begins with a description of the filter removal process and the 
changes in machine operation caused by its removal. Following on from this the basic 
beam characteristics are described and their possible advantages in radiotherapy 
discussed. Sections of this chapter have been published in a paper by the author in 
Physics in Medicine and Biology (Cashmore J, 2008). 
 
2.1 Linac setup 
As discussed in the previous chapter, the flattening filter is mounted at the secondary 
filter-stage on a five-position rotating carrier (the carousel) in the treatment head of 
the machine (figure 2.1). At this stage a low energy Elekta Precise linear accelerator 
located at University Hospital Coventry (Arden Cancer Centre) was being used for 
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measurements. This linac was fitted with a standard 80 leaf MLC (MLCi), and 
operated at 6MV in photon mode and 10MeV in electron mode. Only two of these 
ports in the carousel are used clinically, one for the 6MV flattening filter and the 
other for the 10MeV electron scatter foil. This leaves three ports free, and within the 
machine’s service mode it is a simple matter to rotate the filter out of the beam line to 
an ‘open’ port position. In practice these unused ports are not open, but contain a 
‘blanking plate’ of 2mm aluminium. Initial experiments were carried out using the 
standard clinical beam setup with the carousel rotated to one of these ‘open’ ports to 
remove the influence of the flattening filter from the beam. This beam (exiting 
through the 2mm Al plate) was then used to investigate the basic operational 
characteristics of the unflattened beam. 
 
 
Figure 2.1. The carousel (“egg-poacher”) in the treatment head 
 
As stated, filter removal is a simple process, but once it became apparent that 
further investigation was warranted it became necessary to consider changing the 
running parameters of the beam. This could potentially impact on clinical delivery if 
not corrected between research and treatment, so Elekta Ltd were approached to 
obtain a licence for an additional beam energy for research purposes. It is not 
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possible to have identical energies on the linac so a 10MV licence was obtained for 
research use. All energy specific beam parameters pertaining to 6MV were copied to 
this new energy and the gun servo, steering currents, beam hump and uniformity 
reset to allow the beam to run. The ‘10MV’ research beam was inaccessible for clinical 
use and could not be accessed by the record and verify system, Mosaiq. 
The beam essentially remains unaffected up until the point where it would 
normally strike the flattening filter; hence the vast majority of operational parameters 
remain unchanged. Issues only start to arise when the unflattened beam reaches the 
ionisation chamber; not only does this monitor the dose delivered but also acts to 
servo the radial and tangential steering currents (2R and 2T on Elekta machines) to 
maintain a symmetrical beam. The difference between the inner and outer plates 
(hump error) is also used to control the gun current and hence maintain beam 
energy. 
It is expected that filter removal will cause changes in dose rate, energy spectrum 
and scatter conditions in the head. There are therefore several fundamental questions 
to ask of machine performance/operation when removing the flattening filter:- 
 
1. How does the increased dose rate/dose per pulse affect dosimetry? 
2. Can the gun servo be reset and still function to control the beam energy? 
3. Can the steering servos be reset to allow operation around their new operating 
values? 
4. How does filter removal affect beam energy and energy spectrum? 
5. What the dosimetric characteristics of these beams? 
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2.2 Dosimetric characteristics 
The following sections give details of the measurements taken in order to characterise 
the dosimetric changes to the beam caused by filter removal.  
 
2.2.1 Dose rate 
Flattening filters have a conical shape and are made from medium to high atomic 
number materials. Since they can be several centimetres thick on the central axis the 
dose rate is severely affected by its presence. The first (and most obvious) 
consequence of running the linac with no flattening filter is the huge increase in 
observed dose rate. For the beam in its current state, running both beams at peak 
dose rate and taking measurements at dmax (15mm) with a Farmer chamber, the dose 
rate was seen to rise by an average of 2.3 times for an open beam, and by 1.9 times for 
the wedged beam. The lower value seen for the wedged beams is due to increased 
absorption (lower wedge transmission factor) in the physical wedge due to the change 
in energy spectrum. Due to hardware limitations in the Elekta Desktop software (v. 
5.02) it is not possible to run the linac at full dose rate (capped at 1200 MU per 
minute [12Gy/min under reference conditions). This increase in dose rate could 
clearly be a useful factor in many treatments (e.g. respiratory gated breathing and 
stereotactic radiosurgery [SRS]). In practice the dose rate was higher than necessary, 
so the pulse repetition frequency (PRF) was lowered (from 400 to 200) to regain a 
‘normal’ dose rate. 
A range of dose rates for FFF beams have been reported in the literature 
(Vassiliev et al 2006, Kragl et al 2009, Cashmore 2008, Fu et al 2004 1.92. O’Brien et 
al 1991). To some extent these are influenced by the calibration of the beam and to 
hardware limitations of each accelerator. Factors of 2 are common at 6MV and a dose 
rate of approx. 1200 MU/min is anticipated in a clinically released product. 
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Measurements were also performed to assess the linearity and reproducibility of 
dose delivery (figure 2.2), confirming that the internal ion chambers respond well to 
the higher dose rate and that doses delivered are accurate (<1% error) down to 2mu. 
 
 
Figure 2.2. Dose linearity as a function of monitor units (MU) delivered, and the output per MU 
normalised to the dose recorded for 100MU. 
 
2.2.2 Dose per pulse 
As the electrons are accelerated in bunches, the radiation is delivered in discrete 
pulses of radiation. The increase in dose rate observed with filter removal is therefore 
due to an increase in dose-per-pulse. This effectively stays constant, and the dose rate 
is then changed by changing the pulse repetition frequency (PRF). Although the dose 
rate can be lowered back to the original level if required this increase in dose-per-
pulse will remain and is likely to affect the rate of ion recombination in ionisation 
chambers. 
Even though the dose-per-pulse of the beam is ‘fixed’ it can in fact be varied by 
changing the source to chamber distance (SCD). Figure 2.3 shows the dose-per-pulse 
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dependence of a NE2571 Farmer chamber in the FFF beam; the curves are 
normalized at 100cm SSD for a 10x10cm2 field. The dose-per-pulse will affect the 
response of the chamber, but the two curves overlie each other indicating that these 
corrections should hold even at these high dose rates. The characteristics of 
ionisation chambers to pulsed radiation beams has been well reported (Derikum and 
Roos 1993, Bruggmoser et al 2007) and extended to include FFF beams by Lang et al 
(Lang et al 2012a). 
Finally, it should be noted that in the current software version (Release 5) the 
machine cannot be calibrated to give 1mu = 1cGy under standard conditions due to a 
software limitation on the range of ‘Dose Reference’ values. 
 
Figure 2.3. Dose per pulse dependence of a NE2571 Farmer type chamber. 
 
2.2.3 Head scatter (Sc) 
A reduction in head scatter (Sc) is expected with filter removal as the FF is the major 
source of scatter (Petti et al 1983, Zhu and Bjanrngard 1995), and a reduction in Sc 
could be very beneficial in many ways. Figure 2.4 shows head scatter measurements 
as a function of field size made using a Perspex mini-phantom (90cm SSD, 10cm 
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deep) relative to a 10x10cm2 field. A significant decrease is seen in the range of 
readings compared to the flattened field with a variation of only 3% over the entire 
range 4x4 to 40x40cm2 compared to a 9% variation with the filter in place. This is a 
reduction of approximately a factor of 3, and matches well with other reported data 
(Zhu et al 2006). Modelling of scatter with variations in field size and shape are very 
important, especially for IMRT (see section 6.1). The flattening filter is the dominant 
source of these variations so filter removal could have several favourable 
consequences for the dosimetry of small field and IMRT beams where errors in the 
calculation of head scatter lead to errors in monitor unit calculation. 
 
Figure 2.4. Head scatter measured using a Perspex mini-phantom (normalized to a 10x10cm2 field). 
 
2.2.4 Total scatter (Sc,p) 
Total scatter factors measured at 100cm SSD, dmax (Figure 2.5) also show a reduced 
range when plotted against equivalent square with a significant reduction at large 
field sizes. Sc and Sc,p fall rapidly at small field sizes due to source occlusion. The 
reduction in the range of readings for both parameters should aid dosimetry for 
small-field beams and those measured under non-equilibrium conditions. 
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Figure 2.5. Variation of total scatter factor measured at 100cm SSD, dmax and normalized to a 
10x10cm2 field. 
 
The ratio of 40x40 to 4x4cm2 readings is 1.15 for the flattened beam and 1.08 for 
the filterless beam, i.e. half the variation in total scatter factor. Similar results have 
been shown by Ponisch et al (2006). 
 
2.2.5 Collimator exchange effect 
This reduction in scatter should also lead to a reduction in the Collimator Exchange 
Effect (CEE) – the variation in output seen for same size rectangular fields depending 
on which set of jaws (upper or lower) defines the larger dimension. Measurements of 
this effect were made by sequentially fixing the X and Y jaw at 4cm and varying the 
other jaw dimension from 4 to 40cm (as recommended in ESTRO Booklet 6, 
Mijnheer et al 2001). The magnitude of the effect is on average 1.6% for standard 
operation and 0.6% with the filter removed (figure 2.6). These figures reflect the two 
thirds reduction of head scatter observed in figure 2.5. 
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Figure 2.6. Collimator exchange effect. Output factor is plotted as a function of the long field side, 
keeping either the X or Y collimator fixed at 4cm. Black lines represent the conventional beam and 
red lines with the filter removed. 
 
2.2.6 Leakage radiation 
Reduced head scatter should also lead to a reduction in leakage radiation from the 
treatment head. Leakage measurements were taken in the patient plane as 
recommended by the Elekta acceptance documentation (Elekta 2005) ‘The absorbed 
dose due to leakage radiation at any point in a horizontal plane that passes through 
the isocentre and outside the maximum useful beam area, shall not exceed 0.1% of 
the dose at the isocentre.’ 
A Farmer chamber (with 1.5cm buildup cap) is placed at the cardinal angles at 50 
and 100cm from the isocentre (see figure 2.7). With the diaphragms closed the 
absorbed doses at these points are compared to a ‘reference dose’ measured using a 
10 x 10cm2 field at the isocentre. Table 2.1 shows the results of patient plane leakage 
measurements.  
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Figure 2.7. Specification of points used to measure patient plane leakage. The circles are of radii 
50 cm and 100 cm. Readings at these points are taken with the collimators in the closed position and 
compared to a central axis reading for a 10×10 cm2 field. 
 
Table 2.1. Patient plane leakage measurements. G and T refer to movements towards the Gun and 
Target. A and B refer to movements left and right of centre when standing facing the gantry. 
 
Leakage radiation (% of reference reading) 
Position Filter In Filter Out % Decrease 
50cm G 0.012 0.0068 42.2 
50cm T 0.005 0.0029 45.9 
50cm A 0.018 0.0079 55.4 
50cm B 0.019 0.0072 62.0 
100cm G 0.013 0.0054 58.5 
100cm T 0.011 0.0032 69.6 
100cm A 0.018 0.0079 55.4 
100cm B 0.025 0.0061 76.0 
 Average decrease 58.1% 
 
T 
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Gantry 
B 
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The leakage dose should not exceed 0.1% of the dose at the isocentre and this is 
easily achieved during normal use, however, for IMRT delivery the number of 
monitor units required can be raised significantly (2-4 times) compared to open 
beam delivery and hence leakage radiation will increase proportionally. 
Operating without the flattening filter the dose is seen to be, on average, 58% 
lower than those recorded for normal use, representing a large decrease in the out-of-
field doses that would be received by the patient. 
 
2.2.7 Depth doses 
The FFF beam clearly shows significant differences to the conventional beam. To 
investigate the changes in the beam spectrum sample depth dose (DD) curves were 
measured to compare with standard data. 
The flattening filter significantly hardens the radiation beam on the central axis 
but due to its physical shape the beam quality decreases with distance from the 
central axis. Production of contaminant electrons also affects depth doses beyond 
dmax but differences due to this are mainly observed in the surface region. 
 
Table 2.2. Comparison of beam quality parameters. 
 
Nominal 
Energy 
(MV) 
Beam 
Description 
PDD at 
10cm 
deep, D10 
(%) 
Depth of 
80% 
dose, d80 
(cm) 
Depth of 
dose max. 
dmax (mm) 
QI (TPR 
20/10) 
6 FF in 67.6 6.7 15 0.679 
6 FF out 65.2 6.3 13.5 0.653 
5 BJR 5MV 65.0 6.2 12.5 0.646 
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Central axis depth doses were measured at 100cm SSD and normalised at a depth 
of 15mm for open and wedged square field sizes from 5x5 to 40x40cm2 (30x30cm2 
for wedge). Beam profiles and depth dose measurements were taken using a PTW 
MP3 Tandem watertank with Semiflex 0.125cc chambers and running Mephysto 7.4 
water phantom software. 
 
Figure 2.8. Depth doses for a 10x10cm2 field at 100cm SSD. Lack of beam hardening is seen as an 
energy decrease to approx. 5MV. 
 
In a conventional beam the filter attenuates the low energy component of the 
spectrum increasing the apparent energy of the beam. With FFF beams these soft x-
rays pass through and the addition of these to the beam spectrum lowers the 
observed energy. To quantify this change %DD curves were compared to published 
data (BJR 25, Jordan et al 1996). FF removal at 6MV produces a beam with 
characteristics similar to a 5MV beam (figure 2.8). Table 2.2 shows comparisons for 
most of the commonly used beam specification parameters which also demonstrate a 
good match to 5MV data. The flattening filter obviously hardens the beam 
appreciably, but this drop in energy could easily be compensated for by adjusting 
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accelerator parameters to raise the beam energy to match, if so desired. As yet there 
is very little published depth dose data for unflattened beams and non for Elekta 
accelerators or wedged beams, so if BJR25 were to be updated at some point it might 
be a good opportunity to include FFF data. 
 
2.2.8 Surface dose 
Changes in beam spectrum and scatter will affect the dose in the build-up region, and 
in particular, surface doses. Measurements in the build-up region (made with a 
NACP-02 parallel plate chamber embedded in solid water (Radiation Physics, St 
Bartholomew’s Hospital, London) show that there is a slight increase in surface dose 
with the flattening filter removed (figure 2.9). The reduced head scatter however 
produces appreciably less variation in dose near the surface (measured at 3mm 
depth) with field size (figure 2.10) than is seen for flattened beams. 
 
 
Figure 2.9. Build-up curves for a 10x10cm2 field measured in solid water. Filter free beams show 
slightly increased surface dose compared to filtered beams at 6MV. 
 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0 5 10 15
R
e
la
ti
ve
 d
o
se
Depth in solid water (mm)
6MV FFF
6MV
  
43 
It is also useful to look at the variation in surface dose with increasing field size. 
The reduced head scatter produces appreciably less variation in dose near the surface 
(measured at 3 mm depth) with field size (figure 2.10) than is seen for flattened 
beams. 
The target, primary collimator and flattening filter all act as both producers, and 
absorbers of electrons. Contamination electrons arising from the primary collimator 
act to increase surface doses in the patient. The filter removes the majority of these 
but generates is own electrons. One of the benefits of electrons generated here is that 
as they deliver a position-dependant dose into the ion chamber, which in turn is used 
to servo the beam. If the filter is simply removed the contamination electrons from 
the primary collimator reaching the ion chamber directly. These hold no positional 
information, so cannot be used to control the beam steering. A certain amount of 
material is therefore necessary to provide the correct signals, however, too much 
material will increase surface doses. The material used for the plate, and its thickness, 
need to be optimised.  
 
Figure 2.10. Variation of surface dose (at 3mm depth) with equivalent square normalized to a 
10x10cm2 field. Maximum to minimum ratio is 1.42 with the flattening filter in and 1.23 without, i.e. 
half the variation. 
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Monte Carlo studies have demonstrated that the low-energy components of the 
beam spectrum are significantly enhanced with FF removal (Tsechanski et al 2005, 
Mesbahi 2007) and that these photons would be expected to deposit energy in the 
buildup region. The fact that surface doses are not universally lower indicates that the 
electron contamination in the beam must be lowered by a similar amount. This role 
reversal has a twofold benefit; firstly x-rays are much easier to model than electrons 
leading to possible improvements in the modelling of the buildup region, and 
secondly these low kV photons may act to improve the contrast of portal images. 
As well as utilising an open port in the carousel the additional unused ports were 
also used to house various thicknesses of copper and aluminium (figure 2.11) to study 
the effects of electron contamination on surface dose and machine operation. 
 
 
Figure 2.11. Two copper plates (1.1mm and 1.9mm) mounted in the carousel. 
 
 A variety of plates have been used in the literature. O’Brien originally used a 
13mm Al plug for SRS studies on their Therac-6 linac (O’Brien et al 1991). In a Monte 
Carlo study Titt et al (Titt 2006) investigated the use of both 11mm nylon and a 2mm 
Cu plates. Nylon was found to decrease the photon fluence by 7% and the electron 
fluence by 54% compared to normal operation. For the copper plate these figures 
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were 9% and 78% respectively. Stathekis et al (2009) used a 1mm steel plate in a 
Varian 2300 linac, and Kragl et al (2009) and Tyner et al (2009) have reported data 
using a 6mm Cu plate in an Elekta Precise accelerator. Georg et al have provided an 
excellent summary of this data (Georg et al 2011). 
Buildup measurements were performed with thin sheets of copper and 
aluminium (1.1mm Al, 1.9mm Cu, 1.9mm Al) in place of the flattening filter with the 
hope of reducing surface dose, but no appreciable reduction was seen (figure 2.12). 
Lind et al (2009) studied the optimum thickness for the plate and found 1-2mm 
of Cu to be sufficient, but that a thicker plate may be recommended for additional 
safety. Measurements presented here indicate that a metal plate with a thickness of 1 
to 2mm seems sufficient to allow the monitor chamber to operate correctly, offering a 
good compromise between efficiency, safety and scatter production. Each 
manufacturer is likely to choose a different configuration due to variations in 
operating energy and head design etc. 
 
 
Figure 2.12. Build-up curves for a 10x10cm2 FFF field (measured in solid water) through different 
materials compared to filtered beams at 6MV. 
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2.2.9 Beam profiles 
Beam profile scans in a water tank illustrate the forward-peaked nature of open beam 
profiles (figure 2.13). Flattening filters are designed to give a flat beam over the 
maximum field size (usually 40 x 40cm2) and scans at small field sizes (5x5cm2 and 
below) exhibiting little or no change in profile. Larger field sizes show enhanced 
central axis dose with a rounding of the profiles; similar results have been shown for 
open beams with a Clinac 21EX (Vassiliev et al 2006b). Outside the treatment field 
the doses are lower for non-flattened beams due to the reduction in out-of-field 
scatter. This would effectively act to reduce the dose to surrounding normal tissues. 
At 90cm SSD, 10cm deep for a 10x10cm2 field the dose 2cm outside the field edge is 
reduced from 7.9% to 7.0% (11.3% relative change). 
 
 
Figure 2.13. Lateral dose profiles of unflattened beams at a depth of 10cm. Field sizes are 5, 10, 15, 20 
& 30cm. 
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2.2.10 Beam steering 
Mechanical positioning of the flattening filter and accurate steering of the electron 
beam are crucial to flat beam production as any misalignment will lead to non-flat, 
asymmetrical beams. Only if the electron beam axis coincides with the flattening filter 
axis will the resulting x-ray beam have symmetrical, flat-beam characteristics.  In this 
aspect the flattening filter acts as an amplifier, compounding any effects of inaccurate 
beam steering. For this reason the beam shape is closely monitored by a series of 
ionisation chambers and under active servo control to restore flatness and symmetry 
if the beam is misaligned (section 1.3.1.3). 
The flatness of an X-ray field is specified as ‘the ratio of the maximum absorbed 
dose (anywhere in the radiation field) to the minimum absorbed dose in the 
flattened area’. The ratio should not be greater than 106% for field sizes 10x10cm to 
30x30cm, and no greater than 110% for those fields >30x30cm. Field symmetry is 
defined as ‘the ratio of the absorbed dose at any two points symmetrically displaced 
about the beam axis and within the flattened area’. The ratio should not exceed 
103%. Both flatness and symmetry were designed to specify standard flattened X-ray 
profiles and cannot be used for filter-free beams. These regulations (IEC BS EN 2001) 
will need to be re-defined for these beams, most probably based on maintaining a 
match to a base-line non-flat profile measured during commissioning. 
Although the ion chamber in the head is designed to maintain flatness and 
symmetry by servo control of the steering currents, these currents and control 
amplifiers can drift over time, leading to beam asymmetries. 
The beam exhibits two different kinds of instability: angular divergence and 
lateral displacement, both of which lead to asymmetrical beams (figure 2.14). In 
practice, beam instability is usually a combination of both effects and can be difficult 
to decouple. 
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Figure 2.14. Only when the beam is central is a flat, symmetrical beam produced. If lateral or 
angular displacements are introduced the beam quickly becomes asymmetrical. Beam asymmetry 
for 2R (angular divergence) and Bf (lateral displacement) instabilities is shown. Adapted from 
Karzmark, 1993. 
 
To investigate the influences of these two effects bending fine (Bf) and 2R were 
manually altered (with servos turned off) and the beam shape investigated. Starting 
from a symmetrical beam the 2R current (controlling symmetry in gun-target axis) 
was varied by ±50mA and bending fine by ±20mA. Measurements with a Schuster 
BMS96 linear array (88 diodes with 5mm spacing) demonstrate that for variations in 
beam steering and bending currents the unflattened beam exhibits almost half the 
variation in field asymmetry (ratio of absorbed dose at points ±12 cm about the 
central axis) compared to the flattened beam (see table 2.3). 
For flattened beams the dose is seen to ‘see-saw’ about the central axis with the 
actual shape and magnitude of the shifts depend on a complex interaction of steering 
and bending currents. For FFF beams, rather than altering the beam shape these 
variations simply act to shift the beam off-axis, with the profile remaining the same 
ΔΦ Δr 
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relative shape (figure 2.15). The relative stability of the FFF beam is demonstrated by 
the fact that, as these currents are pushed further, the first interlock to be triggered is 
that for ‘Low Dose Rate’, which is due to a loss of beam current as the beam is driven 
away from the target. 
 
Table 2.3. Beam symmetry measurements recorded at ±12cm off central axis with a Schuster array. 
Values quoted are the percentage difference of readings ±12cm off axis compared to the central axis 
value. 
  6MV 6MVFFF 
2R 
+50mA +7.3% +3.8% 
-50mA -7.5% -4.4% 
Bf 
+20mA +4.1% +1.5% 
-20mA -6.5% -2.4% 
 
In practice, although the flattening filter acts as an amplifier for any beam 
steering problems, it also acts as a useful indicator of steering inaccuracies as any 
changes in beam transport produce large errors which are easily noticed. With the 
filter removed the beam is inherently more stable, but this might make any changes 
in beam steering more difficult to notice. Further work will be required to investigate 
the effects of this to determine whether the current configuration (dose cards) remain 
suitable. 
Small changes in energy and beam positioning during start-up are magnified by 
passing through the flattening filter. This can be a significant problem for IMRT 
where segments may be delivered with low numbers of monitor units (Sharpe et al 
2000). If the beam is unable to stabilise itself fully before the dose has been delivered 
then clearly any delivered dose distributions could be adversely affected by this. Since 
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the flattening filter acts as an amplifier for any changes in beam steering and energy 
these problems are reduced with its removal. The Schuster array again was used to 
study beam start-up characteristics by integrating the dose over a low dose delivery. 
Whereas repeat measurements for a conventional beam shows a 1.5% tilt in beam 
symmetry for a 5mu beam (symmetry measured as defined previously), for the 
unflattened beam this is only 0.3%. 
 
Figure 2.15. Profiles from a Schuster array demonstrating changes in beam symmetry for variations 
in 2R bending current of ±50mA. For the flattened beam the asymmetry (ratio of absorbed doses 
±12cm from the central axis) amounts to 7.4% compared to 4.1% with the filter removed. 
 
The flattening filter is an energy sensitive component producing changes in beam 
profile as the beam energy varies. Elekta machines take advantage of this to servo the 
beam energy by monitoring the differences in the inner and outer plate signals (hump 
error) of the ionisation chamber (figure 1.10). Although the beam runs well under 
normal conditions the energy sensitivity with the filter out may not operate correctly 
under these circumstances and needs further study. In other accelerators the energy 
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is regulated by other means (such as by controlling the voltage on the PFN to achieve 
maximum ion chamber current, Varian), so this might not be problematic. 
 
2.2.11 Penumbra 
The finite dimensions of ion chambers used for water tank measurements means that 
a blurring effect is added to beam profiles; any subtle changes in beam penumbra can 
therefore be missed. Penumbra measurements were assessed by exposing films at 
100cm SSD under 15mm of solid water using Kodak X-Omat V film. Penumbra itself 
was defined in the usual way as the distance between the 20 and 80% isodose lines at 
the field edge. Analysis was performed using a VIDAR scanner and ImageJ software 
(Rasband). Filter removal produces a small change in beam penumbra probably due 
to a reduction in the extra-focal radiation, these effects however are of the order of 
0.5mm and although this is of course a good thing it will probably be of little practical 
advantage. 
As the field size increases in a FFF beam the 80% point will no longer be 
positioned at the field edge and another definition of penumbra is needed to make 
these values meaningful. The most likely definition involves redefining the position of 
the 100% reference point to be at the inflexion point of the curve rather than at the 
central axis. These definitions have been discussed by Ponisch et al (2006) and 
Fogliata et al (2012) but standardisation is still required. 
 
2.2.12 Wedge data 
2.2.12.1 Wedge profiles 
Data for wedged beams was also measured as the effect of filter removal on wedge 
characteristics was completely unknown. As well as shaping the beam profile, the 
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wedge also acts as an absorber, and can indicate information about the relative 
contributions of low-energy photons and electron contamination. Central axis depth 
dose measurements were measured for square fields from 5x5 to 30x30cm2 at 100cm 
SSD and profiles taken at 5 depths. 
Beam profiles of the internal motorised wedge (nominal 60º) again show that 
there is a slightly faster drop-off in dose at the beam edge and lower dose outside of 
the field (figure 2.16). The wedge profiles are slightly convex rather than concave but 
importantly the overall effect of the wedge is retained. The wedge angle itself drops 
slightly from 56º to 53º for a 10x10cm2 field but these factors can easily be taken into 
account within the beam model. 
 
 
Figure 2.16. Comparison of measured wedge profiles for a 20x20cm2 field, normalized at dmax. 
Profiles are at depths of 15, 50, 100 and 200mm. 
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2.2.12.2 Wedge transmission 
Wedge factors were measured using a NE2571 Farmer chamber in solid water (100cm 
SSD, 5cm deep).  The softer spectrum and associated decrease in beam energy to 
approx. 5MV leads to an increase in x-ray attenuation and hence to reduced 
transmission. Reduced head scatter also leads to less variation with field size; the 
ratio of 30x30 to 3x3cm2 readings for the flattened beam is 1.098 compared to 1.055 
with the flattening filter out, i.e. half the relative range (figure 2.17). Again filter 
removal is seen to reduce the variation in field size dependant parameters. 
 
 
 
Figure 2.17. Wedge factors plotted on the same scale to compare variation with field size. The ratio of 
30x30cm to 4x4cm readings is 1.098 with filter in and 1.055 filter out. 
 
2.3 Discussion 
Linear accelerator design has evolved around the need for flat radiation fields and a 
certain number of problems must be expected when the flattening filter is removed. 
Measurements reported here show that these problems, however, are fairly minimal 
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and most likely to be resolved with relatively simple software modifications since the 
vast majority of all machine running parameters remain unchanged. The only 
differences are observed at the ionisation chamber where beam parameters such as 
flatness, symmetry and uniformity need to be reset, but this can be performed 
relatively easily and, with a thin metal plate in place of the filter, the chamber servos 
continue to operate well. In fact with the filter removed the beam symmetry is half as 
sensitive to changes in beam steering, retains a more consistent profile with these 
changes and is more stable during start-up irradiation. 
To operate the machine clinically however it would be necessary to modify 
current IEC specifications (BS EN 2001) which are based upon having square, 
flattened radiation fields. The standards are written to ensure the protection of the 
operator and patient and to define a number of parameters by which users can 
compare accelerator performance. With unflattened beams terms such as ‘flattened 
area’ are meaningless. Uniformity, flatness, symmetry, penumbra and field size 
definitions may need to be redefined for these beams. 
The major benefit of filter removal is in the reduction of head scatter and leakage 
radiation, both of which cause significant problems in radiotherapy and come as a 
direct consequence of producing a flattened beam i.e. forcing a large proportion of 
the beam to interact in the flattening filter. Removal leads to a decrease in head 
scatter (potentially improving dose calculations) and to lower whole body doses 
(reducing the risk of secondary cancers). Reduced scatter also leads to a reduction in 
penumbra, dose outside of the field edge and results in less variation in field size 
dependent factors. Reduced head scatter and increased dose rate should lead to 
simpler, faster and more accurate dose delivery with reduced dose to normal tissues; 
all useful properties. 
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2.4 Summary 
The basic dosimetric properties of filter free beams and linac operation have been 
investigated. In summary: 
 The flattening filter is mounted on a ‘carousel’ that can be rotated out of the 
beam line. 
 It is necessary to use a thin metal plate in place of the flattening filter to 
maintain servo control and to reduce surface doses. 
 Dose rates are approximately doubled by filter removal. 
 The beam positioning and shape are more stable in filter free mode. 
 The magnitude of the scatter component of the beam is much reduced. 
 The variation of field size dependant factors is substantially lowered. 
 Leakage doses are reduced. 
 The beam has similar depth dose characteristics to a 5MV beam. 
 Surface doses are slightly higher. 
 Penumbra is similar or even slightly reduced. 
 It is still possible to produce wedged beam profiles. 
 Definitions of parameters such as penumbra, flatness and symmetry will need 
to be reassessed / redefined. 
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CHAPTER 3 
 
 
ENERGY MATCHING AND FURTHER 
CHARACTERISATION 
 
 
Flattening filter removal produces numerous changes in beam characteristics, many 
of them large, but also some that are subtle. In particular the changes in leakage dose 
and in surface doses could be as much due to the change in beam energy as from any 
inherent property of FFF beams. It is also difficult to assess any changes in treatment 
planning is the beam energy is different between models. For these reasons a decision 
was made to alter the beam energy, bringing it back up to ‘6MV’. In this chapter we 
will consider the changes made to the beam in order to ‘match’ the FFF beam energy 
to that of the conventional 6MV beam, and report in detail some of the dosimetric 
effects of this. 
Sections of this chapter concerning surface doses have been submitted for 
publication in the journal Physics in Medicine & Biology (Appendix D). 
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3.1 Machine configuration 
This work was performed on the linear accelerator at University Hospital 
Birmingham (UHB) with the linac operated through an independent hard drive to 
keep all work separate from anything available clinically. At this stage a decision was 
also made to use a 2mm copper plate rather than 2mm aluminium for the enhancing 
plate as copper filters had been distributed to other Elekta centres interested in FFF 
research. These copper filters were of a thickness of 6mm however, and it was felt 
that this was too thick. A 2mm plate was therefore retained at UHB. 
 
3.2 Energy matching 
A FFF beam can never be completely matched to a conventional beam as there are 
too many changes to the beam spectrum, and in the relative contributions of low-
energy photons and electrons to make this possible. There is also the issue of the 
beam profile – in a conventional beam the flattening filter causes beam hardening on 
the central axis, which gradually reduces with distance towards the field edge. These 
changes in off-axis beam spectrum have been well described by Georg et al (2009). 
A fixed parameter and field size must therefore be chosen to match the beam 
onto. The most common specifiers of beam energy used are D10, the relative dose at 
10cm depth, and the quality index (TPR20/10), usually for a 10 x 10cm2 beam.  For the 
6MV beam the D10 = 67.5% and the quality index = 0.675. Matching was carried out 
on the central axis for a 10 x 10cm2 beam by repeat depth dose plots in a PTW 
watertank as the beam energy was increased. For the beams in question it was 
possible to simultaneously match both D10 and (TPR20/10), but this is not expected to 
be the case at all beam energies. 
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Table 3.1. Changes in bending and gun currents in the FFF beam required to maintain 
quality index of 0.675. 
 
Parameter 6MV 6MV FFF 
Bending Course (Bc) 39.5 49.5 
Bending Fine (Bf) 2.07 2.62 
Gun current (Ig) 7.89 7.71 
 
At the same time the gun, hump, beam uniformity and 2R and 2T lookup tables 
etc. were reset to enable efficient operation around these new running parameters. 
Several other machine parameters were also changed (not detailed here) as 
recommended by an internal report from Elekta on their investigations into FFF 
operation. Gross changes to bending and gun currents are detailed in table 3.1. 
 
 
3.3 Head scatter (Sc) 
As the beam energy increases so will the proportion of radiation scattered in the 
treatment head so increasing the beam energy to match the 6MV depth dose will 
increase the amount of head scatter from the treatment head. Figure 3.1 shows the 
new plot of Sc vs. field size for the matched beam (red line) compared to both the 
conventional 6MV beam (black) and to the filter-free beam pre energy-matching 
(green). Increasing the beam energy to obtain the central axis depth dose match 
increases the amount of scattered radiation in the beam, raising the head scatter 
above that seen for the un-matched beam. However, head scatter variation is still 
significantly reduced compared to standard operation. 
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Figure 3.1. The variation of head scatter (as measured with a mini-phantom) with field size for 
conventional use (filter in) and with filter out. Removal of the flattening filter results in 
approximately 70% less head scatter. 
 
3.4 Leakage radiation 
Measurements were again taken as recommended by the Elekta acceptance 
documentation (Elekta 2005) using a Farmer chamber (with 1.5cm buildup cap) 
placed at the points indicated in figure 3.2. With the diaphragms closed the absorbed 
doses at these points are compared to the reference dose measured for a 10 x 10cm2 
field at the isocentre. 
Table 3.2 shows the results of patient plane leakage measurements. The overall 
reduction in patient plane leakage for FFF operation is seen to be 65.7% at 6MV and 
61.4% at 10MV. 
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(a)
 
 
 
Figure 3.2. (a) Specification of points used to measure patient plane leakage. The circles are of radius 50, 75 and 100cm. (b) Leakage measurements (taken with 
the collimators in the closed position and compared to a central axis reading for a 10x10cm2 field) for conventional (blue) and FFF (red) beams. 
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Table 3.2 Leakage measurements in the patient plane at points specified in figure 3.2. Figures are presented as a percentage of the dose at isocentre for a 
10x10cm2 field. The ratio represents the leakage of the FFF beam in comparison to the 6MV beam [100 x (MV FFF / MV)]. (a) 6MV, (b) 10MV. 
 
(a) 6MV 
 
G T A B 
 
6MV FFF Ratio 6MV FFF Ratio 6MV FFF Ratio 6MV FFF Ratio 
50 0.038 0.013 0.348 0.027 0.009 0.339 0.017 0.005 0.319 0.016 0.016 0.345 
75 0.032 0.010 0.296 0.020 0.008 0.402 0.019 0.006 0.332 0.016 0.016 0.305 
100 - - - 0.013 0.006 0.428 0.024 0.008 0.342 0.015 0.015 0.315 
 
(b) 10MV 
 
G T A B 
 
6MV FFF Ratio 6MV FFF Ratio 6MV FFF Ratio 6MV FFF Ratio 
50 0.039 0.025 0.638 0.034 0.009 0.265 0.014 0.005 0.346 0.014 0.014 0.359 
75 0.030 0.018 0.619 0.024 0.008 0.338 0.017 0.006 0.352 0.016 0.016 0.301 
100 - - - 0.015 0.005 0.362 0.021 0.008 0.362 0.014 0.014 0.306 
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Leakage radiation is not only responsible for whole body dose levels to the 
patient, but will also needs to be taken into account when designing bunker shielding. 
Measurements were performed to assess both the instantaneous dose rate and 
cumulative dose for FFF beam delivery. Due to the increased dose rate of the FFF 
beams compared to those seen under normal operation instantaneous dose rates are 
expected to be higher. Cumulative doses will depend not only on the relative levels of 
leakage radiation associated with each beam, but also on the efficiency of delivery of 
IMRT plans and are presented in chapter 7 and Appendix H. 
Table 3.3 shows the instantaneous dose rates measured (with a compensated GM 
tube) at the gate, within the control area and on the roof of the bunker. These 
measurements were carried out by trainee physicists within the department working 
under supervision. A 40x40cm2 field size was used for all measurements. Readings 
are normalised to clinical dose rate for each energy. 
 
Table 3.3. Instantaneous dose rates measured at 6 and 10MV at the positions indicated (in µSv/hr). 
 
 Filtered FFF Position 
6MV 30.0 19.2 
@ Gate 
10MV 30.0 18.8 
6MV 4.0 1.9 
In control area 
10MV 6.5 3.0 
6MV 150 124 
On roof * 
10MV 300 113 
 
*With gantry at 180° 
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It can be seen that the bunker provides much greater shielding for the FFF 
beams. Operating at the higher dose rate expected during FFF delivery the readings 
will scale accordingly, and instantaneous doses will be higher for FFF operation 
compared to those seen for normal use. Similar effects have been shown by Kry et al 
who investigated the treatment vault shielding for a Varian FFF prototype (Kry et al 
2009), finding that the thickness of the primary and secondary barriers could be 
reduced by 10-20% for FFF operation. This reduction matches well with the observed 
drop in beam energy from 6 to 4 MeV. 
 
3.5 Surface doses 
3.5.1  Introduction 
It is well known that megavoltage (MV) photon beams provide a skin-sparing effect, 
but the actual magnitude of this can depend on a number of treatment parameters. 
Changes in field size, source-to-surface distance (SSD) and beam energy all cause 
changes in surface dose. In particular the introduction of materials into the beam line 
such as shadow trays and patient support devices can cause large increases in dose to 
the skin. At the same time it is also important that doses to targets close to the surface 
(such as for head & neck and breast treatments) are accurately known so that under-
dosage does not occur. 
Doses received by the basal skin layer can result in a range of problems from 
minor (such as erythema/epilation) to serious (desquamation/necrosis) depending 
on the levels of radiation received. A full knowledge and understanding of this is 
therefore necessary if clinical decisions are to be made, and these effects have been 
studied by a number of authors for conventional ‘flattened’ beams (Carl and 
Verstergaard 2000, Lamb and Blake 1997, Kim et al 1998, Parsai et al 2008). 
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Several authors have reported surface dose variations with field size in FFF 
beams (Vassiliev et al 2006, Cashmore 2008, Kragl et al 2009, Wang et al 2012), 
generally reporting higher doses under FFF operation, but data for changes in SSD, 
tray, wedge, couch etc. are unavailable. With this in mind measurements of surface 
doses for FFF beams are required to assess any potential changes in dose that may 
damage the skin. 
The purpose of this investigation was to evaluate and compare trends in surface 
dose for 6 and 10 MV flattened and FFF beams under conditions routinely 
experienced in radiotherapy treatments. Conditions studied were:- 
 
 variations in field sizes (square fields, sizes 3x3 to 40x40 cm2); 
 variation in source-surface-distance (SSD) (55 to 140cm); 
 the presence of 
o motorized wedge (0–60°); 
o shadow tray 
o carbon fibre couch 
 
3.5.2 Background 
3.5.2.1 Skin doses 
Skin doses arise from a combination of effects and will depend on the magnitude and 
relative contributions from contamination electrons, low-energy photons and 
backscattered radiation. Contamination electrons in particular can give rise to 
significant doses in the skin and will be influenced by several factors including head 
design, beam energy, SSD, field size or the introduction of materials into the beam 
close to the patient. Skin dose can therefore vary significantly from one setup to 
another and can be a limiting factor in some treatments (Carl and Vestergaard 2000).  
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Since the flattening filter is responsible for the majority of contamination 
electrons reaching the patient surface (Nilsson and Brahme 1986) its removal is 
therefore likely to reduce this contribution. However, the filter also acts as a beam 
hardener, removing low-energy photons from the spectrum. With the filter removed 
the low-energy component is allowed to pass through to the patient and act to 
increase the surface dose. 
The use of motorized wedges and Perspex shadow trays (blocking trays) in 
conjunction with filter removal could also change these characteristics significantly. 
Since conventional planning with unflattened beams has been shown to be of use 
(Cashmore 2007, Stevens 2011) data has also been measured for the motorized wedge 
and shadow tray. Dose measured under different conditions (wedge, SSD, tray etc.) 
can also be a good indicator of the relative levels of dose from low energy photons and 
from contamination electrons (although no attempt has been made to separate these 
two components here). 
 
3.5.2.2 Dose measurement 
In the buildup region of high energy photon beams electronic equilibrium does not 
exist, therefore percentage depth ionization (PDI) and percentage depth dose (PDD) 
are not equal. Under these conditions electronic fluence perturbations in the air-
sensitive volume of the cavity cause ionization chambers to exhibit an ‘over-
response’, and determining PDD from PDI measurements is difficult. This will occur 
for measurements carried out in the dose build-up region (and in the transition zones 
between different media), with a magnitude depending on the geometrical 
characteristics of the chamber. The over-response will be greatest at the surface and 
decrease as dose maximum (dmax) is approached, and electronic equilibrium restored. 
In these circumstances it is generally accepted that extrapolation chambers 
provide the most accurate means of measurement. These chambers, however, are 
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unavailable in most departments and are also very time consuming to use, therefore 
parallel plate chambers are routinely used to measure surface and buildup doses, and 
corrections must be applied to convert ionisation to dose. 
The over-response of chambers has been shown to be mainly due to electron in-
scattering from the side walls, which is determined by the width of the guard ring 
(Nilsson and Montelius 1986, Gerbi and Kahn 1990). Perturbation factors will 
therefore depend on the dimensions of the chamber and several methods have been 
introduced to correct for the effects seen when using parallel plate chambers in the 
build-up region of high-energy photon beams. These are based either on correction-
based methods from extrapolation chamber measurements, or by direct derivation of 
individual perturbation factors. 
In the first method the chamber reading is corrected by a subtractive factor that 
depends on the beam energy, chamber geometry and depth of measurement (Nilsson 
and Montelius 1986, Gerbi and Kahn 1990, Velkley et al 1975, Rawlinson et al 1992). 
These factors are essentially independent of field size but increase with decreasing 
energy. 
Velkley et al used extrapolation chamber data to develop a correction term for 
parallel plate chambers to account for the in-scattering of electrons in the buildup 
region, introducing an over-response correction factor based on the plate separation 
of the chamber: 
 
      lddEdPdP  max,'     (3.1) 
 
where d is the depth to the front surface of the chamber, E is the nominal maximum 
energy of the beam, P is the percentage maximum ionisation obtained using a 
chamber with plate separation of l mm, and P’ is the corrected percentage maximum 
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ionisation.  max, ddE  is the correction factor in units of percent per mm of plate 
separation. 
These correction factors were intended to be applied to all types of parallel plate 
chambers, but further work by Nilsson showed that the factors are specific to the 
chamber design and depend on guard size, plate separation and volume. 
Gerbi and Kahn extended this to take into account wall perturbation effects by 
introducing the distance to the side wall (thickness of guard ring) into the equation: 
 
       max,0,,' ddelEEdPEdP  
 (3.2) 
 
where d is the measuring depth, dmax is depth of dose maximum of the X-ray beam 
with energy quality E. The ξ function is the correction to the surface %DD per mm of 
plate separation independent of the ion chamber used. l is the plate separation of the 
chamber, and α is an exponent that decreases the correction with depth. 
In some chamber designs the guard ring is very small leading to large correction 
factors. Gerbi and Khan (1990) show that Markus-type chambers require greater 
correction than most chambers due to small guard ring (0.1mm), with corrections 
exceeding those recommended by Velkley. Mellenberg (1995) reported a complete set 
of over-response correction factors for the Markus-type chamber at several photon 
energies. 
Rawlinson et al (1992) then developed an empirical method which accounted for 
side wall effects in the chamber. This was an improvement on the original method 
developed by Velkley and later adapted by Gerbi and Khan. Here, the collector edge 
to wall distance is assumed to be the appropriate parameter. This method works well 
for chambers with small collector diameters but over-estimates the correction for 
larger chambers. 
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Perturbation factors can also be derived explicitly. For parallel-plate chambers 
the PDD at depth d can be expressed as 
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Where  med
air
L  is the mean restricted collision stopping power from medium to 
air and Pfl, Pwall and Pcel are perturbation factors for the fluence, wall and central 
electrode respectively. When d>dmax these factors do not change and can be 
considered as invariant and the dose ratio is then equal to the ionization ratio (PDD = 
PDI) (Abdel-Rahman et al 2005). In the buildup region however, perturbations in the 
electron fluence cause these chambers to over-respond so that PDI>PDD. Since 
perturbation factors are known to have a strong dependence on chamber design, 
depth of measurement and beam energy, Pfl, Pwall, Pcel and  medairL  must be 
independently evaluated. 
Recent studies have shown that the product PflPwallPcel changes by less than 1% 
from the surface to dmax (Gerig et al 2009, McEwen et al 2008) and that  medairL   
changes by less than 4% for beams up to 18MV. The maximum deviation occurs at the 
phantom surface and will be less than 5%, reducing to 0% at dmax. 
For certain ion chambers and beam energies some of these factors have been 
evaluated (e.g. Mellenberg 1995). The presence of beam modifiers such as the wedge 
can change the photon beam spectrum appreciably, so removal of the flattening filter 
and associated changes in the beam spectrum are therefore likely to cause significant 
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changes to this. For FFF beams in general these are unknown and an independent set 
of over-response factors would be required for more accurate prediction. 
In more recent years work has been concentrated on Monte Carlo modelling and 
the discrepancies observed between measurements using extrapolation chambers and 
those from Monte Carlo simulations. McEwen et al (2008) has shown that with 
advances in the physics and description of beam geometry MC results match well 
provided the correct effective point of measurement (EPOM) for the chamber is used. 
The EPOM method has therefore been employed to calculate dose in the buildup 
region, accepting limitations. 
 
3.5.3 Materials and methods 
The Elekta Synergy FFF prototype linear accelerator (Elekta AB, Stockholm, Sweden) 
with a standard 80 leaf MLCi head has been used for measurements. The linac is 
fitted with a motorized wedge (nominal 60° wedge angle) and an iBEAM evo carbon 
fibre couchtop, both of which were assessed. 
The flattening filter is replaced with a 2mm stainless steel plate that is used to 
shield out contamination electrons from the primary collimator, and to provide build-
up into the ionisation chamber. This is now the standard configuration expected for 
clinical use. 
Removing the flattening filter changes the energy spectrum of the beam since 
lower energy photons are no longer removed from the beam. This results in 
unflattened beam having ‘softer’ beam spectra than their filtered counterparts. The 
6MV beam can be energy matched to the conventional beam by adjusting the beam 
running parameters. In this way the depth doses at 10cm depth, TPR20/10 QI/TPR20/10 
[0.675] for a 10x10cm2 field are the same. FF removal also affects the variation in the 
energy spectrum across the beam (making it much more uniform) but energy 
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matching across the beam is not possible. In contrast, and for consistency with other 
work (Kragl et al 2009, Georg et al 2010) the 10MV beam has not been adjusted. The 
TPR20/10 for the 10MV and 10MV FFF beams are 0.737 and 0.716, respectively. 
 
 
3.5.3.1 Experimental setup 
Measurements were taken in a phantom composed of 30x30cm2 WT1 Solid Water 
slabs (Radiation Physics, St Bartholomew’s Hospital, London) of varying thickness, 
with 15 cm of backscatter material to ensure full phantom scatter conditions. Further 
sheets of Solid water were added to take readings in the buildup region (maintaining 
SSD) (Figure 3.3a). Doses were measured with an NACP-02 (Scanditronix, IBA 
Dosimetry) parallel plate ionization chamber. The NACP chamber has a ‘coin-shaped’ 
sensitive volume with a diameter of 10mm, a height of 2mm and a guard ring of 3mm 
in width (NACP 1981). In the literature a guard ring of at least 5mm is recommended 
for measuring skin doses (Gerbi and Kahn 1990), but both Carl (Carl and Vestergaard 
2000) and McEwen (McEwen et al 2008) have investigated its use and found it to be 
suitable. 
The chamber is embedded in the phantom such that the entrance window of the 
chamber was flush with the surface with the central axis perpendicular to this. Doses 
at depth were measured by adding layers of phantom material while maintaining the 
SSD at 100cm to the top of the phantom (Figure 3.3a). The effective point of 
measurement itself was taken as the inside of the entrance window which, for the 
NACP-02 chamber (with a composite window of 0.1 mm Mylar and 0.5 mm graphite) 
is equivalent to 1 mm of water. Surface dose measurements therefore represent a 
measurement depth of 1mm, and all results are plotted relative to the dose measured 
at dmax (15mm 6MV, 22mm 10MV) for the same field size. 
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Surface dose readings are reported as relative surface dose (RSD) where: 
 
maxddRSD surface  
 
Buildup curves through the carbon fibre couch we measured according to the 
setup shown in figure 3.3 (b, c), with the gantry rotated to 180° to deliver radiation 
through the couch. Couch transmission factors were measured using a Farmer type 
chamber (NE2577 Nuclear Enterprises Ltd. (now supplied by QADOS, UK)) set at 
isocentre within 10cm of WT1 (Figure 3.3c). Couch factors are expressed as the ratio 
of the posterior to anterior electrometer readings. 
 
  
 
 
 
 
Figure 3.3. Experimental setup for (a) surface dose and buildup, (b) surface dose and buildup 
through the couch, (c) couch transmission factors. 
 
Polarity corrections in x-ray beams are generally small, but can become 
significant for parallel plate chambers, especially in the buildup region (Gerbi and 
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Kahn 1987). It is expected that the largest differences will occur at the surface, and 
that this will reduce as dmax is approached. To estimate polarity effects buildup curves 
were measured at ±200V over the buildup region, representing the full range of 
contamination conditions at 6 and 10 MV. 
 
3.5.4 Bias effects 
Surface doses were measured at positive and negative polarity (±200V) under 
representative high and low conditions (surface and dmax). Figure 3.4 shows these 
buildup curves for both 6 and 10MV FFF beams (for a 10x10cm2 field), and the ratio 
of these readings (+ve/-ve) vs. depth. 
As expected, the correction becomes larger as the measurement point moves 
closer to the surface and was found to differ by <1.3% (1.3% at 6MV, 1.1% at 10MV) 
and fall to unity at dmax. This was considered to be of small enough magnitude to 
disregard as the main purpose is to compare surface doses and evaluate trends. 
Readings were therefore taken at -200V only for the remainder of the study. 
 
(a)  
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
0.990
0.995
1.000
1.005
1.010
1.015
0 5 10 15
R
e
la
ti
ve
 S
u
rf
ac
e
 D
o
se
+v
e
 /
 -
v
e
Depth (mm)
+ve/-ve
-200V
+200V
 73 
(b)  
Figure 3.4. Fractional surface dose as a function of depth for +ve and –ve polarization voltages for 
(a) 6MV and (b) 10MV photons. The +ve/-ve ratio shows the increasing disequilibrium towards the 
surface. 
 
3.5.5 Field size variation 
Surface doses are seen to increase fairly linearly with increasing field size, albeit at a 
shallower incline for FFF beams than for the conventional (figure 3.5). At 6MV the 
unflattened beam shows a slight increase in RSD at smaller field sizes (+3.4% at 
3x3cm2) but a decrease at larger (-7.1% at 40x40cm2) with equivalency at 15x15cm2.  
At 10MV there is again far less variation in the RSD with field size for the FFF 
beams, but the conventional beam generally exhibits lower surface doses. At small 
field sizes the unmatched 10MV FFF shows an increase of 10% in absolute terms over 
the conventional 10MV beam; in contrast, the largest field size the FFF beam shows a 
5% decrease. The surface doses are equivalent for a field size of 25x25cm2. 
For the 6MV beam there is a variation in RSD of 26.7% (absolute) in changing 
from a 3x3 to 40x40cm2 field (0.353 to 0.620) compared to only 16.2% (0.387 to 
0.549) for the FFF equivalent. At 10MV these values are 31.0% for 10MV (0.242 to 
0.552) and 16.0% for FFF (0.344 to 0.504). 
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(a)  
(b)  
 
Figure 3.5 Variation of surface dose with field size for Flattened and FFF beams for jaw settings of 
3x3 to 40x40cm2. (a) 6MV and (b) 10MV. 
 
The variation of surface dose with field size is very similar for the 6 and 10MV 
FFF beams showing only minor differences with field size (0.44%cm-1 FFF at 6MV 
and 0.43%cm-1) at 10MV. For conventional operation these gradients are 0.72%cm-1 
at 6MV and 0.84%cm-1 at 10MV. 
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3.5.6 Wedge 
The skin dose for wedged field increases as field size is increased in a similar manner 
to the skin dose for open fields. With the wedge in place surface doses at both 6 and 
10MV are seen to be generally lower for FFF beams. This is true for all field sizes at 
6MV (figure 3.6a) and those beyond 12x12cm2 for 10MV (figure 3.6b). The slope of 
the curves is also much shallower for the unflattened beams. This is demonstrated 
clearly in figure 3.6c where wedge only data is plotted for each beam. 
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(c)  
Figure 3.6. Variation of RSD with field size for wedged beams. (a) 6MV FFF and conventional open 
and wedged beams, (b) variation at 10MV, (c) wedge only data for 6 and 10MV. 
 
 
Figure 3.7. RSD variation with wedge angle for motorized wedge, 6MV. Field size is 15x15cm2. 
 
The gradient of these lines is 0.66%cm-1 vs. 0.99%cm-1 (6MV FFF vs. 6MV) at 
6MV and 0.65%cm-1 and 1.09%cm-1 at 10MV, again demonstrating much less 
variation with field size for filter free operation. 
Skin doses for wedge angles of 15°, 30°, 45°, and 60° were also measured for the 
motorized wedge at 6MV only (figure 3.7). Since the wedge is shown to reduce RSD 
the greatest difference is observed when the field is fully wedged. 
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3.5.7 SSD variation 
At 6MV there is little difference between the FFF and conventional beams, except 
near the treatment head where the FFF beams show a reduction in surface dose of up 
to 5%. Increasing the beam energy to 10MV shows the typical reduction in surface 
dose. The FFF beam again shows reduced doses at the shortest SSD’s, but this quickly 
reverses with the conventional 10MV beams exhibiting a marked reduction in dose 
beyond 60cm SSD (figure 3.8). 
RSD is very stable between 90 and 140cm SSD then shows a sharp rise for 
measurements closer to the treatment head. Again, there is a reduction seen in the 
variation in FFF beams than for conventional beams. 
SSD variations were also investigated with the wedge in place. At both 6 and 
10MV a larger dose difference is seen between FFF wedge and open data than is seen 
for the conventional beams. The highest RSD is seen for 10MV FFF beams, and 
lowest for the 10MV wedge. A 10% reduction in RSD is seen for 10MV FFF compared 
to only 4% for 10MV. At 6MV these figure are 11% vs. 7%. 
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(a)  
(b)  
(c)  
Figure 3.8. Effect of changes in source to surface distance on surface dose for 6MV and 10MV beams 
for open and wedged beams (15x15cm2). 
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3.5.8 Shadow tray 
Inevitably the insertion of an acrylic shadow tray (10mm thick acrylic [polymethyl 
methacrylate]) into the beam causes an increase in the observed surface dose. At 
6MV the smallest field sizes exhibit very similar readings, but these rapidly diverge as 
field size increases with the FFF beam having a much shallower slope (figure 3.9a).  
 
(a)  
(b)  
 
Figure 3.9. Variation of RSD when passing through Perspex shadow tray for (a) 6MV and (b) 10MV. 
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For a 40x40cm2 field the reduction rises to 12% for the FFF beam. For the 10MV 
beams the slope is once again much shallower for the FFF energy (figure 3.9b). There 
is a switch over from higher to lower surface doses at around 20x20cm2 with doses 
being approximately 10% higher for 3x3cm2 and 15% lower for 40x40cm2. 
 
3.5.9 Carbon fibre couch 
Figure 3.10 (a, b) show the buildup characteristics when passing through the iBEAM 
evo treatment couch. The curves for both 6 and 10MV show very little difference 
between FFF and conventional beams. At 6MV there is a slight decease for FFF (~3%) 
at the surface, but nothing large enough to be of clinical significance. 
As the field size is varied from 5x5 to 40x40cm2 the difference is slightly 
exaggerated (up to 6%) (Figure 3.10 c, d). 
Couch transmission factors follow a similar pattern between FFF and 
conventional energies with the FFF beams showing a greater factor at both energies, 
0.976 vs. 0.982 for 6MV and 0.982 vs. 0.988 for 10MV. 
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(b)  
(c)  
(d)  
Figure 3.10. Buildup curves for (a) 6MV and (b) 10MVwith and without the treatment couch 
intersecting the beam. Relative surface dose vs. field size for (c) 6MV and (d) 10MV. 
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(a)  
(b)  
 
Figure 3.11. Couch transmission factors vs. gantry angle at 6MV (a) and 10MV (b). 
 
The variation of couch transmission factor with changing gantry angle and with 
field size show a similar trend to conventional beams at both energies, albeit with 
greater attenuation, and are shown in figures 3.11 (a) and (b). 
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3.6 Discussion & Conclusions 
By passing through the flattening filter conventional beams exhibit a hardened beam 
spectrum so they tend to contain less low-energy x-rays, leading to lower surface 
doses, but high amounts of contamination electrons which act to raise surface doses. 
FFF beams on the other hand contain larger amounts of low-energy photons, since 
these are no longer filtered out by the flattening filter, but less contamination 
electrons, reversing the situation seen in the conventional filtered beam. In practice it 
seems that these effects almost cancel each other out so that the overall magnitude of 
surface doses from FFF beams are not too dissimilar to those seen in the original 
beams. 
The increase in surface dose with increasing field size is a well known effect and 
it is electron contamination that gives rise to most of this variation (Lopez Medina et 
al 2005), so the overriding effect of filter removal is a reduction in the variation of 
surface doses with field size. Here, the reduction in electron contamination means 
that the FFF beams exhibit much less variation with changes in field size compared to 
filtered beams. In general surface doses for FFF are higher for small field sizes and 
lower for larger field sizes with a cross-over point at approx. 15x15cm2 for 6MV, and 
at 25x25cm2 for 10MV. 
Kragl et al (2009) observed a similar variation in surface dose with field size for a 
6MV energy-matched Elekta linac (42.3% at 5x5cm2, 56.5% at 30x30cm2 compared 
to 39.7% and 53.1% seen here). Their readings are 2-3% higher than those seen in this 
study but can be explained by the use of a 6mm Cu plate in earlier versions of the 
filter plate, instead of the 2mm stainless steel plate used in this work. Kragl also 
reported data for a non energy-matched Elekta linac at 6MV reporting surface doses 
of 47.1% at 5x5cm2 and 61.6% at 30x30cm2, and increase of approx. 5% over those 
values seen for operation in the energy-matched linac. For an un-matched machine 
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the average energy is reduced to around 5MV by filter removal so this increase in 
surface doses (by approx. 5%) can be explained by the change in beam quality. 
A similar situation is seen for the Varian TrueBeam accelerator where the beam 
energy is not adjusted and FFF doses are seen to be higher at all field sizes for both 6 
and 10MV compared to operation with the filter in place (Vassiliev et al 2006, Wang 
et al 2012). Surface doses are strongly dependent on beam energy, so by altering the 
beam energy to match, maintaining TPR20/10 on the central axis, surface doses can be 
reduced. 
Materials in the path of the beam can both generate electrons and absorb them 
from further upstream. Since it is relatively thin, and of low-Z material, the shadow 
tray generates more electrons than it stops, and these pass through to reach the 
patient, raising skin doses. As the field size increases more electrons are emitted from 
the shadow tray, therefore higher doses are expected for larger field sizes compared 
to open fields. 
Fontenla et al (1994) showed an increase in skin dose of approximately 16% 
when a tray was added into a 25x25cm2 field at 6 MV.  Our data shows an increase of 
13% for the conventional beams and 9.5% for the 6MV FFF. At 10MV these figures 
are 14.2 and 10% respectively. 
Electrons generated by the shadow tray are likely to be similar in both beams 
indicating that the initial contamination from upstream must be higher in the 
conventional beam. 
The wedge is of sufficient thickness to absorb all of the contamination electrons 
arising from the head of the linac (Rao et al 1988), but surface doses will be 
influenced by electrons generated within the wedge. These are produced in a thin 
layer close to the exit surface equivalent in thickness to the range of the secondary 
electrons. 
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Regardless of beam energy the presence of the wedge is seen to reduce surface 
doses, by up to 10% for larger field sizes. Compared to conventional fields the FFF 
beams again show a reduction in RSD across all field sizes with the slope of the curve 
being much shallower for FFF operation, and filter removal is seen to have a much 
larger effect on the 10MV FFF beam than the 10MV (10% at 10MV FFF compared to 
4% for 10MV). Considering the blocking tray, wedged fields and open fields together 
the overall reduction in the slope of the curves with field size is seen to be reduced by 
36.1% at 6MV and 44.4% at 10MV. 
Considering the variation of RSD with SSD at 6MV it seems that this remains 
very stable at SSD’s beyond 90cm. At shorter SSD’s there is a significant rise in 
surface dose for both beams, but to a greater extent for the conventional 6MV. This 
again indicates the presence of greater number of contamination electrons in the 
filtered beam, which are gradually absorbed by the air column as SSD increases. At 
10MV the surface dose is generally higher for the FFF beams at all but the shortest 
SSD’s, but the variation is much reduced for FFF operation. Again an approximate 
10% reduction in RSD is seen on filter removal at both beam energies with the wedge 
in place, and this is consistent across all SSD’s. 
Increasing the beam energy is known to reduce surface doses,, so even though 
10MV FFF doses are seen to be slightly higher than for standard 10MV operation, 
they are still lower than those seen at 6MV. At 10MV differences in surface dose may 
be due to the lower effective energy of the beam compared to the standard, since the 
10MV FFF beam has not been energy matched. However, the small variation seen 
between 6MV FFF and 10MV FFF over a range of conditions indicates that a change 
in beam energy to a matched 10MV beam is likely to have little overall effect. 
Several authors have studied the effects of carbon fibre couchtops on surface 
dose (e.g. Smith et al 2010, McCormack et al 2005, Meydanci and Kernikler 2008). 
The proximity of the patient to the couch means that the skin sparing effect is almost 
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completely lost and surface doses increase to 85-95% of that seen at dmax, and for FFF 
beams a similar pattern is observed. At 6MV a very slight reduction in %DD is seen 
for FFF operation, and at 10MV the buildup curves are almost identical. The variation 
of RSD with field size is again seen to be reduced for FFF use being universally lower 
for 6MV over all field sizes, and lower at 10MV beyond 15x15cm2. 
Since the unflattened beams contain more low-energy photons than conventional 
beams the transmission factor of the couch is greater for both FFF energies (by 
approx. 0.5%), showing a similar variation with gantry angle to that observed for 
normal use. 
 
3.7 Summary 
Removal of the flattening filter has been shown to have many benefits over 
conventionally filtered beams for the delivery of treatments techniques such as (but 
not limited to) SRT, SBRT and IMRT. The present study indicates that the surface 
doses from these beams are very similar to those experienced for conventional 
flattened beams, and are therefore unlikely to cause concern in a clinical setting. 
However, as variations in electron contamination with SSD, or from the introduction 
of wedges, trays and couches are not taken into account in most treatment planning 
systems (Lopez Medina et al 2005), it is possible that the use of FFF beams may help 
to reduce the uncertainty of dose calculations in the buildup region by reducing the 
potential range of these values. 
By increasing the beam energy to maintain the quality index of the beam it is 
hoped that any reported differences in dosimetric characteristics or treatment 
planning can be more readily related back to filter removal rather than changes in 
beam energy. This energy matching procedure is in contrast to research reported for 
other accelerators. 
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CHAPTER 4 
 
BEAM MODELLING 
 
The dosimetric characterisation of FFF beams has shown that they are of potential 
benefit in radiotherapy, but this can only be translated into use if patient treatments 
can still be planned and delivered on the accelerator. Three treatment planning 
systems have been commissioned for FFF use: XiO, Monaco and Brainlab – and these 
are described below. 
This chapter therefore discuses the beam data requirements of each treatment 
planning system and the modelling of the FFF within the software, concentrating on 
the implementation and commissioning of the Monaco TPS, as this is where most 
effort was required. The implementation of FFF for Monaco has been published in 
the journal Medical Physics (Cashmore et al 2012), and was performed in 
conjunction with staff at Elekta based in large part on work performed by Marcin 
Sikora and Markus Alber (Sikora et al 2007, Sikora et al 2009, Sikora 2011). 
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4.1 XiO 
Commissioning data has been measured and used to create a beam model within the 
XiO treatment planning system (Elekta AB, Stockholm, Sweden, version 4.34.02). 
XiO is a treatment planning system for both 3D conformal radiotherapy and IMRT, 
and is the main software package for radiotherapy planning at UHB. Within the 
software is a separate program for beam modelling called ‘Source File Maintenance’. 
Here it is possible to create, edit and copy existing machine data files. 
To create the FFF beam model the existing 6MV model for this linac was used as 
a starting point. The beam remains unaffected up until the FF so the basic machine 
parameters for the model (machine limits etc.) obviously remain the same but a new 
beam spectrum, depth doses and profiles along with total scatter (Sc,p) and phantom 
scatter (Sp) factors are required. In practice total scatter and head scatter (Sc) have 
been measured (and Sp calculated) since published Sp data are inaccurate for 
unflattened beams (Satherberg et al 1996, Kragl et al 2009). 
Beam profiles and depth dose measurements were taken using a PTW MP3 
Tandem watertank with Semiflex 0.125cc chambers and running Mephysto 7.4 water 
phantom software. For scatter and wedge factor measurements an NE2571 Farmer 
chamber was used. Build-up measurements were made with a NACP-02 parallel plate 
chamber in WT1 solid water. 
A full set of commissioning data as recommended by Elekta (CMS XiO 2003) 
were measured along with surface and out-of-field doses to compare with 
concurrently measured 6MV data (table 4.1). 
Central axis depth dose measurements were measured for square fields from 5x5 
to 30x30cm2 at 100cm SSD and profiles taken at 5 depths. Wedged beam data was 
also measured as the effect of filter removal on wedge characteristics has not been 
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studied previously. A 40x40cm open field diagonal profile was also taken for beam 
modelling purposes. 
 
Table 4.1. Measurements made for XiO commissioning. Depth doses and profiles were measured 
with a Semiflex 0.125cc chamber, scatter factors with a Farmer NE2571 chamber and build-up and 
surface doses with a NACP chamber in solid water. 
 
Depth Doses Open / Wedge 5, 10, 15, 20, 30 cm2  
Profiles Open / Wedge 15, 50, 100, 150, 200mm depths 
  For 5, 10, 15, 20, 30 cm2   
 Open Diagonal 40x40 cm2 
Total Scatter 
Factors 
 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 
20, 25, 30, 40 cm2  
Head Scatter 
Factors 
 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 
20, 25, 30, 40 cm2  
Wedge Factors  3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 
20, 25, 30 cm2 
Build-up Open 5, 10, 15, 20 cm2 0-17mm depths 
Surface dose Open 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 
20, 25, 30, 40 cm2 at 3mm depth 
Leakage  50cm and 100cm from isocentre, 
patient plane 
Dose rate Open / Wedge 10x10, dmax (15mm) 
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4.1.1 Modelling variations in energy spectrum 
The flattening filter significantly hardens the radiation beam on the central axis but, 
due to its physical shape, the average beam energy decreases with distance from the 
central axis (due to differential absorption of soft x-rays). 
The conical shape of the flattening filter therefore produces a variation in beam 
spectrum across the field. This can be modelled to some extent in the XiO TPS by the 
use of central axis and off-axis spectra. Modelling of the beam spectra is a matter of 
informed trial and error through an iterative process. Low-energy components are 
added to increase dose near the surface, and higher energy for doses at depth, all the 
while trying to maintain a smooth spectrum. 
 
 
Figure 4.1. A simple diagram to illustrate the need for different beam spectra on and off axis. 
 
Figure 4.1 illustrates the need for an off-axis spectrum for treatment planning. 
The XiO system uses two spectra for beam modelling to account for changes in beam 
quality across the flattening filter, one on the central axis and the other 7° off-axis. 
Figure 4.2 (a) shows the spectra used to model a conventional 6MV unit in XiO; in 
black is the central-axis (CAX) spectrum and in brown is the off-axis spectrum. For 
dose calculation at fan-lines between these two angles the spectrum is interpolated. 
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As yet there are no published spectra for unflattened beams, but conventional 
central axis spectra are simple to derive from standard published spectra (Mohan et 
al 1985). Some off-axis spectra have also been published (Sheikh-Bagheri and Rogers, 
2002) and are used to modify attenuation towards the field edge, giving a better fit to 
measured data in the shoulder region of beam profiles. 
(a)
 
(b)
 
Figure 4.2. Central and off-axis spectra used for beam modelling. (a) 6MV. (b) 6MV FFF beam, 
notice the coincidence of the off-axis spectrum for the FFF beam. 
 
 92 
Although there is still a change in beam spectrum across the field with the 
flattening filter removed it is much reduced and a separate spectrum is not required 
in XiO to model the off-axis component and fit to measured profiles (figure 4.2b). 
A selection of beam profiles and depth dose measurements are presented in 
figures 4.3 and 4,4 respectively. At smaller field sizes the filter has no observable 
effect on the beam shape, but as the size increases the forward-peaked nature of the 
beam becomes more apparent. 
Figure 4.5 shows a selection of beam profiles for a 30x30cm2 field normalised to 
remove beam divergence and output. In the shoulder region the beam profiles for the 
conventional beam show considerable variation, which is the reason why flattening 
filter can only be designed to give a ‘flat’ field at one particular depth. The FFF plot 
shows the reduction in this variation due to the similarity of the energy spectrum 
across the portal. 
 
Figure 4.3. FFF beam profiles for field sizes of 5, 10, 15, 20, 30cm2 at depths of 1.5, 5, 10, 15, 20cm. 
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Figure 4.4. Percentage depth dose plots for FFF beam (100cm SSD) for the field sizes indicated. 
 
Figure 4.5. A half-beam profile plot comparing standard 6MV flattened beam (left of plot) against 
the energy matched FFF equivalent (right) for a 30x30cm2 beam. Profiles are normalised to 100% on 
the central axis and scaled to remove divergence, this illustrates the changes in beam profile with 
depth. Note the relative reduction in beam shape change with depth for the FFF beam. 
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Figure 4.6 (a to e) shows example beam profiles and percentage depth doses from 
beam model calculations in XiO (vs. measured data) to illustrate the quality of the 
beam model. A good match to measured data is achieved at all field sizes. 
 
(a)  
(b)  
(c)  
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(d)  
(e)  
 
Figure 4.6. Depth dose and beam profile comparisons (measurements vs. TPS predictions) for field 
sizes of (a) 2x2, (b) 10x10, (c) 15x15, (d) 20x20 and (e) 35x35cm2 fields to illustrate beam modelling of 
FFF. 
 
4.2 Monaco 
MonacoTM (Elekta AB, Stockholm, Sweden) is a treatment planning system that uses 
biological cost functions and constrained optimisation for IMRT treatment planning. 
Plan optimisation is carried out using a pencil beam algorithm for speed, but final 
dose calculations are computed using a Monte Carlo dose engine. 
In the standard clinical release (version 2.03) the TPS was not capable of 
modelling the triangular profiles of the FFF beams, and modifications were needed 
by to support FFF modelling and dose calculation. Alterations to the Monaco 
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software were implemented by Elekta staff based on dosimetric, beam modelling and 
verification data acquired for FFF beams at UHB. 
To maintain consistency, all IMRT specific beam data for both the 6MV and 6MV 
FFF modes were measured concurrently using the same equipment and techniques. 
Both models were generated at the same time and to the same standard. 
The following sections describe the beam modelling within Monaco and the 
modifications to the model needed to support FFF beams.  
 
4.2.1 VSM - Source densities and particle fluence distribution 
For MC simulations a beam can be described by the phase space parameters 
(position, direction of motion and energy) of the constituent photons and electrons. It 
is possible to generate these parameters analytically in a phase space plane in front of 
the patient and use MC transport for particles passing through the patient. A ‘virtual 
source model’ (VSM) allows for efficient generation of particle parameters and can be 
commissioned for conventional linear accelerators with semi-automatic modelling 
tools. The VSM-based MC computes dose in the following way: 
 
1) Source type, energy, position and direction of particles are sampled from the 
VSM. The required number of particles is generated on the fly in an arbitrary 
plane above the collimators to achieve a predefined level of statistical noise in 
the patient. 
2) The particles are transported through collimators or transmission probability 
filters (Sikora 2011), e.g. in the multileaf collimator (MLC) plane. 
3) The dose deposited in the patient is calculated using the XVMC code (Fippel 
1999, Kawrakow and Fippel 2000) 
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The VSM treats particles coming from different parts of the accelerator as if they 
were coming from three different virtual sources. These sources are the primary 
photon source, the secondary photon source and the electron contamination source, 
with relative contributions priP , secP , and econP  respectively. The primary source is 
defined in the plane of the electron beam target. The secondary source then models 
all of the photons that result from interactions occurring in places other than the 
target. The positions of the secondary source and the electron contamination source 
are free parameters which are set according to the machine geometry. The secondary 
source is located at the base of the primary collimator and the electron contamination 
source at the base of the FF (or the build-up plate). 
It is assumed that each of the sources has a Gaussian shape with standard 
deviations prisececon for primary photon distribution, energy-dependent 
secondary photon distribution and energy-dependent electron contribution 
respectively, according to the following expressions: 
 
34.0
0
secsec )()(

E
E
E  if E   0.511 MeV  (4.1) 
34.0
0
secsec )
511.0
()( 
E
E  if E < 0.511 MeV  (4.2) 
where: 
E  = particle energy 
0E = 1 MeV 
sec = free parameter, the base data standard deviation of the secondary 
source. 
18.0
0 )/()(
 EEE econecon       (4.3) 
econ = free parameter, the base data standard deviation of the electron source. 
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Upon generation of a photon in the source location, the particle fluence in a 
phase space plane that is located above the collimators is initially flat. The particle 
weight is altered depending on the angle between its direction and the central axis 
(CAX) according to a tabulated profile. 
 
 
4.2.2 VSM – Energy spectra 
The primary photon spectrum (Spri) on the central axis before the flattening filter is 
described by 
0)( ES pri       if minEEEbin   (4.4) 
1)()(
max

 prib
pri
E
E
ES    if minEE    .  (4.5) 
where: 
E  = photon energy (MeV)  
maxmin , EE = are minimum and maximum photon energies. 
For  minE  a fixed value of 0.5 MeV is used.  
0 ,= low energy bin parameter 
prib  = free parameter. 
 
In the implementation of this VSM for flattened beams this primary spectrum is 
attenuated with an appropriate, radially-dependent filter function (Sikora and Alber 
2009). 
The secondary photon spectrum )(sec ES  describes the secondary photons on the 
CAX after the flattening filter. 
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SES )(sec     if minEEEbin   (4.6) 
maxsecsec)(sec
EbEb
eeES
     if minEE  ,  (4.7) 
where: 
binE , S = low energy bin parameters 
secb  = free parameter. 
 
The off-axis energy softening is approximated by two parameters ( prib  and secb ) 
which define the relative change of the primary and secondary spectrum with respect  
to the tangent of angle to the CAX (tan( ) ) at the scoring plane. 
 
)tan()(  pripripri bbb       (4.8) 
)tan()( secsecsec  bbb       (4.9) 
 
The energy spectrum of the contaminating electrons is approximated by an 
exponential function  
 
)exp()(


e
econ
E
E
NES ,     (4.10) 
 
where: 
eN = Normalization factor 
 eE  = mean electron energy 
 
The VSM is defined by fixed and open parameters. Fixed parameters are derived 
from a BEAMnrc (Rogers et al 1995) simulation of the treatment head which is 
performed only for a given accelerator type. Open parameters are fitted in the poly-
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energetic kernel superposition commissioning routine for each individual linac 
(Fippel 1999). The free parameters of the VSM are derived from basic beam data 
measurements performed in water, and by minimizing the differences between 
calculated and measured data. 
For the purpose of verifying the dose calculation accuracy of this model the 
Monaco treatment planning system (TPS) (Elekta CMS software, St. Louis, Mo) was 
used (version 3.1), which incorporates a commercial implementation of this VSM 
model (VSM v.1.6). 
Beam modelling (parameter fitting) was carried out by Elekta staff. 
 
 
4.2.3 Beam data requirements  
Measurements for beam modelling included depth dose curves and profiles for 
various field sizes measured in a water phantom (Blue Phantom2, IBA Dosimetry, 
Germany). Measurements were performed at SSD = 100cm with suitable detectors 
(CC01, CC13 IBA Dosimetry, NE2577 Nuclear Enterprises Ltd, (now QADOS, UK)).  
At the time of implementation, the model required both in air and in water scans to 
be performed (see table 4.2). 
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Table 4.2. Beam data requirements for Monaco. Depth doses and profiles were measured with a 
Semiflex 0.125cc chamber, scatter factors with a Farmer NE2571 chamber. 
 
In Water   
Depth Doses 
Square 
 
 
Rectangular 
2, 3, 4, 5, 7, 10, 15, 20, 30x30 cm2  
5x30, 10x30, 30x5, 30x10 cm2 
Profiles 
Square  
Rectangular 
2, 3, 4, 5, 10x, 20, 30x30 cm2 
5x30, 10x30, 30x5, 30 10 cm2 
  At dmax, 5, 10, 20, 30 cm depths 
Output Square 1, 2, 3, 4, 5, 7, 10, 15, 20, 30, 40cm2  
In Air   
Profiles 
Square 
 
 
Rectangular 
2, 3, 4, 5, 7, 10, 15, 20, 30, 40x40 cm2  
5x30, 10x30, 30x5, 30 10 cm2 
at 85, 100 and 115cm SCD 
CAX scan 
Square 
 
 
Rectangular 
2, 3, 4, 5, 7, 10, 15, 20, 30, 40x40 cm2  
5x30, 10x30, 30x5, 30 10 cm2 
From 85 to 115cm SCD 
Relative 
output 
factors 
 
2, 3, 4, 5, 7, 10, 15, 20, 30, 40x40 cm2  
5x30, 10x30, 30x5, 30 10 cm2 
Normalized to 40x40cm2 
Films Square 
1x1, 2x2, 3x3, 4x4, 5x5cm2 
10x10cm2 shaped by 4x4 MLC 
 
The dataset consisted of water, air and film measurements of depth dose curves, 
in-plane and cross-plane profiles for field sizes, diagonal profiles for the largest field 
size: 40x40cm2 and output factors. These measurements are detailed in table 4.2. 
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Monaco is used clinically at UHB with conventional flattened beams and the data 
set and equipment used for FFF measurements matched those originally used to 
commission this beam energy. In this way the FFF and FF data can be said to be of 
the same standard and can be directly compared against one another. 
 
4.2.4 Model commissioning 
The unique feature of the VSM is that it represents the primary photon spectrum 
before it reaches the flattening filter. Therefore, turning off the flattening filter 
correction corresponds to physically removing the flattening filter from the 
accelerator head. The procedure for modelling the FFF machine is very similar to 
modelling a standard machine and as a starting point a previously created model of 
the FF linear accelerator from the same vendor was used. The model parameters were 
modified as follows: 
 
1) The radially dependent, differential attenuation of the FF in the conventional 
model was turned off. Further variations in off-axis spectrum were kept 
constant (eq. 4.8). 
2) The relative contribution from primary photons priP  was increased. 
3) 
maxE was increased along with prib  to provide a better agreement of the depth 
dose, especially in the Dmax region. This accounts for the re-tuning of the 
machine to produce a typical 6 MV quality index. 
4) The secondary source Gaussian sigma was made wider by a factor of approx. 
two, due to the fact that in the absence of the flattening filter, the primary 
collimator contributes most of the scatter. 
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5) To correct the fluence profile for FFF beams the tabulated parameters for 
radial energy fluence variation were adjusted to the diagonal cross-profiles at 
Dmax. 
 
The results of the VSM phase space reconstruction are independent of the 
calculation engine used; therefore it can be coupled with other MC dose engines. MC 
simulation and treatment planning were performed in the Monaco TPS using a water 
phantom of size 50x50x35 cm3. The voxel size was set at 2mm for the smallest 2x2 
cm2 field and 3mm for the rest of the fields with statistical uncertainties set to 0.5%. 
 
4.2.5 Results of water phantom data verification 
Figure 4.7 shows a plot of output factor variation with field size for FFF and 
conventional beams (a) and also the difference in calculated relative output factor 
curve against measurement (b). These are absolute values as predicted by the 
planning system and not scaled to measured data. The absolute outputs can be 
predicted within 1.5% of measurements over the entire range of field sizes. 
To illustrate the match achieved figure 4.8(a) shows a sample depth dose curve 
for a 2x2 cm2 field size, and figure 4.8(b) profiles for a 30x30cm2 field at depths of 
dmax, 5cm, 10 cm, and 20 cm for a 30x30 cm2 field. Good agreement is seen in each 
case. 
A more detailed analysis is presented in figure 4.9 where, for various depths and 
fields sizes, the percentage difference between measured and calculated depth dose 
curves is presented. The spread in values is approximately 1.5% (+0.5 to -1.0) in both 
cases indicating that the beam model is of similar quality for both FFF and 
conventional beams, and is within the measurement uncertainty for these fields. 
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(a)  
(b)  
 
Figure 4.7 (a) Absolute output factors as a function of field size for FFF and conventional 6MV beams 
as predicted by the TPS compared to measurement. b) Difference in output factors, calculated minus 
measured. 
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Figure 4.8. Sample beam data (a) PDD curve for 2x2 field, (b) cross-profiles for a 30x30cm2 field for 
the FFF model. 
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(a)  
(b)  
Figure 4.9. Absolute dose difference between measured and calculated depth doses curves (100cm 
source-surface distance) for the field sizes indicated for (a) the 6MV FFF beam, and (b) 6MV. Monte 
Carlo variance is set at 0.5%. 
 
Beam profiles are analysed in figure 4.10 which shows comparisons of FFF beam 
profile measurements against TPS predictions for field sizes from 2x2 to 30x30cm2. A  
1D γ-analysis (written by Mark Ramtohul at UHB) was performed for each profile 
with criteria of 2% / 2mm. It can be seen that all points had γ <0.8. For set criteria of 
1% / 1mm 93% of all points had γ<1 (figure 4.10). 
-1.5
-1.0
-0.5
0.0
0.5
1.0
0 10 20 30
A
b
so
lu
te
 d
o
se
 d
if
fe
re
n
ce
 (%
)
Field Size (cm)
2x2
3x3
4x4
5x5
7x7
10x10
15x15
30x30
Mean
-1.5
-1.0
-0.5
0.0
0.5
1.0
0 10 20 30
A
b
so
lu
te
 d
o
se
 d
if
fe
re
n
ce
 (%
)
Field Size (cm)
2x2
3x3
4x4
5x5
7x7
10x10
15x15
20x20
30x30
Mean
 107 
a) 
 
b) 
 
c) 
 
d) 
 
e) 
 
f) 
 
 
Figure 4.10. Comparison of calculated vs. measured beam profiles for sample field sizes of a) 2x2, b) 
5x5, c) 10x10, d) 15x15, e) 20x20 and f) 30x30cm2 at 100cm SSD and a depth of 5cm. Criteria for 
gamma analysis are 2%/2mm. 
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Beam modelling of the 6MV FFF beam within Monaco is seen to be as accurate as 
that used clinically. Depth dose predictions are generally within 0.5% for the FFF 
beam, with only a few outliers up to 1% which is more consistent than for the 
conventional beam model. 1D gamma analysis of beam profiles for selected criteria 
(2%/2mm) also show excellent agreement. This matches well with commissioning 
results reported by Hrbacek et al (2011), and Kragl et al (2011b) for FFF beams from 
Varian and Elekta linacs respectively. Any differences between prediction and 
measurement where γ exceeded 1 occurred mainly within the out-of-field regions of 
the beam profiles and only for the larger (>15x15cm2) field sizes. 
 
4.3 BrainLab 
Commissioning data has also been measured for six BrainLab stereotactic collimators 
(10, 12.5, 15, 17.5, 20 and 22.5mm diameter). These have been commissioned in both 
conventional and FFF modes (at 6MV) to compare beam data and treatment plans. 
Profiles and depth doses were measured with a CC01 chamber in a BluePhantom2 
watertank (iBA dosimetry) at 92.5cm SSD. 
The beam profile is preserved on filter removal, with only small deviations from 
those seen under normal operation. Figure 4.11 shows half-beam profile plots of the 
standard 6MV and FFF beams normalised to reflect the changes in output observed. 
Small differences are seen in the beam penumbra (20-80%) measured for each 
beam, as well as the output factor. These are detailed in table 4.3 below. 
There are additional changes in the beam profile outside of the treatment area, 
where the doses are approx. half of those seen for conventional operation. This is 
discussed in more detail in section 7.7 and appendix H. 
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Figure 4.11. Half-beam profiles normalised to the output factor for each cone (relative to a 5x5cm2 
field). 6MV data is on the left of the plot, 6MV FFF data on the right. 
 
Table 4.3. Field with and penumbra (80-20%) measurements for stereotactic cones (10 to 22.5mm) 
for 6MV and 6MV FFF operation. 
 
 
Field width 
(mm) 
Penumbra 
(mm) 
Output Factor * 
Collimator 6MV FFF 6MV FFF 6MV FFF 
10 10.5 10.4 5.3 4.8 0.806 0.825 
12.5 12.9 12.8 5.5 5.2 0.883 0.896 
15 15.5 15.5 6.0 5.6 0.918 0.927 
17.5 18.0 18.0 6.4 5.9 0.923 0.936 
20 20.5 20.4 6.6 6.3 0.928 0.942 
22.5 23.0 22.9 6.9 6.6 0.932 0.948 
 Output factor is relative to a 10x10cm2 field. 
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The TPS used for SRS is the BrainLab (BrainLAB, AG, Germany) BrainSCAN 
(version 5.31), which utilises a simple ray-tracing algorithm for dose predictions. 
These are based on the input of %DD and beam profile data along with output 
factors, so beam modelling is not required. 
 
4.4 Summary 
Removal of the flattening filter invalidates the assumption of energy fluence and 
phantom scatter homogeneity in the incident beam a TPS must be able to model an 
arbitrary shape of the energy fluence. It is therefore important to be able to handle 
the incident particle fluence either by means of a sufficiently general calculation 
algorithm or through modelling of changes in the beam spectrum with off-axis 
position. 
Within the XiO TPS it is seen that the use of two energy spectra, on and off-axis is 
sufficient to model standard filtered beams, and that removal of the flattening filter 
only acts to reduce the variation in the beam spectrum. Although some variation still 
exists, it is possible to model the FFF beam with a single energy spectrum and match 
%DD and beam profile variations with depth and off-axis position. 
In Monaco the virtual source model for flattened beams was successfully adapted 
to a flattening-filter free beam production by modifying the energy spectrum to 
account for the lack of angular differential absorption and general beam hardening. 
Since the VSM model was initially derived from studies of phase spaces created by 
BEAMnrc (Rogers et al 1995) it captures the salient features of the various sources of 
radiation in a linear accelerator without overly-limiting assumptions, and thereby 
provides enough latitude to model flattening filter removal. 
Beam modelling within BrainSCAN is not an issue as dose calculation is via a 
simple ray-tracing algorithm utilising tabulated data.  
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CHAPTER 5 
 
TREATMENT PLANNING 
 
Unflattened photon beams have been shown to have many beneficial properties such 
as reduced leakage and increased dose rate. Although these beams can be modelled 
within modern treatment planning systems there is still the potential issue of whether 
the triangular intensity profile can be of use when planning treatments. In principle 
this beam shape may be useful in many conventional planning circumstances and 
should be suitable for IMRT provided an algorithm is used that takes the beam profile 
into account. 
This chapter discuses the basic beam properties of FFF beams and their use in 
planning conformal and IMRT treatments. 
 
5.1 Introduction 
The use of a flattening filter to produce large, flat fields has been considered to be a 
prerequisite for single beam and parallel pair techniques used to treat large slabs or 
boxes of tissue, but modern radiotherapy techniques often require the active 
production of non-flat fields; the most obvious example of this being IMRT. Non-flat 
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distributions are also produced by field-in-field techniques (to treat boost volumes) 
and more mundanely by the simple use of wedges. 
The characteristics of flattening filter free linacs show many potential benefits for 
radiotherapy treatments. The only problem with these beams, of course, has always 
been the forward-peaked intensity profile of the beam. 
So far the possibility of utilising FFF beams for conventional treatment planning 
has not been explored or quantified but the forward-peaked profile in essence 
provides a central axis boost to the distribution which could potentially be useful in 
many planning situations. 
 
(a)     
 
(b)     
 
Figure 5.1. Comparison of isodose distributions for a 5x5cm2 square field a) 6MV flattened beam, b) 
6MV unflattened beam, illustrating the minor changes seen for small field sizes. 
 
Figure 5.1 shows a single 5x5 beam both with and without the flattening filter in. 
As beam flatteners are designed to give a uniform field over large areas (typically 
40x40cm2) at these small field sizes the filter has no real effect on the beam profile. 
This means that small field work could be performed as usual with no real effect on 
the plans produced. Although treatment machines are capable of delivering treatment 
fields up to 40x40cm2 these size fields are rarely ever used (exceptions being whole or 
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half body techniques TBI, CNS). Over 50% of planned treatments at UHB are seen to 
have an equivalent square of 10cm2 or less, with very few greater than 15cm2. Modern 
treatments therefore require small fields. 
 
5.2 Basic beam properties 
The use of single applied beams is now a relatively unusual occurrence and the 
properties of a single beam, flat or otherwise, are not of huge relevance. It is the 
properties of beam combinations that are important and these are best studied by 
examining the basic situations encountered in treatment planning. An interesting 
effect is illustrated by considering the 4-field brick technique using 10x10cm2 fields 
(figure 5.2). Although the distribution for the FFF beams in figure 5.2(b) is different 
to that seen in 5.2(a), there are several potentially beneficial features in that (1) the 
95% isodose has rounded, not square corners and (2) the normal tissues near the 
surface receive a lower dose than normal. A 3D rendering of the 95% isodose contour 
(figure 5.2 c, d) shows that the high dose region for the conventional beams is cuboid 
in shape (hence the name 4 field ‘brick’), whilst the same combination of FFF beams 
produces a spherical distribution. This is more likely to be of use in treatment 
planning terms as tumours tend to be more spherical in nature. 
 
(a)     (b)     
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(c)    (d)  
 
Figure 5.2. For a 4-field ‘brick’ plan the unflattened distribution (b) shows a smaller 50% isodose 
(green) in the normal tissues near the phantom surface compared to the conventional plan (a). The 
central target region in (b) also has a rounded 95% region (d) that tends to match the general shape 
of tumours rather than the square distributions seen in normal planning situations (c). 
 
On moving to larger fields the forward peaked nature of the beam becomes more 
apparent. Figure 5.3 shows an isodose distribution for a 20x20cm2 beam and a beams 
eye view of this field to illustrate the conical nature of the beam intensity. The 
utilisation of these beams requires some consideration. 
(a)  
 
 
 
 
 
(b)   
 
 
Figure 5.3. (a) Axial and (b) coronal isodose distributions for a 20x20cm2 FFF beam (6MV FFF). 
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Historically, flat, uniform fields have been used almost exclusively for treatment 
planning, but modern radiotherapy often relies more on modulated radiation 
profiles. In particular, the uptake of forward-planned IMRT (field-in-field) 
techniques are rapidly increasing as they can be used to provide uniform doses over a 
region or to enhance (boost) the dose to a particular volume. 
The forward peaked shape could therefore be a useful property if utilised 
correctly. The addition of a conventional flat beam with the FFF beam in different 
weightings can produce a beam anywhere between the fully ‘flat’ and fully ‘unflat’ 
simply by changing the relative weights of the two beams (much the same as for a 
motorised wedge) (figure 5.4). 
 
 
 
Figure 5.4. A dose distribution anywhere between ‘unflat’ and ‘flat’ can be produced by mixing the 
beams together in differing weights. 
 
In this way the peak can be customised to the planning situation raising the 
central dose by the required amount to produce a uniform distribution. This is 
illustrated in figure 5.5 where a whole brain radiotherapy treatment is to be planned. 
The target area (the skull) is convex in both dimensions, causing problems for regular 
flattened beams (figure 5.5a), with hotspots occurring towards the edge of the beam. 
The use of the FFF beam in figure 5.5b overcompensates for the curvature of the 
skull, producing a central hotspot, but the combination of these two beams can 
produce an even dose distribution (figure 5.5c). When an opposing beam is applied 
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the overall distribution removes the original hotspots of either technique. The degree 
of boosting required can therefore be tailored to the situation. 
 
(a)          (b) 
  
 
     (c) 
Figure 5.5. (a) Whole brain radiotherapy with conventional beams tends to produce hotspots. The 
addition of the FFF beam in (b) gives an overall distribution that is much more even in dose (c). 
 
One of the most commonly used conventional planning techniques is the use of 
angled wedged pairs as seen in figure 5.6. Although the wedges act to even out the 
dose distribution to produce a box shape, it also generally produces two hotspots 
under the thin parts of the wedges. For the 10x10cm2 beams shown these hotspots are 
at 105% and this value is seen to increase as the field size increases. Whilst these 
values are acceptable within the +7/-5% ICRU recommendations they are obviously 
not ideal, especially since they occur away from the centre of the tumour. If hotspots 
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are to exist then it is preferable for them to be within the tumour itself, away from 
surrounding normal (dose limiting) tissues. 
By simply substituting these for FFF beams the hotspot drops to only 101% and 
target coverage is maintained. This effect could obviously be achieved by other means 
(e.g. by IMRT, or the addition of a lateral beam) but this achieves the same result 
with no further complications in technique. 
 
(a)     (b)     
 
Figure 5.6. Comparison of plans for an angled wedged pair arrangement with 10x10cm2 beams. The 
conventional plan (a) exhibits hotspots of 5% compared to the plan with unflattened beams (b) in 
which the forward peak of the radiation beam ‘fills-in’ the dose to the beam centre. 
 
Unflattened wedges retain the characteristic shape of wedged fields, albeit with a 
more rounded profile. This is useful as many wedge applications occur in situations 
where the body is curved (such as the head & neck or breast) and/or at shallow depth 
(<10cm). Under these conditions the beam is over-flattened by the flattening filter 
producing horns (figure 5.7), leading to hotspots at the beam edge. The use of an 
unflattened wedge reduces the dose at the periphery, evening out the dose 
distribution. 
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Figure 5.7. Comparison of measured wedge profiles for a 20x20cm2 field, normalised at dmax. Profile 
depths are at 15, 50 and 100mm. 
 
Figure 5.8 shows the results of increasing field size on an angled wedged pair 
applied to a phantom. As the field size increase so does the size of the hotspot. The 
FFF beams act to counteract this by filling in the dose to the centre of the target. 
 
Figure 5.8. Graph depicting the increasing value of the planning hotspot with increasing field size for 
a wedged-pair distribution. 
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Another interesting situation is the half-beam block which, for a FFF beam, is 
seen to produce a wedge-shaped distribution. Again this wedge angle can be modified 
by altering the relative weighting of flattened to unflattened beams. The shape of the 
wedge is like a half cone, falling off in all directions from the central value (figure 
5.9). 
 
 
 
Figure 5.9. A half-beam blocked FFF beam produces a dose distribution similar to that of a 
conventional wedged beam. By changing the relative weights of the FFF and 6MV beams it is 
possible to create a ‘wedge’ angle between these two extremes. 
 
The addition of a conventional flattened beam can again be used to modify this 
‘wedge’ angle anywhere between the maximum (fully FFF) and minimum (fully 
flattened) by changing the relative weights of each beam. A three-quarter beam block 
produces a field that slopes from one diagonal to the other i.e. that is wedged in two 
directions at the same time. 
 
5.3 Breast planning 
Breast planning has been traditionally performed in a relatively simple manor using 
tangential wedged fields but has undergone a revolution in recent years with the 
advent of forward-, inverse- and hybrid planning techniques. Hotspots of 10-15% in 
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the dose distributions are not untypical and are located at the superior and inferior 
portions of the breast where the entrance-exit distance of the tangential beams is 
significantly shorter than on the central plane (figure 5.10). This is a direct 
consequence of using flat radiation fields on such a curved target region. 
 
  
 
Figure 5.10. A typical breast plan highlighting the hotspots seen in a conventional plan. 
 
To cover the entire volume uniformly a plan really needs to incorporate 
forward/inverse planning techniques or the use of custom made tissue compensators. 
The unflattened beam can be used to boost the dose to this central region, evening 
out the dose across the target volume with no further complication in technique 
(figure 5.11). The degree of boosting can be tailored by the relative weighting of flat 
and unflattened beams. 
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Figure 5.11. By combining the conventional plan with a FFF beam the central region can be boosted 
(without further field shaping) to produce an even dose distribution. 
 
5.4 Lung planning 
In general small beams are used when planning treatments for lung tumours, with 
the main objective being to treat the tumour without compromising lung function. 
Figure 5.12 shows a comparison of plans for a typical lung case. No real differences 
are seen in the dose distribution except for small variations above 90-95% of the 
prescription dose. No real gains are seen in planning with un-flattened beams, but a 
significant benefit may come from the increased dose rate and associated benefits to 
gated breathing; a doubling in dose rate obviously allows the treatment to be 
performed in half the time. 
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(a)   (b)   
 
Figure 5.12. No major differences are seen in the plans produced (a) with and (b) without the 
flattening filter in place except in the central target region. 
 
5.5 Stereotactic radiosurgery 
It has already been shown (chapter 4) that the flattening filter has very little effect on 
beam profiles for small fields (i.e. <5cm2). For these beams the flattening filter is 
essentially an unnecessary component. 
To test the FFF beam model a series of clinically accepted patient plans were re-
calculated with the FFF model. Three plans were selected: an acoustic neuroma, a two 
lesion brain metastisis and an ateriovenous malformation (AVM). BrainLab’s 
BrainSCAN version 5.31 (BrainLAB, AG, Germany) was used to generate a treatment 
plan using a Clarkson dose algorithm. 
 123 
 
 
 
 
 
Figure 5.13. Typical beam arrangement for SRS 
plans designed with non-opposing beams so 
that the entrance and exit doses do not overlap. 
 
The acoustic neuroma plan required 2 isocentres to cover the 2.42cc PTV. One 
isocentre used a 20mm collimator of 4 arcs (1000, 1000, 850, and 1000) and the 
second used a 10mm collimator with three 1000 arcs (figure 5.13). The dose to the 
lesion (2.42cc), brainstem (14.31cc) and normal brain (3005.58cc) were assessed. The 
number of arcs and monitor units required for each plan are presented in table 5.1. 
 
Table 5.1. Monitor units required to deliver each of the SRS plans for the cases indicated. 
 
Plan Arcs 6MV 6MV FFF 
Acoustic Neuroma 7 3703 3715 (+0.3%) 
2 Metastasis 9 6105 6091 (-0.2%) 
AVM 12 9971 10026 (+0.6%) 
 
No significant changes in the number of monitor units needed to deliver the 
plans are seen. The treatment plans show very little effect when switching to the FFF 
beam model, as would be expected as the flattening filter has no real effect at small 
field sizes (figure 5.14). The dose coverage and dose volume histograms for the targets 
remain unchanged in each case; however additional tissue sparing is seen for 
brainstem and normal brain for FFF. The most significant differences were observed 
for the low isodoses. These effects are studied further in chapter 7. 
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Figure 5.14. Axial, sagital and coronal sections through an ateriovenous malformation (AVM) (6MV 
FFF plan). 
 
5.6 IMRT planning 
Studies have shown that IMRT plans can be successfully generated with FFF beam 
models to produce usable plans but with an increase in the number of segments and 
monitor units needed. These studies, however, used the beam energy as it exits the 
machine (4MV Varian (Vassiliev et al 2006), 5MV Elekta (Fu et al 2004) so any 
differences observed could simply be due to this change in energy rather than any 
inherent property of unflattened beams. Critically in this work the beam energy has 
been raised back to the nominal energy by matching D10 (67.5%) and QI/TPR20/10 
(0.675). By raising the beam energy back to nominal values any differences in 
treatment plans can be correctly evaluated without reference to changing beam 
energy. 
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5.6.1 XiO IMRT 
A series of 11 paediatric head and neck patients were outlined by a consultant 
paediatric oncologist for IMRT planning. For each case a plan has been produced 
using the conventional IMRT beam model in the XiO TPS. When a set of dose 
constraints had been found to produce an optimised plan they were used in turn to 
produce conventional and unflattened treatment plans (thus removing any inter-
planner or inter-plan bias from the system). Plans have been evaluated for target 
coverage using the criteria in table 5.2. 
 
Table 5.2. Summary of dosimetric parameters used for IMRT plan evaluation. 
V90 Volume of target (%) receiving 90% of prescribed dose 
V95 Volume of target (%) receiving 95% of prescribed dose 
V100 Volume of target (%) receiving 100% of prescribed dose 
V107 Volume of target (%) receiving 107% of prescribed dose 
D2 Dose to 2% of volume 
D98 Dose to 98% of target volume 
HI Homogeneity index (D2-D98/Dose prescribed)*100 
VPTV Volume of PTV 
CI Conformity Index V95/TV 
 
Dose priorities changed for each case but in general the PTV was given priority 
and doses to critical structure lowered until the PTV dose started to become 
compromised. The number of beams and their gantry angles remained the same in 
each case (generally 5 equally spaced fields) unless significant differences were 
observed between plans or planning objectives not met. There should, of course, be 
no reason why IMRT without the flattening filter could be not be used as long as the 
beam is accurately modelled within the TPS and the segmentation process takes this 
into account. 
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Table 5.3. Target coverage for each of the indicated IMRT plans. 
 
 Plan1 Plan2 Plan3 Plan4 Plan5 
 
6MV 
6MV 
FFF 
6MV 
6MV 
FFF 
6MV 
6MV 
FFF 
6MV 
6MV 
FFF 
6MV 
6MV 
FFF 
V90 99.1 99.1 98.1 98.3 99.8 99.6 99.4 99.5 98.6 98.9 
V95 96.4 95.7 91.3 91.9 97.9 96.6 93.3 94.2 90.5 90.9 
V100 50 50 50 50 50 50 50 50 50 50 
V107 0.05 0 1.2 0.7 0 0.5 0.1 0.1 0 0 
D2 56.2 56.1 57.3 57.1 56.0 56.8 56.1 56.2 56.1 56.4 
D98 50.5 50.3 48.6 48.9 51.2 50.7 50.1 50.2 49.2 49.3 
HI 11.3 11.5 17.3 16.3 9.5 12.1 11.9 11.9 13.7 14.1 
VPTV 310 310 362.9 362.9 60.2 60.2 431.6 431.6 471.9 471.9 
CI 0.964 0.957 0.913 0.919 0.979 0.966 0.933 0.942 0.905 0.909 
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Table 5.4. Organ at risk sparing for each of the indicated IMRT plans. 
 
 Plan1 Plan2 Plan3 Plan4 Plan5 
 
6MV 
6MV 
FFF 
6MV 
6MV 
FFF 
6MV 
6MV 
FFF 
6MV 
6MV 
FFF 
6MV 
6MV 
FFF 
Lt Eye 27.9 28.6 - - 7.9 6.3 44.0 43.5 12.5 12.4 
Rt Eye 30.7 30.2 41.8 42.1 7.7 6.6 51.6 52.1 14.0 13.4 
Optic Chiasm - - - - 23.5 21.1 - - - - 
Brainstem - - 53.9 53.9 - - 55.7 55.5 - - 
Spinal cord - - 40.8 41.3 - - - - - - 
Lt cochlea - - 38.3 39.9 - - - - 41.9 41.7 
Rt cochlea - - - - - - - - 41.1 41.2 
Pituitary 54.3 53.2 - - - - - - - - 
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Table 5.5. Segments and monitor units required to deliver identical plans by different each method. 
 
Case No. fields 6MV 6MV FFF 
Ratio of 
segments 
Ratio of 
MUs 
  Segments MUs Segments MUs   
Plan1 5 123 22856 111 26327 0.90 1.15 
Plan2 7 168 24808 162 24502 0.96 0.99 
Plan3 5 103 18239 103 20363 1.00 1.12 
Plan4 7 164 22258 161 22528 0.98 1.01 
Plan5 5 90 18681 90 20291 1.00 1.09 
Plan6 5 121 25516 118 25820 0.98 1.01 
Plan7 5 70 15300 71 14798 1.01 0.97 
Plan8 5 61 13928 56 13883 0.92 1.00 
Plan9 5 94 16884 95 18762 1.01 1.11 
Plan10 5 86 14883 87 15992 1.01 1.07 
Plan11 5 100 26452 108 27477 1.08 1.04 
Plan12 5 54 12557 58 13453 1.07 1.07 
Plan13 5 86 17624 85 17924 0.99 1.02 
     Average 0.99 1.05 
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Conventional 5-field IMRT 
 
6MV FFF 5-field IMRT 
 
Figure 5.15. Transverse, sagital and coronal slices through the target region showing comparison 
between techniques conventional IMRT a) and IMRT with flattening filter removed, b) for a 
midbrain astrocytoma. 
 
For all planned cases the target coverage, homogeneity and OAR doses both with 
and without the flattening filter were the same (within statistical bounds). Figures 
5.14 shows slices through the target centre for one of the cases to illustrate the 
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similarity of the plans. Tables 5.3 and 5.4 list the target coverage, homogeneity and 
OAR doses for 5 planned cases with and without the flattening filter. Table 5.5 
compares the number of segments and MUs required to deliver the same dose 
distribution with the two techniques. 
The average ratio for the number of segments required for the 5 plans was 0.99 
and the MU ratio is 1.05 over 11 patients (13 plans). Where large differences are seen 
between conventional and unflattened delivery in terms of segments or MU it can be 
seen that moving to a 7-field plan brings these back in line with each other. 
There is therefore no significant effect on target coverage, OAR sparing, 
segments or monitor units required to deliver IMRT with unflattened beams 
compared to conventional use for these plans. The question remains as to whether 
the beams are more deliverable and simpler to calculate etc. 
 
5.6.2 Monaco IMRT 
In order to expose the FFF model to a range of conditions and test the beam model 
and the accuracy of the dose calculation, a series of treatments with increasing 
complexity and treatment volume were planned. These sites consisted of skull base, 
oesophagus, prostate, and head and neck cases. To test the model under the extreme 
influence of the unflattened beams, the isocentre for the prostate and head and neck 
plans were placed asymmetrically so that large parts of the fields were exposed to the 
off-axis region of the beam. 
For each plan, a set of constraints were found to give an optimal distribution. The 
plans were then re-optimised using the FFF beam model and adapted as necessary to 
fulfil the dose constraints. 
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Table 5.6. Number of segments and monitor units needed for each treatment plan, and the relative 
increase in each necessary to deliver the FFF plans. 
 
 
PTV 
Volume 
(cm3) 
Segments Monitor Units 
  6MV FFF % Diff 6MV FFF % Diff 
Skull Base 23.2 20 21 +5.0 416 446 +7.2 
Esophagus 555.4 64 67 +4.7 785 931 +18.6 
Prostate 804.5 66 68 +3.0 828 951 +14.9 
Head & Neck 918.7 168 183 +8.9 1343 1682 +25.2 
 
 
As the volume of the tumour (treatment length) and complexity of the plan 
increase there is a tendency to see an under-dosage in regions far from the central 
axis, which is seen as a sloping shoulder on the DVH curve. It is possible to 
compensate for this by further penalizing cold spots within the tumour, and in the 
Monaco TPS this can be achieved by increasing the cell sensitivity (α) of the tumour 
or adding a quadratic underdose penalty. This acts to maintain plan quality but 
brings about an increase in both the number of segments and monitor units needed 
to deliver the plan. It can be seen from Table 5.6 that as the treatment volume and 
plan complexity increase there is a corresponding increase in the number of segments 
and MU needed to deliver the FFF plans. Figure 5.16a shows a colour-wash dose 
distribution on sagital and coronal CT slices through the tumour for a head and neck 
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FFF IMRT plan. The dose volume histogram (figure 5.16b) indicates that the plans 
are equivalent in terms of both PTV coverage and organ at risk sparing. 
 
a) 
 
b) 
 
 
Figure 5.16. Beam setup for IMRT planning of a head and neck case showing sagital and coronal 
colorwash maps (a) and dose volume histogram (b). The FFF beam is displayed as the dotted line, 
6MV solid. 
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It has been observed that as the field sizes needed for planning increase then so 
do the number of MU required to deliver these plans; this is a natural consequence of 
the FFF beam profile since it will require longer beam on times to deliver doses off-
axis. The complexity of the plan is also seen to increase the number of segments 
required to treat the FFF plans compared to the conventional IMRT plans if plan 
quality is to be maintained. This may be more specifically related to the fact that 
segmentation algorithms are optimized for flattened rather than unflattened beam 
profiles. Commercial planning systems do not currently consider the non-flat beam 
profile during optimization. This is discussed in further detail in chapters 6 and 8. 
 
5.7 VMAT 
5.7.1 Prostate 
Retrospective studies (e.g. Zelefsky et al 2001 & 2002) show that IMRT can provide 
lower treatment toxicity than 3DCRT for localised prostate cancer without 
compromising tumour control. VMAT is now used routinely in many centres around 
the world as a technique to provide fast IMRT delivery using either single or multiple 
arcs (see Appendix A), resulting in significantly reduced delivery times. 
A study was carried out to retrospectively compare standard 3DCRT with IMRT 
and VMAT techniques using conventional 6MV and 6MV FFF beams. Five patients 
were randomly selected and re-planned and assessed according to departmental 
protocol. The PTV coverage for each plan is summarised in table 5.7, and the doses to 
organs at risk presented in table 5.8. 
Significant differences (determined by a 2-tailed, paired T test) were seen for a 
number of dose parameters, as noted in each table. On moving to modulated 
techniques extra sparing of the bladder was possible and a reduction in the mean and 
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maximum doses received by the hips. No significant differences were observed 
between 6MV and 6MV FFF plans. Comparing VMAT plans the only parameter that 
reached significance was the (near-) maximum dose (D2) delivered to PTV2, but in 
reality, although significant, this only amounts to a dose difference of 0.1Gy. IMRT 
and VMAT are therefore of very similar quality for 6MV flattened or unflattened 
beams. 
As expected, significantly more MU are required to deliver IMRT compared to 
3DCRT (table 5.9). For the 6MV beam the average increase was 38.0%, and for the 
FFF beams this increased to 66% representing a 20.2% overall increase in MU in 
moving from conventional to FFF delivery. This is expected because of the shape of 
beam and the necessity to deliver dose off-axis. There is also a much larger variation 
in the number of MU required for FFF delivery compared to standard IMRT, but no 
increase in the number of segments required or the delivery time. 
For VMAT delivery further MU are needed, with an extra 15.2% for 6MV and 
3.4% for FFF compared to IMRT. There is also a reduction in delivery time 
transferring from IMRT to VMAT of approx. 54% using either technique. The FFF 
beam model does not include the dose rate enhancements that will be available on 
the clinical machine, both models delivering dose at a maximum of 600 MU/min, so 
a shorter delivery time will be expected for FFF in reality. 
Figure 5.17 shows a screenshot from the Monaco TPS to illustrate the beam 
arrangements used for the treatment planning techniques. The VMAT plans are 
optimised over a reduced gantry rotation to avoid entering through the treatment 
couch as this is not currently modelled to sufficient accuracy within the TPS. 
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Table 5.7. Summary of PTV coverage and OAR doses for prostate plans optimised by 3DCRT, IMRT and VMAT for standard and FFF delivery. Numbers in 
brackets are ±1SD. 
 
   
IMRT VMAT Significance 
Organ Parameter 3DCRT 6MV 6MV FFF 6MV 6MV FFF  
PTV3 D99 71.1 (0.5) 71.2 (0.2) 71.0 (0.2) 71.1 (0.3) 71.1 (0.2)  
140.2cc (±133.8cc) D95 72.0 (0.6) 72.0 (0.2) 71.9 (0.2) 72.1 (0.1) 72.0 (0.1)  
 
D50 74.1 (0.3) 74.0 (0.0) 74.0 (0.0) 74.0 (0.0) 74.0 (0.0)  
 
D2 75.9 (0.5) 76.5 (0.2) 76.5 (0.2) 76.5 (0.1) 76.6 (0.1) b, e,  
PTV2 D99 68.3 (0.4) 68.6 (0.1) 68.5 (0.5) 69.0 (0.3) 68.3 (0.3) b, d, f 
211.4 (±172.5) D50 73.6 (0.2) 73.3 (0.2) 73.4 (0.1) 73.4 (0.2) 73.3 (0.2)  
PTV1 D99 58.9 (3.1) 59.9 (1.3) 59.3 (1.8) 60.0 (2.1) 59.6 (2.1)  
292.0 (±173.4) D50 71.5 (2.2) 71.6 (2.0) 71.6 (2.0) 71.6 (2.1) 71.5 (2.2)  
 
a = 3DCRT vs. IMRT, b = 3DCRT vs. 6MV VMAT, c = 6MV IMRT vs. 6MV FFF IMRT, d = 6MV IMRT vs. 6MV VMAT, e = 6MV FFF IMRT vs. 6MV FFF VMAT, f = 
6MV VMAT vs. 6MV FFF VMAT. 
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Table 5.8. Summary OAR doses for prostate plans optimised by 3DCRT, IMRT and VMAT for standard and FFF delivery. Numbers in brackets are ±1SD. 
 
   
IMRT VMAT Significance 
Organ Parameter 3DCRT 6MV 6MV FFF 6MV 6MV FFF  
Rectum V50 50.5 (9.0) 48.1 (6.6) 47.9 (5.8) 46.6 (8.0) 47.5 (8.0)  
67.2 (±12.8) V60 32.2 (6.4) 30.9 (6.8) 30.4 (6.7) 31.3 (8.0) 31.5 (6.9)  
 
V65 17.2 (2.0) 16.7 (2.7) 16.8 (2.2) 21.4 (9.2) 21.2 (8.3)  
 
V70 5.6 (2.0) 7.7 (2.4) 7.2 (2.1) 13.4 (11.1) 12.6 (11.0)  
 
V74 0.2 (0.4) 2.5 (4.3) 0.5 (0.4) 6.4 (12.6) 6.3 (12.4) b,  
Bladder V50 37.4 (11.6) 32.4 (9.7) 32.4 (9.8) 34.4 (8.2) 34.7 (8.6) a, b, d, e 
229.1 (±109.9) V60 26.5 (10.8) 23.4 (9.0) 23.6 (9.1) 25.0 (81.) 25.0 (8.4) a, b,  
 
V74 2.4 (1.0) 3.0 (2.3) 3.5 (2.8) 6.2 (5.5) 6.1 (5.6)  
Lt Hip Max 46.9 (3.9) 42.2 (10.3) 42.9 (9.3) 40.1 (4.1) 40.8 (4.0) b,  
59.0 (±4.6) Mean 35.4 (13.3) 27.3 (12.4) 27.2 (12.3) 23.2 (6.8) 23.3 (7.0) a, b,  
Rt Hip  Max 47.6 (1.9) 46.8 (6.1) 47.2 (4.5) 39.0 (7.7) 37.6 (7.1) e 
62.2 (±8.2) Mean 36.2 (10.5) 31.9 (5.4) 31.6 (4.7) 21.8 (5.3) 21.9 (6.4) b, d 
a = 3DCRT vs. IMRT, b = 3DCRT vs. 6MV VMAT, c = 6MV IMRT vs. 6MV FFF IMRT, d = 6MV IMRT vs. 6MV VMAT, e = 6MV FFF IMRT vs. 6MV FFF VMAT, f = 
6MV VMAT vs. 6MV FFF VMAT. 
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Figure 5.17. Sample screenshot from Monaco showing prostate plans for three treatment techniques. Top left: 5 field IMRT, bottom left: VMAT, bottom right: 
field-in-field 3DCRT (XiO). In the top right is DVH comparing the PTV coverage and OAR sparing of each technique. 74Gy in 37# prescribed. 
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Table 5.9. Number of MU, segments and estimated time to deliver prostate radiotherapy by 3DCRT, 
IMRT and VMAT (averaged over 5 patients). Numbers in brackets are ±1SD. 
 
 
MU 
Number of 
Segments 
Time (s) 
3DCRT 526 (35.0) a, b 6 - 
IMRT 726 (80.3) a, c, d 56.8 (8.9) d 300 (32.1) d 
IMRTFFF 873 (180.2) c 55.8 (13.8) e 315 (47,.2) e 
VMAT 836 (55.8) b, f 101.6 (14.8) d, e 139 (7.7) d 
VMATFFF 903 (63.1) f 95.8 (2.2) 142 (7.0) e 
 
a = 3DCRT vs. IMRT, b = 3DCRT vs. 6MV VMAT, c = 6MV IMRT vs. 6MV FFF IMRT, d = 6MV IMRT 
vs. 6MV VMAT, e = 6MV FFF IMRT vs. 6MV FFF VMAT, f = 6MV VMAT vs. 6MV FFF VMAT. 
 
 
5.7.2 SBRT / SABR 
Stereotactic body radiotherapy is intimately tied to image-guidance, without which it 
would not be possible to deliver the high doses of radiation with the necessary 
precision. SBRT was first developed at the Karolinska Institute in the 1990s along the 
same lines as intra-cranial radiosurgery. Multiple beams are directed towards the 
target to deliver a high radiation dose, sparing the surrounding critical organs, 
typically heart, spinal cord, oesophagus, and the lungs themselves. Recently SBRT 
has been renamed to SABR (stereotactic ablative radiotherapy) to standardise the 
naming used across countries. SABR techniques are used most often in the treatment 
of lung cancers where local control rates of >95% are seen for peripheral stage 1 non 
small cell lung cancer (NSCLC) (Timmerman et al 2003). 
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A range of planning techniques can be used for SABR treatments including 
3DCRT, IMRT and VMAT. Because of the small field size and relatively low 
modulation involved in these plans it is desirable to use VMAT as this should be able 
to deliver the radiation in the shortest time period. In fact, because of the high dose 
per fractions used the use of FFF should significantly reduce treatment times when 
operating in high dose-rate mode. 
A short planning study was undertaken to ensure the plan quality of FFF VMAT 
plans against the standard technique used in our centre (3DCRT) and against 
conventional VMAT at 6MV. Three patients treated under SABR protocol were 
planned by each method and the target and OAR doses recording according to 
standard protocol. The data for these comparisons are reported in tables 5.10 and 5.11 
below. Figures 5.18 and 5.19 show plan comparisons for Plan1 and Plan2 respectively. 
There is a significant increase in the number of MU required to deliver FFF plans 
via VMAT compared to the standard beam (20.2%) which is much greater than for 
other series reported in the literature e.g. Zhang et al saw an increase of 8.7% for FFF 
VMAT delivery on the Varian TrueBeam accelerator. This difference is explained by 
the fact that the plans produced in this study have the beam isocentre not at the 
centre of the PTV, but at the centre of the body. This allows the patient to be set up in 
the middle of the couch allowing unrestricted rotation of the cone-beam CT unit for 
image-guidance (see figure 5.18). The tumour is then a considerable distance off-axis, 
requiring more MU for the FFF delivery. 
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Table 5.10. PTV coverage and OAR doses for 3 SABR lung cases. Each case has been planned with 3DCRT, 6MV VMAT and 6MV FFF VMAT as indicated. 
 
 
Volume 
(cc) 
XiO 6MV 
6MV 
FFF 
Volume 
(cc) 
XiO 6MV 
6MV 
FFF 
Volume 
(cc) 
XiO 6MV 
6MV 
FFF 
Prescription 
 
Plan 1: 55Gy / 5# 
 
Plan2: 60Gy / 8# 
 
Plan 3: 55Gy / 5# 
PTV 129.4 
   
97.6 
   
29.5 
   
D95 
 
55.2 55.0 55.0 
 
60.1 60.0 60.0 
 
55.31 55.0 55.0 
D99 
 
52.9 52.3 52.3 
 
56.5 57.5 57.5 
 
52.9 54.1 54.2 
1cc max 
 
69.1 72.2 69.9 
 
71.7 72.6 71.7 
 
75.3 62.5 62.1 
V100%/VPTV 
 
1.03 1.09 1.06 
 
1.10 1.04 1.06 
 
1.17 1.28 1.21 
V50%/VPTV 
 
3.23 3.33 3.36 
 
4.02 4.00 4.15 
 
5.54 6.91 7.02 
Max > 2cm 
 
35.86 36.31 34.31 
 
39.27 39.86 37.88 
 
76.6 64.7 64 
OAR 
            
D0.01 Cord 62.7 20.95 20.3 19.5 79.3 11.1 7.8 5.4 74.3 6.7 9 9.7 
D0.1 Oesophagus 22.5 14.05 14.05 12.6 48.7 12.2 11.1 9 31.2 10.4 7 4.2 
Heart 0.1 465.9 23.95 24.3 23.5 956.0 49.2 44.2 45 625.9 10.8 6.8 3.6 
D0.1 
Trachea/Bronchus 
31.7 26.2 28.6 26.2 37.4 6.75 14.6 14.6 61.6 12.5 9.4 11 
V20 Lungs - GTV exhale 4179.7 11.55 10.93 10.81 5957.9 6.35 6.31 6.9 5976.7 4.45 7.16 6.59 
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Table 5.11. MU, segments and delivery time for each of the plans in table 5.10. 
 
 
 
 
 
Plan 1 Plan 2 Plan 3 Average (±SD) 
 
3DCRT 6MV FFF 3DCRT 6MV FFF 3DCRT 6MV FFF XiO 6MV FFF 
MU 1680.1 2743 3760 1086.5 2449 2916.4 2316.4 3602.7 4465.6 
1694.3 
(615.1) 
2931.6 
(599.5) 
3714.0 
(775.6) 
Segments 7 72 85 8 91 91 7 85 98 
7.3 
(0.6) 
82.7 
(9.7) 
91.3 
(6.5) 
Time (s) 
 
288.1 376.3 
 
251.2 296.4 
 
428.8 499.6 
 
322.7 
(93.7) 
390.8 
(102.4) 
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Figure 5.18. Lung SABR plan (Plan1 of Table 5.10) showing the 7-field 3DCRT beam arrangement (top left), and single arc VMAT plans for 6MV (bottom left) and 
6MV FFF (bottom right). 
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Figure 5.19. 6MV and 6MV FFF VMAT plans for Plan 3 showing a 3-arc beam arrangement to avoid the right arm. 
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5.8 Discussion and conclusions 
Treatment without the flattening filter offers many potential benefits both in terms of 
treatment planning and machine operation. The main application for unflattened 
beams is seen to be for small-field applications where the beam profile is unaffected 
by FF removal, and for modulated techniques since the intensity profile can easily be 
modulated by the MLCs to alter the profile as necessary. Now that treatment 
machines are clinically available for unflattened delivery these FFF techniques should 
quickly gain popularity as a way of providing faster, more accurate dose delivery with 
whole body doses half that of current levels. The possibility of using non-flat beams in 
general planning only strengthens the case. 
The literature covering the uses of FFF beams for 3DCRT is currently very 
limited with only one author dedicating any time to their properties (Kretschmer et al 
2013). 
Far from being unusable the forward peak could be very useful as this central 
axis boost is exactly what is needed under many treatment circumstances. An 
unflattened beam is, of course, not appropriate in all planning situations in much the 
same way as a wedge is not always appropriate. As with all treatment planning the 
choice of energy/wedge angle etc. is chosen according to the individual needs of the 
case at hand; the same reasoning should be applied here. 
FFF VMAT techniques have now been studied for a variety of treatment sites 
(Nicolini et al 2012, Zwahlen et al 2012, Scorsetti et al 2011, Zhang et al 2011, Zhuang 
et al 2012, Alongi et al 2013) and found to produce plans of equivalent quality to 
those seen for standard flattened beams. 
 The greatest gain in moving towards FFF delivery comes from the increased dose 
rate and associated reductions in treatment time. Intra-fraction movement of the 
tumour and surrounding tissues is still an issue, even with daily image-guidance, so 
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reducing the time for delivery is still of great benefit. Reduced treatment times also 
aid throughput on the accelerator allowing more patients to be treated, and for the 
patient to be more comfortable. The potential of FFF to reduce scatter and leakage 
doses is also of importance and is discussed in chapter 7. 
It is interesting to note that even though treatment planning systems are not yet 
fully optimised for FFF beams (see chapter 8) plan quality is still maintained between 
techniques. The variation in the number of MU required for VMAT delivery for FFF 
techniques (seen in table 5.9) might be indicative of this fact. Hopefully once these 
modifications take place further increases in plan quality, calculation accuracy and 
speed may be possible. 
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CHAPTER 6 
 
IMRT VERIFICATION 
 
In the previous chapters it was demonstrated that unflattened beams can be 
successfully modelled and used to create treatment plans for both conventional and 
intensity modulated treatments. It is a logical step to then assess the accuracy of the 
dose prediction against machine measurements. A key benefit of filter removal is the 
reduction in head scatter which could possibly lead to greater accuracy in dose 
calculation. 
In this chapter we will discuss the verification of IMRT delivery on the linac for 
plans generated in the XiO and Monaco treatment planning systems. 
Parts of this chapter have been published by the author (Cashmore et al 2011, 
Cashmore et al 2012). 
 
6.1 Introduction 
The key to any improvements in the accuracy of dose calculations for FFF beams 
originate in the reductions in head scatter, as discussed in previous chapters. The 
flattening filter adds further degrees of complexity to dose modelling by creating a 
significant source of extra-focal radiation and the need to model the changing energy 
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spectrum with off-axis position. This makes the small, complex, off-axis and often 
elongated fields used for IMRT delivery particularly problematic, leading to 
uncertainties in the dose calculation. The consequences of this are the need to 
perform patient specific quality assurance tests on IMRT plans before delivery to the 
patient (appendix A). 
With a key source of extra-focal radiation removed both the magnitude and 
variation of head scatter with field size is reduced as discussed in chapters 2 and 3. 
 
6.2 Head scatter predictions 
To test the validity of these arguments a simple test was devised: a step-and-shoot 
IMRT plan for a head & neck treatment was delivered segment-by-segment in order 
to measure the head scatter component of each field and compare these against XiO 
predictions. The plans for each delivery mode were optimised independently to 
achieve the dose objectives using the XiO TPS. These were then transferred to the 
linac and measurements of head scatter made using a Farmer chamber (NE 2571) 
fitted with a 2mm brass cap. For each segment of a beam the chamber was moved to 
a suitable point to take a measurement of the Sc for that field. Head scatter 
measurements are presented relative to a 10x10cm2 field and compared to the 
predictions from XiO. 
Referring to figure 6.1 it is clear that for each of the FFF segments delivered the 
variation in head scatter is reduced compared to that seen for the standard 6MV 
beam. In each case the TPS predictions for Sc are also closer to the measurements for 
the FFF beam. 
In figure 6.2 these results are plotted showing the difference between prediction 
and measurement for each segment. The mean error, represented by the horizontal 
lines, is reduced from 0.9% to 0.5% for FFF operation. 
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Figure 6.1. Head scatter measured using a brass build-up cap vs. segment number. 
Measurements were made at the centre of the segment and are relative to a 10x10cm2 reading at 
the same position. 100 x (Measured - XiO) / Measured. 
 
Figure 6.2. Percentage difference from TPS predicted value for each segment. The horizontal lines 
indicate the mean error for each of the two beams. 
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It is also interesting to note the variation in the magnitude of the error with 
segment number. Segments at the beginning and end of the beam delivery have a 
much larger deviation from predictions than those in the middle (segments 7 to 13). 
This can be explained with reference to figure 6.3. XiO uses a sliding window 
segmentation algorithm, attempting to optimise fluence delivery by minimising leaf 
travel between segments over the course of the delivery. Segments therefore sweep 
from one side to the other. 
The mid-range segments are usually fairly large and centrally placed compared to 
those at the beginning and end of the beam that are often small, elongated and off-
axis. These are the situations where dose modelling is most problematic and the dose 
predictions are therefore less accurate for these segments. 
 
   
Segment 1 Segment 10 Segment 18 
 
Figure 6.3. Sample segments from the measured field to illustrate the variation in beam size/shape 
and position with increasing segment number. Segments at the beginning and end tend to be smaller 
and off-axis, whilst midpoint segments are larger and nearer the central axis. 
 
This helps to validate the assumption that by reducing the range of possible 
values for head scatter (less variation with field size) it is possible to more accurately 
predict its value. 
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6.3 XiO IMRT 
Treatment plans were generated for 3 cases; breast (40Gy in 15 #, with a 5 Gy boost 
to the tumour bed), a parotid carcinoma (2 dose levels, 65Gy to PTV1, 54Gy to nodes 
in 30#) and an oropharynx case (65Gy to PTV1, 60Gy PTV2, 54Gy PTV3 in 30#). 
Each was planned according to standard departmental or clinical trials guidelines. 
For each case a set of dose constraints was found to give an optimal plan for both the 
flattened and unflattened beam models. 
These plans were then transferred to a solid water (WT1) phantom setting a 
nominal gantry angle of 0° (95cm SSD), and re-calculated. Fluence maps were 
generated at a depth of 5cm within the phantom and transferred to a 2D array 
(MatriXX, IBA, Germany) for verification. 
The MatriXX is a two dimensional array consisting of 1024 parallel plate 
cylindrical ionisation chambers in a 32x32 matrix arranged over a 24x24cm area. 
Each detector has a diameter of 4mm and a height of 5.5 mm giving a sensitive 
volume of 70 mm3. The centre to centre distance between each ionisation chamber is 
7.5mm. The array is calibrated both for uniformity (to account for variations in 
detector response across the array), and for absolute dose by reference to a 10x10cm2 
field. The FFF beam exhibits not only a variation in fluence across the field compared 
to standard operation, but a significant change in beam spectrum too. An 
independent set of calibration factors were therefore determined for the FFF beam 
before measurements were taken. Each reading is background corrected. 
Figure 6.4 shows the array response to an exposure from a 24x24cm2 FFF beam 
to demonstrate the detector spacing and response to the forward peaked beam. 
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Figure 6.4. 24x24cm2 open field delivered to the MatriXX array demonstrating chamber separation 
and forward-peaked nature of the FFF beam. 
 
The fluence maps are also corrected for difference in output by delivering a 100 
MU 10cmx10cm2 field, measuring the dose at the centre of the field and then 
rescaling the fluence maps to correct for the difference in output on the day of 
measurement. 
A region of interest encompassing the whole segment was used when calculating 
the gamma value and a tolerance of 3% dose and 3mm distance was used. Gamma 
index evaluation was performed using OmniPro I’mRT (v1.6, IBA dosimetry). Figure 
6.5 shows a sample fluence map and gamma analysis from one of the plans. In figure 
6.6 (a) to (c) individual pass rates for each of the fields for plans 1 to 3 are presented. 
The number of points with γ < 1 should be greater than 95% in order for that 
beam to pass and it can be seen from these figures that all of the beams from all plans 
pass this comfortably. With the filter removed there is a trend towards greater 
consistency and a higher percentage of points passing the gamma evaluation than for 
conventional delivery - this trend was observed for relative and absolute doses in all 
of the plans delivered.  
950-1000
900-950
850-900
800-850
750-800
700-750
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550-600
500-550
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Figure 6.5. Results from the intensity-modulated radiotherapy quality assurance analysis of Case 3. (a) 
typical fluence map (beam 1), (b) gamma analysis (3%/3 mm) two-dimensional array vs. treatment 
planning system. 
  
 
 
Figure 6.6. Gamma pass rates for each of the 3 IMRT plans. Plot of percentage of points passing 
evaluation for each beam. 
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6.4 Monaco IMRT 
A similar experiment was carried out with the Monaco TPS as part of the validation of 
the virtual source model (VSM 1.6) for FFF beams. In order to expose the FFF model 
to a range of conditions a series of plans in the head and neck, skull base, oesophagus 
and prostate were generated. To test the model under the extreme influence of the 
unflattened beams, the isocentre for the head and neck plan was placed 
asymmetrically, so that large parts of the fields were exposed to the off-axis region of 
the beam. Plans were calculated on a 2mm grid spacing and a MC variance of 2%. 
Figure 6.7 shows a colourwash representation of the dose in the sagital plane of the 
head and neck case, and the associated fluence map. 
 
a) 
 
b) 
 
 
Figure 6.7. Beam setup for IMRT planning of a head and neck case showing relative fluence map (a) 
and colourwash dose display (b). 
 
The beams for each plan were transferred to a cylindrical phantom representing 
the Delta4 QA device and re-calculated. The Delta4 (ScandiDos, Uppsala, Sweden) is a 
cylindrical phantom for pre-treatment patient QA. Absolute dose is measured using 
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1069 p-Si diode detectors arranged in two orthogonal detector arrays. The spacing 
between each detector is 5mm over the central region (8x8cm2) and 10mm outside 
this (20x20cm2). The diameter of each detector is 1mm. Properties of the phantom 
have been described in detail by Bedford et al (2009). 
Figure 6.8 shows a sample beam from an the head and neck plan demonstrating 
a) the fluence map generated by Monaco, b) the fluence recorded for that field and c) 
the difference map between calculated and measured data. 
(a)  (b) 
(c)  
Figure 6.8. Sample beam from an asymmetric Head and Neck plan a) Fluence map generated by 
Monaco, b) fluence recorded by 2D array, c) difference map. 
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Table 6.1. Gamma analysis and absolute dose difference of individual beams for the IMRT plans. 
Percentage of points passing gamma analysis (γ < 1) at 3%/3mm and 2%/2mm for the individual 
beams of each plan. 
 
Treatment 
site Beam 
Gamma 
analysis 
3%/3mm 
Gamma 
analysis 
2%/2mm 
Absolute dose 
difference (%) 
  6MV FFF 6MV FFF 6MV FFF 
Skull base 1 100.0 100.0 99.5 100.
0 
-0.8 0.2 
 2 99.8 100.0 93.5 92.4 -0.2 0.5 
 3 100.0 99.8 90.6 89.4 -0.9 -0.1 
 4 99.8 99.3 92.9 92.3 -0.1 0.0 
 5 99.8 100.0 92.4 91.2 -0.6 0.1 
Oesophagus 1 100.0 99.0 98.3 89.9 0.6 1.2 
 2 100.0 99.8 99.1 95.9 0.0 1.0 
 3 100.0 100.0 100.0 99.8 -0.1 0.3 
 4 100.0 100.0 100.0 99.1 -0.7 0.5 
 5 100.0 99.8 98.8 97.2 0.2 1.0 
Prostate  1 99.4 97.2 93.5 86.2 0.8 1.4 
+ nodes 2 99.8 100.0 97.6 98.4 0.2 0.7 
 3 100.0 99.8 97.7 92.8 0.1 0.9 
 4 100.0 100.0 98.8 98.8 0.0 0.7 
 5 100.0 99.9 98.0 94.9 0.0 0.6 
Head & neck 1 97.7 98.3 87.8 84.8 0.9 1.4 
 2 100.0 98.8 97.6 94.6 0.4 1.1 
 3 99.7 99.5 97.5 94.3 0.3 1.1 
 4 99.5 100.0 95.7 96.9 0.3 0.9 
 5 99.4 99.2 92.0 84.0 0.4 1.2 
 6 99.1 98.3 94.4 87.6 0.6 1.3 
 7 99.7 99.8 97.5 95.8 0.3 0.9 
    Average 0.1±0.4
9 
0.8±0.4
6  
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Table 6.1 shows the absolute dose differences and statistics for the gamma 
analysis of the sample plans analyzed at both 3%/3mm and 2%/2mm acceptance 
criteria. It can be seen that as the volume of tumour and the complexity of the plan 
increase the pass rate begins to fall (as expected), but all plans pass the standard 
IMRT acceptance criteria of 95% of points <1 using a 3%/3mm tolerance. The data 
indicates that the pass rates are slightly higher for the conventional IMRT plans. This 
is not statistically significant at 3%/3mm but does becomes significant at 2%/2mm 
(p<0.001). 
There is also a systematic offset in the absolute doses measured for FFF (0.8%) 
that is not present in the conventional plans. This figure ties in well with the data 
presented in figure 4.7(b), where an offset is observed in the output factors curve for 
FFF beams. This could be minimised by applying a global calibration factor to the 
beam model. 
 
6.5 Discussion and conclusions 
All beams in the planning exercises passed the defined acceptance criteria used for 
standard IMRT patient specific quality assurance tests. Once the test criteria are 
tightened to 2%/2mm slight differences can be seen between the flattened and FFF 
deliveries, with the conventional beams generally receiving slightly higher pass rates. 
There may be several reasons for this including the increased number of segments 
delivered and also the fact that the linac is still a prototype (non clinical) release. 
Once the Elekta FFF linac is released for clinical use with fully optimized hardware 
and dosimetry these tests should be repeated to assess any possible improvements in 
dose calculation and delivery. 
Several other authors have now demonstrated the accuracy of IMRT QA for FFF 
delivery. Stathekis et al (2009) studied flattening filter delivery on the Varian 23EX 
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linac using the Pinnacle TPS, finding equivalence in treatment plan quality and 
delivery. Lang et al (2012b) have shown equivalence in 224 pre-treatment plan 
deliveries for FFF delivery for a combination of Eclipse TPS and TrueBeam 
accelerator. Kragl et al (2011b) tested the dosimetric accuracy of the Monaco TPS 
using an older version of the VSM (VSM 1.5 within Monaco version 2.03), finding 
improvements in dose calculation accuracy for off-axis profiles. This did not directly 
translate into better verification results for IMRT QA delivery, as seen in this study 
(reported in Cashmore et al 2012). 
Treatment planning systems, like linear accelerators, have evolved around the 
use of the flattening filter. In a TPS with simplistic beam modelling, like XiO, the 
reduction in the magnitude and range of head scatter is likely to have a direct impact 
on the accuracy of dose predictions, as this will be a dominating factor in calculation 
uncertainty. In more sophisticated planning systems like Monaco, with much more 
accurately modelled treatment head and scatter, it is more likely that additional 
factors will come into play. In particular these IMRT systems do not contain leaf 
sequencers optimised for FFF segmentation and delivery. The optimisation of non-
uniform beam profiles has been discussed by Kim et al (2010) who found that 
number of segment required for FFF beams can be significantly reduced once this is 
taken into account in the optimization process. Such an addition is likely to reduce 
the number of segments required to deliver modulated FFF plans. This is discussed 
further in chapter 8. 
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CHAPTER 7 
 
PERIPHERAL DOSES 
 
This chapter focuses on the measurement of those doses received by the patient 
outside of the treated area. These out-of-field, or peripheral doses are increased for 
IMRT delivery, and planning studies (chapter 5) have shown that more MU are 
required to deliver modulated beams without the flattening filter  This increase in 
MU can only be justified if the overall scatter received by the patient is reduced 
during delivery. Data is also presented for stereotactic treatments where the change 
in MU is not significant but the advantages of increased dose rate (and hence faster 
delivery) make FFF attractive. 
Parts of this chapter forms the basis of an article published by the author in Int. 
J. Radiat. Oncol. Biol. Phys. (Cashmore et al 2011). 
 
7.1 Background 
Intensity modulated radiotherapy (IMRT) is now a well established technique used to 
concentrate dose into a target region/s whilst sparing normal tissues, and is 
recognised as superior to 3D conformal radiotherapy (3D-CRT) in these respects (see 
Chapter 5). However, the increased number of beam directions used in IMRT 
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compared with 3D-CRT means that a low level ‘dose-bath’ is given to a larger volume 
of normal tissues. Leakage radiation from the treatment head is also raised since 
IMRT delivery is wasteful of monitor units (MU), which can increase by a factor of 2-
10 (typically 2-3) depending on the techniques and equipment used.  Since leakage 
radiation is proportional to the number of monitor units delivered, IMRT is known to 
increase whole-body doses to the patient.  
Several authors have compared the delivery of 3D conformal plans against IMRT 
and reported that IMRT delivery may double the incidence of solid cancers in long-
term survivors (Hall &  Wuu 2003, Hall 2006, Kry et al 2005, Ruben et al 2008, 
Verellen & Vanhavere 1999). The range of reported values varies considerably (1.2 to 
8) since the MU demand for IMRT is largely dependent on both the software and 
hardware used for planning and delivery and also on the radiobiological models used.  
Radiation induced secondary cancers are not a serious concern until at least 5 
years after treatment (NCRP report 115, 1993) with patients surviving longer than 10 
years being most at risk. Following successful treatment of the original disease 
secondary cancers are diagnosed on average 15 years after treatment (Bassal et al 
2006). A recent study (Diallo et al 2009) showed that of 115 paediatric patients 
diagnosed with secondary cancers after radiotherapy 22% of these were >5cm from 
the PTV, and some were detected up to 1m away. The peak frequency was seen to be 
in tissues receiving 2.5Gy or less. 
With treatments becoming more successful and survival rates rising, the 
importance and incidence of second cancers will also increase and is likely to be of 
particular concern in children. 
Peripherals doses are influenced by many factors and have been reported for a 
range of accelerators and beam energies (Followill et al 1997, Klein et al 2006, 
Mansur et al 2007, Van der Giessen 1994, Xu et al 2008). The dose to tissues close to 
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the target site (within several cm) is dominated by internal scatter and head scatter 
(Lillicrap et al 2000) and is dependent on field size and energy. 
At distances beyond the range of internal scatter, peripheral doses are dominated 
by head leakage and therefore proportional to MU, so are unavoidably higher for 
IMRT. Since paediatric patients are also physically smaller, geometric factors play an 
important role in these patients. The distance from the field edge to any organ at risk 
in a child (and also the depth from surface) will be reduced, raising organ doses 
relative to comparable exposure in an adult. 
One of the major sources of head scatter and leakage radiation from the 
treatment head is the flattening filter, and operation of an Elekta Precise linear 
accelerator without  the flattener has been shown to reduce patient-plane leakage at 
1m by 58% at 6MV (Cashmore 2007, Kragl et al 2011). Several groups have 
investigated the treatment planning aspects of unflattened IMRT (Cashmore 2007, 
Stathekis et al 2009, Vassiliev et al 2007) and one author has investigated peripheral 
doses through Monte Carlo modelling (Kry et al 2007), but no direct measurements 
has been made between out-of-field doses for clinical delivery of comparative plans. 
If IMRT can be planned and delivered utilising a system with no flattening filter then 
peripheral doses could be significantly reduced, potentially lowering the incidence of 
secondary cancers. 
This study aims to investigate the potential of IMRT with unflattened photon 
beams by directly comparing the treatment planning and delivery of unflattened 
beam IMRT against the conventional IMRT standard. Since peripheral doses are so 
dependent on the software, hardware and energy used these have been kept constant 
i.e. the same planning system, plan quality, beam energy and accelerator are used 
throughout. 
Since the dose rate is roughly doubled by filter removal for unflattened beam 
delivery the pulse repetition frequency has been lowered to maintain the same dose 
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rate between delivery techniques. Baring any small changes in monitor units (MU) 
and segmentation the plans therefore took the same time to deliver in each case. 
Although the dose per pulse is approximately doubled by filter removal the machine 
had been recalibrated so that 1MU = 1cGy under standard conditions (10x10cm2, 
90cm SSD, Dmax), as for any other clinical beam. 
 
7.2 Measurements in a slab phantom 
To establish a reference and provide base-line measurements, peripheral doses were 
measured for standard field sizes in a slab phantom consisting of tissue equivalent 
material (figure 7.1). Peripheral doses are relatively independent of measurement 
depth and a depth of 5cm was chosen as being representative for the cases studied. 
 
 
Figure 7.1 Experimental setup for measuring peripheral doses using a slab phantom construction. 
Three piles of slabs are used, each of dimension 30x30x20cm, giving an overall length of 90cm. 
 
Measurements were taken at regular intervals, from the central axis out to 70cm 
away from the CAX, and recorded for a variety of field sizes and at collimator 
rotations of 0 and 90°, both with and without the filter. Readings were performed 
using a cylindrical ionization chamber (NE2571) and repeated with TLD-100 
(Harshaw Chemical Company, Solon, OH) LiF thermoluminescent dosimeters 
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(TLDs). For each position ten TLDs were used and readings normalised to the dose 
recorded for delivery under standard conditions (10x10, 90cm SSD, Dmax). These 
were then compared to the dose measured under the same conditions with the 
ionisation chamber to characterise any differences in the energy response of the TLDs 
due to the altered spectrum of scattered/leakage radiation. 
As expected, peripheral doses are seen to decrease with distance from the field 
edge approximately exponentially, and to increase with increasing field size. In each 
case the readings generally start to converge beyond 40cm from the central axis, 
however doses measured with the filter removed drop more quickly and to a lower 
level (figure 7.2 a-e). 
For a 10x10cm2 field at 40cm from CAX the dose is only 50% of that seen for the 
standard field, and at 70cm from CAX this falls to 38.5%. For a 3x3cm2 field the 
values are even lower at 34.7% and 27.8% respectively. There is a significant drop in 
dose with the collimator rotation set at 0° due to extra shielding (from the MLC 
carriage) within the treatment head which is seen in both treatment modes with 
readings diverging at approximately 10cm from the CAX and then re-converging at 
approximately 40cm. At 20cm this accounts for a 45% decrease in dose and whenever 
possible IMRT plans are produced at collimator 0° to reduce this leakage dose. 
TLD-100 chips are known to show variations in dose response at low energy, but 
have been used previously to measure out-of-field doses (Vassiliev et al 2006). The 
differences in beam spectrum between scattered and leakage radiation mean that the 
TLDs may respond differently. To account for these differences the ratio between 
ionisation chamber and TLD readings under the same conditions was taken, and 
these factors used to correct measurements taken in the anthropomorphic phantoms. 
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(a)  
(b)  
 
Figure 7.2. Peripheral dose measurements as a function of distance from the central axis with 
NE2571 chamber. Measurements are in water equivalent material at a depth of 5cm. a) flattening 
filter in, b) flattening filter out for field sizes of 3x3, 6x6 and 10x10 cm2. c) Shows a comparison 
between filter in and filter out for 3x3 and 6x6 cm2 fields (10x10 cm2 removed for clarity). Variation 
in dose for collimator rotations of 0° and 90° d) filter in, e) with the filter out. 
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(c)  
(d)  
(e)  
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Under the same delivery conditions the TLDs showed significant differences 
compared to the ionization chamber readings, with the conventional beams under-
responding on average by 7.5%, whilst the unflattened beams over-responded by 
almost 17%. These differences are most likely due to the changes in energy spectrum 
between conventional and FFF delivery but requires further investigation. 
For each position ten TLDs were used and readings normalised to the dose 
recorded for delivery under standard conditions (10x10, 90cm SSD, Dmax). These 
were then compared to the dose measured under the same conditions with the 
ionization chamber to characterise any differences in the energy response of the TLDs 
due to the altered spectrum of scattered/leakage radiation. 
 
 
7.3 IMRT Treatment Planning 
7.3.1 Patient selection 
For this study we retrospectively selected 5 paediatric patients recently treated for 
intracranial tumours with conventional 3D-CRT at our institution. Additional 
outlining was then performed by a consultant paediatric oncologist to enable IMRT 
planning for these patients. Intracranial tumours have been chosen because they 
offer a challenge for the beam models involved and the opportunity to measure out-
of-field doses over a large distance through the rest of the body. 
Treatment plans were produced both with and without the flattening filter (10 
plans in all). The number of beams and their gantry angles remained the same in each 
case (generally 5 equally spaced fields). Dose optimisation priorities changed for each 
case but the planning target volume (PTV) was given priority unless a critical 
structure was compromised. In many cases organs at risk were contained within the 
PTV in which case care was taken to avoid dose hotspots occurring in these regions. 
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All plans received 50.4 Gy in 28 fractions prescribed to the mean of the PTV dose 
i.e. D50 = 50.4Gy. In each case calculations were performed using the superposition 
algorithm, a step increment of 5mm on the MLCs and a 2mm grid spacing. 
For each IMRT case a plan was produced using the conventional IMRT beam 
model first then, having found a set of dose constraints to drive the optimiser to meet 
target and OAR limits, these same objectives were used to produce an optimised 
unflattened treatment plan. This process removes any inter-planner or inter-plan 
bias from the evaluation. Plans were then evaluated according to standard dose 
indices to assess PTV coverage, homogeneity and OAR sparing. 
 
7.3.2 IMRT plan evaluation 
All 10 plans have been assessed using standard evaluation criteria as shown in table 
7.1. Values are reported in table 7.2 for each of the 10 plans created. 
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Table 7.1. Summary of dosimetric parameters used for plan evaluation 
 
PTV coverage 
V90 Volume of target (%) receiving 90% of prescribed 
dose 
V95 Volume of target (%) receiving 95% of prescribed 
dose 
V100 Volume of target (%) receiving 100% of 
prescribed dose 
V107 Volume of target (%) receiving 107% of prescribed 
dose 
D2 Dose to 2% of target volume 
D98 Dose to 98% of target volume 
HI Homogeneity index (D2-D98/Prescribed 
dose)*100 
VPTV  Volume of the PTV 
CI Conformity Index volume of tissue VNT 95/ VPTV 
 
Normal tissue sparing 
VNT 5 Volume of tissue receiving 5% of prescribed dose 
VNT 95 Volume of tissue receiving 95% of prescribed dose 
 
 
Figure 7.3 shows slices through the isocentre for Case5 (a midbrain astrocytoma) 
to illustrate the similarity of the plans. For all planned cases the target coverage, 
homogeneity and OAR doses both with and without the flattening filter were similar 
with no one technique producing better plans than the other. This can be seen 
diagrammatically in figure 7.3a which shows the dose volume histogram (DVH) for 
the 2 plans in figure 7.3a. The correlation between plans for each case was tested and 
differences were found to be statistically insignificant. 
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Table 7.2. Summary of doses (in Gy) recorded for PTV coverage in each plan for flattening filter in (In) and filter out (Out) according to evaluation 
parameters of table 1. Volumes are expressed as a percentage except the PTV volume which is in cc. 
 
 Case1 Case2 Case3 Case4 Case5 
 In* Out* In Out In Out In Out In Out 
V90 99.4 99.3 99.9 99.9 99.9 99.9 99.1 99 100 100 
V95 95.3 94.9 98.1 98.3 99.0 98.9 94.2 95.4 96.2 96.3 
V100 50.0 50.0 50.0 50.0 50.0 50.0 50 50 50 50 
V107 0.2 0.1 0.1 0.2 0.9 0.3 0.4 0.9 0 0 
D2 52.6 52.4 52.4 52.9 53.2 52.5 52.6 53.1 51.6 51.5 
D98 46.8 46.6 47.9 47.9 48.2 48.2 46.6 46.7 47.3 47.4 
HI 11.5 11.5 8.9 9.9 9.9 8.5 11.9 12.7 8.5 8.1 
VPTV 420.5 420.5 497.8 497.8 309.9 309.9 441.6 441.6 60.3 60.3 
CI 1.13 1.10 1.09 1.10 1.22 1.16 1.05 1.07 1.26 1.23 
VNT 5 1445.3 1433.9 939.1 934.3 1345.2 1313.2 1053.8 1038.1 1331.7 1321.8 
VNT 
95 
475.2 462.0 542.3 547.0 378.9 360.6 463.6 471.9 76.1 74 
 
* ‘In’ refers to the flattening filter in position (i.e. conventional IMRT) and ‘Out’ refers to unflattened IMRT (flattening filter out). 
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Figure 7.3. Transverse slice through the centre of the target region for Case5 (a midbrain 
astrocytoma) showing dose distribution comparisons between each technique. On the left (a) is the 
conventional IMRT plan and on the right (b) that with the flattening filter removed. The PTV is 
marked in green and the pituitary in red. Figure 7.3b. DVH comparison between conventional (solid 
lines) and unflattened (dotted lines) plans for Case5. 
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Table 7.3. Organ at risk doses (in Gy) for the 10 treatment plans (5 cases). All doses are the maximum point dose to that organ unless marked with a † in 
which case the mean dose is listed. 
 Case1 Case2 Case3 Case4 Case5 
OAR      *In *Out In Out In Out In Out In Out 
Lt Eye † 34.3 33.6 13.3 13.1 32.0 32.4 36.9 36.6 3.7 3.4 
Rt Eye † 33.7 33.8 11.5 11.3 12.9 13.0 36.7 35.9 2.6 2.4 
Lt lens 38.3 39.5 9.3 9.3 27.8 28.4 40.4 37.1 4.4 4.2 
Rt lens 29.6 29.0 5.4 5.2 5.8 6.1 35.8 36.2 3.3 3.1 
Optic Chiasm 52.8 52.9 32.7 35.3 50.5 50.4 48.9 49.4 11.8 11.8 
Brainstem 50.3 50.6 53.1 52.6 53.2 52.1 49.6 50.6 50.5 50.8 
Spinal cord 2.9 2.7 49.8 49.7 2.0 1.8 49.6 48.6 0.6 0.5 
Lt cochlea † 42.2 42.8 45.9 45.3 50.4 50.2 38.9 39.0 9.0 8.5 
Rt cochlea † 44.6 43.5 45.8 47.7 31.5 33.6 48.8 48.5 8.1 7.6 
Pituitary 51.8 51.6 53.6 52.6 51.6 49.5 50.0 51.3 14.9 15.3 
 
* ‘In’ refers to the flattening filter in position (i.e. conventional IMRT) and ‘Out’ refers to unflattened IMRT (flattening filter out). 
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Table 7.4. Segments and monitor units required to deliver identical plans by the two different delivery methods. 
 
Case 
No. 
fields 
Conventional 
IMRT 
Unflattened 
IMRT 
Ratio of 
segments* 
Ratio of 
MUs* 
  Segments MUs Segments MUs   
Case 1 5 89 18146 89 19186 1.000 1.057 
Case 2 5 94 18105 98 20695 1.043 1.143 
Case 3 5 85 17928 76 17767 0.894 0.991 
Case 4 5 100 22462 104 24667 1.040 1.098 
Case 5 5 57 10924 59 11310 1.035 1.035 
    Average 
1.003 ± 
0.063 
1.067 ± 
0.058 
 
* ratio is taken as Unflattened / Conventional IMRT 
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Table 7.3 lists the maximum point doses to the OARs for each case with and 
without the flattening filter. In many of the cases OARs were within the PTV and so 
received unavoidably high doses. 
Table 7.4 compares the number of segments and MUs required to deliver the 
same dose distribution with the two techniques. Taking the ratio of (Unflattened 
IMRT/Conventional IMRT) for each of the 5 cases the average for the number of 
segments required is 1.003 and the MU ratio is 1.067. 
 
7.4 Anthropomorphic phantom construction 
Out-of-field doses are difficult to calculate with any degree of accuracy and peripheral 
doses to organs at risk cannot be reliably or accurately predicted from large-field 
phantom studies (Followill et al 1997). With an unflattened beam there may be 
significant changes in the number and shape of the beam segments required and the 
number of MUs needed to deliver the prescribed dose. Scatter and leakage will also 
depend on the direction and energy of the scattered radiation so may be affected by 
the changes in beam spectrum. It is therefore important to measure these changes 
under representative conditions. 
Phantom measurements yield dose values at the correct distance from the 
isocentre, at the correct depth and for clinically usable plans. Therefore, to measure 
and compare peripheral doses for IMRT delivery an anthropomorphic paediatric 
phantom of a 3-year-old child was constructed with dimensions based on published 
statistical data (Hall 1995, Stovall et al 2004) (figure 7.4). The design of the phantom 
is necessarily simple as the manufacture of a detailed paediatric phantom is beyond 
the scope of this thesis; no attempt was made to manufacture the phantom from 
water equivalent materials or include inhomogeneities. The aim of the study is not to 
provide definitive data for risk of cancer induction but to compare treatment 
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techniques under the same conditions; therefore it is relative doses that are of 
interest. 
With the beam isocentre in the centre of the head doses were measured at 
clinically relevant points i.e. thyroid, breast, ovaries and testes. In particular, thyroid 
cancer is the only tissue with clear evidence for risk even at doses of <0.1 Gy (Shore 
1992) and is also the second most frequent secondary cancer reported. 
 
 
 
 
Figure 7.4. Details of the paediatric anthropomorphic phantom used for measurements, distances as 
marked (mm). Measurements were performed with an NE2571 chamber. 
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Table 7.5. Summary of doses at specified points of interest in the wood phantom for the five cases treated both with the flattening filter in (In) and out (Out). 
All doses are relative to the beam isocentre (head) which is equal to 1.8Gy (50.4Gy/28#). 
 
 
  Case 3  Case 4  Case 5   
 
Distance 
(mm) In Out Ratio In Out Ratio In Out Ratio 
Average 
Ratio 
Head 0 100 100 1.00 100 100 1.00 100 100 1.00 1.00 
Thyroid 195 1.085 0.837 0.77 1.073 0.789 0.74 0.512 0.422 0.82 0.78 
Breast 265 0.260 0.191 0.74 0.320 0.206 0.64 0.148 0.103 0.70 0.69 
Ovaries 510 0.082 0.034 0.42 0.131 0.045 0.34 0.062 0.025 0.40 0.38 
Testes 600 0.062 0.021 0.34 0.096 0.030 0.31 0.049 0.017 0.34 0.33 
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Table 7.5 shows the doses received at each of these points for three of the IMRT 
plan deliveries. In each case the peripheral doses from the flattening filter plans are 
significantly lower than for conventional IMRT. Figure 7.5 plots the peripheral dose 
vs. off-axis distance for the average of the datasets. 
 
 
Figure 7.5. Sample data from Case5 illustrating the drop in peripheral dose for the unflattened beam 
delivery in the clinical IMRT plans (wood phantom). Figure b) shows a plot of relative dose on a 
linear scale with the point doses for the conventional plans normalised to 1 to illustrate the drop seen 
in relative dose with the unflattened IMRT plans. 
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7.5 ATOM phantom 
Scatter and leakage will depend on the direction and energy of the scattered radiation 
so readings may be affected by the phantom material. It is therefore important to 
measure these changes under representative conditions. For these reasons a 
commercially available anthropomorphic paediatric phantom (ATOM dosimetry 
model 706) (CIRS Inc., Norfolk, VA, USA) of a 10-year-old child was used to measure 
and compare peripheral doses for IMRT delivery (kindly loaned from The Christie 
NHS Foundation Trust). 
The phantom consists of 25mm thick contiguous sections pre-drilled to hold 
TLDs. For each plan delivery 5 LiF TLDs were placed at each of 6 points within the 
phantom corresponding to clinically relevant anatomical locations outside of the 
treated volume representing the thyroid, breast, lung, intestines, ovaries and testes. 
Plans were delivered with the beam isocentre in the centre of the head and each plan 
was delivered three times to ensure adequate dose levels were recorded by the TLDs. 
  
 
Figure 7.6 CIRS ATOM paediatric phantom used for peripheral dose measurements. 
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7.5.1 Doses to distant organs 
These measurements are summarised in table 7.5 for each of the regions of interest 
and shown graphically in figure 7.7. Even for doses close to the target volume the 
doses are seen to be consistently lower for unflattened delivery. On average the 
thyroid was only 5cm from the field edge but still shows a 24% reduction in dose 
compared to the standard IMRT delivery. 
 
 
Figure 7.7. Sample data from Case5 illustrating the drop in peripheral dose for the unflattened beam 
delivery in the clinical IMRT plans (a). Figure b) shows a plot of the average dose ratio 
(unflattened/flattened) for all of the plans delivered. 
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Table 7.6. Summary of doses at specified points of interest for three of the five cases treated both with the flattening filter in (In) and out (Out) 
 
  Case 1 Case 2 Case 5  
 
Distance 
(mm) In* Out* Ratio In Out Ratio In Out Ratio 
Average 
Ratio 
Head 0 100 100 1.00 100 100 1.00 100 100 1.00 1.00 
Thyroid 100 1.730 1.288 0.745 2.256 1.778 0.778 0.755 0.570 0.755 0.763 
Breast 200 0.202 0.167 0.825 0.248 0.195 0.784 0.010 0.078 0.781 0.797 
Lung 250 0.159 0.112 0.701 0.189 0.132 0.701 0.082 0.057 0.700 0.701 
Intestines 425 0.082 0.031 0.374 0.090 0.036 0.402 0.057 0.021 0.367 0.381 
Ovaries 550 0.059 0.019 0.328 0.064 0.024 0.373 0.042 0.015 0.353 0.351 
Testes 650 0.057 0.015 0.268 0.064 0.020 0.312 0.041 0.013 0.321 0.300 
 
* ‘In’ refers to the flattening filter in position (i.e. conventional IMRT) and ‘Out’ refers to unflattened IMRT (flattening filter out). Distances are from the 
central axis (isocentre).
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7.6 Room survey 
The reduction in scatter, and hence leakage radiation effectively lowers the whole 
body dose received by the patient, even taking into account the increased number of 
monitor units required for IMRT delivery with FFF techniques. 
A head and neck IMRT plan was delivered to assess the cumulative doses 
received at various points around the treatment room. Radiation was delivered to a 
20cm thick solid water phantom to simulate patient scatter and doses measured 
using calibrated Harshaw lithium fluoride TLD-100s (Harshaw Chemical Company, 
Solon, OH). 
Table 7.7 shows the doses received at each position. Despite the FFF plan 
requiring 33% more MU than the conventional IMRT plan, the cumulative doses are 
significantly lower for unflattened delivery with a dose reduction of 31.6% averaged 
over all positions. Dose measurements and analysis for this survey were carried out 
not by the author, but by trainee physicists within the department working under 
supervision. Further results are presented in Appendix H. 
 
Table 7.7. Cumulative doses measured during IMRT plan delivery for 6MV and 6MV FFF plans. 
Doses are in mSv. 
TLD Position 6MV 6MV FFF 
A side wall 17.0 13.3 
B side wall 40.2 23.2 
G side wall - - 
T side wall 11.0 7.8 
Maze entrance 8.2 6.4 
Machine head 201 115 
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7.7 Stereotactic radiosurgery (SRS) 
The stereotactic cones commissioned for the FFF linac were used to assess the out-of-
field doses received during radiation delivery. Figure 7.8 shows the beam profile of 
two SRS cones on a log scale to illustrate the reduction in dose immediately outside of 
the field edge for the FFF beams. Doses measured at 25mm from the central axis 
were lower for all FFF beams compared to the flattened beams for all the collimators 
due to the reduction in the linac head leakage observed when the flattening filter is 
removed. 
 
 
Figure 7.8. Comparison of 6MV (black) and 6MV FFF (red) profiles for 2 conical stereotactic 
collimators (10 & 22.5mm diameters). On the log plot it is possible to see the reduction in out-of-field 
dose for the FFF beam compared to standard data. 
 
The peripheral dose measurements of section 7.2 were repeated using a 20mm 
SRS cone using the slab phantom as illustrated in figure 7.1. 
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Figure 7.9. Peripheral doses measured for a 20mm SRS cone. 
 
 
Figure 7.10. Ratio of peripheral doses (6MV FFF / 6MV) measured for a 20mm SRS cone illustrating 
the increasing reduction in out-of-field dose for the FFF with distance from the field centre. 
 
0.01
0.1
1
0 20 40 60 80
R
e
la
ti
ve
 d
o
se
 (C
A
X
 =
 1
0
0
)
Distance from CAX (cm)
6MV
6MV FFF
0
0.2
0.4
0.6
0.8
1
1.2
0 20 40 60 80
6
M
V
 F
FF
 /
 6
M
V
Distance from CAX (cm)
 182 
There is a significant reduction in dose for FFF operation (figure 7.9), and this 
difference increases with distance from the central axis (figure 7.10). This reduction 
in the dose outside of the treatment field for FFF beams provides normal tissue 
sparing within the patient, and this is magnified for stereotactic radiosurgery over 
conventional radiotherapy due to the fact that the stereotactic plan involves multiple 
small field arced (typically 100°) beams, each with a high number of monitor units. 
The FFF beam shape means that the photon fluence naturally falls off with 
distance from the central axis (falling to 50% at the beam edge). The magnitude of the 
leakage radiation through the collimators will scale directly with that of the photon 
fluence, so the dose outside the field edge (to normal tissues) will also be lower. This 
is a simple consequence of there being less primary radiation present at off-axis 
positions. 
The plan below (produced by Geoff Heyes [appendix H]) for an acoustic neuroma 
(figure 7.11) required 2 isocentres to cover the PTV, one using 4 arcs and a 20mm 
collimator, the second 3 arcs with a 10mm collimator, each arc covering 100°. 
 
 
 
 
Figure 7.11. Comparison of dose between 6MV and 6MV FFF beams through an axial slice of an 
acoustic neuroma. 
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Figure 7.12. A plot of the dose profile through a lesion indicating the reduction in dose for FFF 
delivery within the close critical structures and more distant normal tissues. Cross-section plane is 
indicated in figure 7.11. 
 
These treatment plans show very little effect when switching to the FFF beam 
model, as would be expected as the flattening filter has no real effect for small beams. 
The dose coverage and dose volume histograms for the targets remain unchanged in 
each case; however additional tissue sparing is seen for brainstem and normal brain 
for FFF. The dose to the lesion, brainstem and normal brain were assessed and are 
shown in table 7.8 below. 
The most significant differences were observed for the low isodoses. For a 
prescribed dose of 12Gy, the V10 for normal brain and brainstem were reduced by 
nearly 60% and 10% respectively by using the FFF beam model (figure 7.12 & table 
7.7). 
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Table 7.8. Assessment of doses to the Normal Tissue, Brainstem and the Lesion for the acoustic 
neuroma plan shown in figure 7.11 (from Heyes G and Cashmore J, Appendix H). 
 
  
V10 (cc) V20 (cc) V50 (cc) V100 (cc) 
Normal 
Tissue 
(3005.6cc) 
6MV FFF 249.3 61.9 11.7 2.9 
6MV 396.6 80.5 12.6 3.0 
 
% Reduction using FFF -59.1 -30.1 -7.7 -3.8 
Lesion 6MV FFF 2.4 2.4 2.4 2.4 
(2.42cc) 6MV 2.4 2.4 2.4 2.4 
 
% Reduction using FFF 0.0 0.0 0.0 0.0 
Brainstem 6MV FFF 12.5 7.5 1.7 0.2 
(14.31cc) 6MV 13.6 8.7 1.8 0.2 
 
% Reduction using FFF -8.7 -15.7 -8.5 0.0 
 
 
7.8 Discussion 
There is a slight increase in the number of MU needed to deliver the same dose (6.7% 
for the cases studied) but this is an expected consequence of unflattened delivery 
because of the shape of the beam profile; delivering any dose off-axis will require the 
beam to be on for a longer period of time. Even taking this increase into account the 
rise in MU required for unflattened delivery is modest compared to the reduction in 
leakage dose seen. 
The risk of second cancer induction can be related back to these values and will 
scale with the ratio of absorbed doses. Taking a nominal distance of 50cm to 
represent whole-body dose (Xu et al 2008), doses here are reduced on average by 
64% for unflattened IMRT delivery, and this obviously represents a significant 
reduction in risk from leakage radiation.  
Under both standard and clinical conditions out-of-field doses are seen to be 
lower at all positions relative to conventional delivery. In a recent Monte Carlo study 
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by Kry et al (2010) however, unflattened beams were seen to increase the dose in the 
region from 3-15cm from the field edge for IMRT delivery on a Varian accelerator. 
These differences may be due to variations in head design between Elekta and Varian 
machines, or due the Varian accelerator having a slightly lower effective energy 
(4MV). As the field size increases beyond the range used in this study it is possible 
that there may be similar issues for larger PTVs and in adults, and further study is 
required to quantify this. 
Machines operating without a flattening filter are now commercially available 
such as the Tomotherapy HI-ART (TomoTherapy, Inc., Madison, WI) and CyberKnife 
(Accuray, Inc., Sunnyvale, CA), indicating that in a ‘bottom-up’ design the flattening 
filter is seen to be unnecessary. Helical delivery systems, however, are inefficient in 
MU delivery as dose is delivered in a slice-by-slice fashion so to deliver the same dose 
in clinical treatment plans requires 5-15 times as many MU (Ramsey et al 2006). The 
Tomotherapy system has been designed with this in mind with 23cm of attenuation 
(tungsten jaws and MLC leaves) meaning that for static field delivery leakage doses 
are reduced by 3-11 times compared to a conventional accelerator. When these factors 
are combined together, this results in similar, if not lower leakage than for a 
conventional linac delivering IMRT (Ramsey et al 2006). 
Leakage may be reduced by increasing the shielding around the head, but this is 
both costly and cumbersome. Removal of the flattening filter is a relatively simple 
way of achieving the same effect on a conventional linac, and since the flattening 
filter doesn’t actually seem to be required for IMRT one can argue that it should be 
removed for IMRT treatments. A filter free conventional linac could combine the best 
aspects of both delivery methods - a machine that combines the inherent dose 
delivery efficiency of a linac combined with the reduction of scatter from flattening 
filter removal. 
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7.9 Summary 
Removal of the flattening filter for IMRT removes an unwanted and unnecessary 
source of scatter from the treatment head significantly reducing whole-body radiation 
doses. 
The flattening filter has no effect on beam profiles for the small field sizes 
employed in stereotactic treatments. In these cases there is no reason why the filter 
should be in place and its removal for these treatments is recommended. FFF offers 
the opportunity for faster treatment times with reduced out-of-field doses to the 
patient. 
If IMRT is to be used then this risk must be balanced by an increase in local 
control and reduced toxicity. Any increase in whole-body dose must be justified for 
paediatric patients who have the potential for such long-term survival and as much as 
possible should be done to reduce these doses and lower the risk of cancer induction. 
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CHAPTER 8 
 
SUMMARY & FURTHER WORK 
 
 
This final chapter provides a summary of the research presented in this thesis and 
discusses the scope for continuing research into FFF beams. 
 
8.1 Overview 
Removal of the flattening filter from the beam line produces profound changes in the 
operation and dosimetric characteristics of the treatment beam. Without the filter the 
electron contamination from the primary collimator is not only allowed to reach the 
ionisation chamber, but also has a negative effect on servo control as the direction of 
these electrons is somewhat random. By mounting a 2mm stainless steel plate in its 
place the electron contamination is reduced, and electrons generated in the plate 
have a strong directional component, which allows the beam steering servos to 
operate correctly. 
The beam hardening offered by the flattening filter is obviously lost with its 
removal, but so also is the strong variation of the energy spectrum with distance from 
the central axis. The beam energy can be raised to maintain the same beam quality 
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and depth dose profile for the FFF beam, but matching off-axis is not possible, or in 
fact desirable. 
By removing the differential absorption effect of the flattening filter the beam 
becomes far simpler to model, and commercial treatment planning systems seem 
capable of modelling these beams with the same accuracy as that observed for 
conventional beams. 
The key benefit to filter removal comes from the reduction in scattered radiation 
from the treatment head. Not only do parameters like head scatter, output factors 
and surface doses show much less variation with field size, the leakage radiation 
reaching the patient is significantly reduced, as is the dose received by staff outside of 
the treatment bunker. The introduction of IMRT into routine use has raised 
questions regarding the additional out-of-field radiation received by patients. These 
techniques, which are inherently inefficient in MU delivery, can raise peripheral 
doses by a factor of 2 and raise concerns for secondary cancer induction later in life, 
particularly for paediatric patients. By introducing FFF the reduction in scatter, and 
hence leakage radiation, means that these doses are reduced by a similar factor, 
returning these doses to the levels seen for 3DCRT delivery. 
The rapid expansion of IMRT delivery as the technique of choice for many 
treatment sites also removes the reason for having flattening filters in the first place. 
Previously, a flat radiation field was a prerequisite for treatment planning as 
radiotherapy was based on the delivery of radiation to ‘box-like’ structures within the 
body. With improvements in, and the widespread use of, imaging techniques such as 
CT, MRI the accurate identification and delineation of tissues is possible, and the 
delivery of radiation is sculpted to match the shape of the tumour, avoiding 
surrounding normal tissues as much as possible. This active production of ‘non-flat’ 
beams contradicts the use of a flattening filter – why flatten the beam only to go onto 
modulate the fluence to actively change this? 
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Although modern treatment planning systems were not specifically designed to 
cope with FFF beams the inherent flexibility of these systems to model treatment 
beams from various linac manufactures and energies means they also seem capable of 
modelling FFF beams accurately. Fluence optimisation of these beams for IMRT 
delivery remains the same, provided the beam profile is taken into account, and 
commercial planning systems have been shown to demonstrate equivalency in plans 
generated for conventional and FFF beams for a variety of treatment sites. Likewise 
the verification of these plans has shown no particular concerns for FFF delivery. 
 
 
8.2 FFF linacs 
Several medical accelerators are now available operating in FFF mode. The 
CyberKnife and TomoTherapy systems (Accuray) have shown that in a bottom-up 
design the flattening filter is not deemed a necessary component for either SRS 
(CyberKnife) or IMRT (TomoTherapy) delivery. Varian have also released the 
TrueBeam accelerator, and now Elekta have recently (March 1st 2013) released their 
version of the FFF linac (figure 8.1), the VersaHD (http://www.versahd.com/) 
incorporating the research and development and publications of data from this work 
and others. 
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Figure 8.1 The Elekta FFF linac, VersaHD, released March 1st 2013 (http://www.versahd.com/). 
 
8.3 Scope for future work 
Although the FFF linac has now been commercially released for medical use there is 
still a considerable amount of scope for continued research. 
 
8.3.1 Beam specification and QA 
Although FFF accelerators have been released there is still some ambiguity 
surrounding the specification of beam parameters and the quality control tests 
necessary. Parameters such a beam flatness and penumbra take on a different 
meaning for these beams and several attempts have been made to standardise these 
specifications (Ponisch et al 2006, Fogliata et al 2012). Many of these tests rely on 
reference to a flat beam, but this obviously relies on having filtered and FFF beams of 
the same energy on the linac. IMRT continues to increase in popularity and since the 
flattening filter is not necessary for modulated treatments it is likely that the use of 
flattened beams will decrease. It can therefore be envisioned that the FFF linac may 
 191 
become the standard, so beams specification and QA tests must be designed so as not 
to be reliant on a flattened equivalent. The use of the Elekta AutoCAL software for 
MLC leaf calibration has been investigated by Mark Ramtohul (Appendix H) and 
found to be suitable for FFF beams (providing strict procedures are followed), but 
further testing will be required. 
There is also the issue of long term performance under FFF operation. In theory 
the FFF beam is more stable, so this should result in increased reliability of the beam 
steering. Any improvements in this will need to come from long-term monitoring of 
QC tests. By operating in FFF mode there is also a reduced wear on the HT 
components of the linac as the beam needs to be on for only half the time (at 6MV) 
compared to normal operation. Again, in theory, this should translate into greater 
reliability and increased component lifetime. This remains to be seen. 
 
8.3.2 Dose calculation (TPS) 
FFF beams naturally lend themselves to SRS and IMRT treatments as, for small fields 
the flattening filter essentially has no effect on the beam profile, and for IMRT the 
fluence optimisation takes the non-flat profile into account. The subject of 3DCRT 
with FFF beams has not really been addressed and there is certainly scope for these to 
be used in conventional planning. The wedge profile is maintained without the filter 
in place, and the central axis boost inherent to these beams could be useful in many 
situations and warrants further investigation beyond that reported here. 
Regarding the treatment planning systems themselves, there is still much work 
that could be done to optimise the calculation algorithms for FFF use. In particular 
the scatter kernels used for dose calculation are based on Monte Carlo studies using 
energy spectra from conventional beams, incorporating beam hardening from the 
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flattening filter. Ideally these kernels should be re-calculated and incorporated into 
the TPS. 
IMRT plans generated with FFF beams also tend to contain more segments that 
those seen for flattened beams, so there is scope to improve the fluence optimisation 
and segmentation for FFF beams by taking the beam profile more fully into account. 
Hopefully this will improve the efficiency of the delivery, making full use of the 
increase in dose rate. 
It is expected that the reduced scatter in FFF beams will increase the dosimetric 
accuracy of patient dose distributions, but so far this has not been demonstrated. This 
may be due to the reasons discussed above, and once treatment planning systems are 
optimised for FFF delivery it should be possible to determine if this is true.  
 
8.3.3 Beam steering and isocentre accuracy 
As discussed in section 2.2.10, when operating with a flattening filter in place (i.e. 
under standard operating conditions) the beam positioning is critical, as any 
misalignment will lead to asymmetrical beams. This is therefore closely monitored 
and under constant feedback control. The FFF beam is inherently more stable as the 
amplifying effect of the flattening filter is no longer present; the beam steering coils 
therefore perform a slightly different function in FFF beams. Instead of acting to 
maintain a symmetrical beam, the 2R and 2T currents simply move the beam from 
side to side, maintaining the initial beam shape (figure 2.15). Removing this 
restriction means that the bending and steering coils could be used for another 
purpose. 
The intercept of the beam central axis with the gantry, collimator and couch 
rotation axes is known as the isocentre (figure 1.11). Ideally this is a single point in 
space, but due to the weight of the gantry arm and the torque exerted by the 
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treatment head the isocentre is realistically confined to a sphere with a diameter of 
approx. 1mm (figure 8.2). For stereotactic treatments this is on the limit of what 
would be acceptable, and improvements on this would be desirable. By changing the 
2R, 2T and bending fine (Bf) currents the beam can be shifted in space, therefore it 
should be possible to actively reposition the beam as the gantry rotates so that the 
variation in radiation isocentre is minimised. This concept is not possible on a non-
FFF linac due to the reasons discussed earlier, but as the need for these servo systems 
is reduced and their original function is changed it might be a possibility to utilise 
this effect. The 2R and 2T lookup tables would therefore be used, not to maintain a 
flat beam, but to reposition the central axis of the beam according to a set pattern as 
the gantry rotates, counteracting the effects of gantry sag (figure 8.3). 
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Figure 8.2. Ideally, the mechanical and radiation isocentre should form a single point in space (a) 
and (b). As the gantry rotates the sag and twist of the treatment head causes the isocentre form an 
ellipse of approx. 1mm diameter (c) and (d). 
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Figure 8.3. By changing the currents in the bending magnets and steering coils it could be possible to 
redirect the beam along a path to counteract the sag of the treatment head with gantry rotation. This 
would reduce the size of the isocentre enabling more accurate stereotactic treatments.  
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APPENDIX A 
 
INTENSITY MODULATED 
RADIOTHERAPY (IMRT) 
 
Starting in the 1980s and through the 1990s the mainstay of treatment planning was 
3D conformal radiotherapy (3DCRT). However, depending on the size, shape and 
position of a tumour it is often found that the use of uniform intensity beams is often 
not sufficient to adequately treat the tumour whilst sparing surrounding tissues, 
especially if the target has concave surfaces. The ability to adjust the intensity of 
individual rays within a beam can be utilised to achieve better target homogeneity, 
conformity and/or better sparing of normal tissues. This need for beams with non-
uniform intensity was first described by Brahme et al in 1982 and is the basis of 
intensity modulated radiotherapy (IMRT), and refined since by many authors (e.g. 
Bortfeld 1993 and 1999, Webb 2003). 
IMRT is therefore a radiation delivery technique where multiple beams are 
incident on a target site from different directions in which at least some of the beams 
are intensity-modulated so that each beam intentionally delivers a non-uniform dose 
to the target (figure A.1).  
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Figure A.1. In (a) the tumour (orange) is treated with 3D conformal therapy using three beams of 
radiation, all of uniform intensity. The red region shows the area treated by this combination of 
beams which includes the organ at risk (green). By using non-uniform beam intensities (b) the 
treatment area can be created to match the tumour shape, sparing the OAR from the high dose 
region. 
 
The traditional approach in treatment planning is for the planner to create a plan 
based on a manual trial-and-error process using a suitable arrangement of beams. 
The treatment goal is to maximise the dose to the target while minimising the dose to 
the surrounding anatomy and critical structures. This is achieved by manually 
manipulating the beam parameters such as beam angle, shape, weighting etc. to 
achieve a suitable dose distribution. 
 ‘Inverse’ planning reverses this process by defining the clinical goals upfront, 
and using an optimisation algorithm to find the best beam parameters to meet the 
solution. ‘Intensity modulation’ means that the intensity of radiation in a given 
treatment field varies across the field. This is achieved by splitting each field into 
individual ‘beamlets’, where a beamlet is the area representing a potential MLC 
opening (figure A.2). In one dimension this is set by the physical width of the MLC 
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leaf (fixed by MLC design), and in the other by the step increment of the leaf (which 
can be controlled). 
IMRT can be used to either reduce normal tissue complications by more 
conformal shaping of the high dose region thereby improving quality of life, or to 
escalate the dose to the tumour, maintaining NTCP but potentially increasing tumour 
control. 
 
 
 
Figure A.2. (a) The beam can be broken up into individual beamlets, the intensity of each can be 
varied to obtain a more optimal dose distribution. (b) A multileaf collimator (MLC). 
 
Optimisation 
The task of the optimisation algorithm is to find to best combination of beam 
intensities to meet the dose objectives for the tumour whilst maintaining the dose 
constraints set for the organs at risk, usually set as DVH limits (see figure A.3). 
All targets, organs at risk and sensitive structures must therefore be outlined. The 
IMRT prescription defines the limits, priorities, and goals for the optimization 
algorithm. 
Numerous algorithms can be (and have been) used to perform this task. In 
simplistic terms the optimisation engine calculates a cost function, a single number 
describing the difference between the desired plan and the current plan. Then, during 
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each iteration, the intensity of each beamlet is altered to try and minimise this value 
until an optimum dose distribution is achieved. The stopping point is reached either 
when the dose objectives are met or the convergence criterion and/or a set number of 
iterations are reached. 
As with any data reduction technique, this translation of treatment objectives 
into a single objective function results in significant loss of information about the 
dose distribution, so it is important to review the plan thoroughly. The plan with the 
lowest objective function may not necessarily be the best plan, and clinical judgement 
must be applied when reviewing dose distributions. 
 
 
 
Figure A.3. A simple IMRT prescription for prostate IMRT (XiO TPS). 
 
Segmentation 
At the end of the optimisation process the TPS has an ‘ideal’ fluence map 
representing the relative intensities of the each beamlet which does not take into 
account any beam delivery constraints. A second step is generally required where the 
‘ideal’ fluence map must be translated into a series of MLC segments using a leaf 
sequencing algorithm. This discretises the ideal fluence map (figure A.4) and converts 
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it into a series of control points specifying leaf positions as a function of MU delivery 
(figure A.5). 
 
 
10 levels 
 
5 levels 
 
Segmented 
Figure A.4. In this XiO plan the ‘ideal’ fluence map needs to be converted into a discrete format by 
choosing a fixed number of intensity levels. With more levels the ideal map is reproduced more 
faithfully, but more segments are needed to deliver the plan. 
 
 
Seg 1 
 
Seg 2 
 
Seg 3 
 
Seg 4 
 
Seg 5 
 
Seg 6 
 
Seg 7 
 
Seg 8 
 
Figure A.5. The ideal fluence map is converted into a series of MLC shapes by the leaf sequencer. 
When superimposed on top of each other these beams will produce the segmented distribution. 
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The resulting superposition of MLC shapes may fail to reproduce the ideal 
fluence due to constraints on the shapes that can be made by the MLC (e.g. due to 
limits on over-travel distance, inter-digitation, leakage and scatter). Therefore, 
during this second stage the plan quality is often degraded. This can be reduced by 
decreasing the step size and increasing the number of intensity levels. The plan will 
have more segments and take longer to deliver, but will more closely resemble the 
optimised plan. The more complex the intensity distribution, the greater the 
deviation possible. 
 
IMRT delivery techniques 
IMRT can be delivered by a diverse range of delivery techniques (figure A.6), but the 
common feature is that they all try to control the dose distribution through the 
superposition of a large number of fields either from a number of fixed beam 
directions, or on one or multiple arcs. 
 
 
 
Figure A.6. Modified from Mundt (Intensity Modulated Radiation Therapy: A Clinical Perspective). 
IMRT 
Fixed-gantry 
IMRT 
MLC-based 
Step-and-shoot 
delivery 
Dynamic delivery 
Compensator 
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Fan beam IMRT 
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Helical 
Tomotherapy 
Cone beam IMRT 
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(aperture 
modulation) 
Multiple arc 
(intensity 
modulation) 
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Throughout this thesis we are concerned with two aspects of inverse IMRT; that 
of step-and-shoot (MLC-based, fixed gantry angle), and VMAT (single or multiple 
arc-based cone beam IMRT). 
In step-and-shoot IMRT the fluence is optimised at a set of fixed gantry angles. 
The fluence is then delivered by the superposition of a number of MLC shapes, one on 
top of the other. The beam is turned off whilst the MLCs are moving, and turned on 
again once the new shape has been formed. The gantry then rotates to the next angle 
and the process repeated. 
VMAT (volumetric modulated arc therapy) is an advancement of the intensity-
modulated arc therapy (IMAT) technique first proposed by Cedric Yu (Yu 1995). 
VMAT adds extra degrees of freedom to IMAT in that the gantry speed, dose rate and 
collimator angle, as well as MLC shape, can all be varied during delivery. Single or 
multiple arcs can be delivered depending on the complexity of the problem and the 
degree of modulation required. 
IMRT is an inherently complex process, subject to a multitude of potential 
problems, some of which are discussed below. Several review and guidance 
documents have been published to assist departments in the complex processes of 
IMRT implementation (Ezzel et al 2003 & 2004, IPEM Report 96 2008, Purdy et al 
2001, Van Esch et al 2002). 
 
 
Problems/limitations of IMRT 
Outlining 
Dose placement is controlled by the optimisation algorithm which can only control 
dose in structures which it knows about. All targets and organs at risk must therefore 
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be outlined, which can be very time consuming, even when automatic outlining 
software is utilised. 
 
Optimisation 
All things being equal an IMRT plan should always produce a more homogeneous 
plan than uniform intensity beams from 3D conformal techniques, but in general this 
is not the case. The inhomogeneity occurs due to the overriding need to spare one or 
more critical organs, with the severity depending on the dose constraints and their 
proximity to the target. 
Beam configuration can also have a significant effect on the plan quality. For 
fixed-beam IMRT beam angles are generally chosen so that the shortest path to 
irradiate the target, avoiding OARs, often placed in equi-angular steps, but the best 
distribution will be achieved by a large number of beam angles. Depending on the 
complexity of the plan the quality is seen to saturate above a certain number. If 7 to 9 
beams are employed at evenly spaced gantry angles this is usually sufficient and 
beam angle optimisation does not add much to the plan. Stein et al found that this 
was most valuable for less than 6 beams (Stein 1997). Das et al (2003) showed that 3 
to 5 beams optimised for beam angle gave similar results to a large number of beams 
evenly spaced. In general it is seen that 5 to 7 beams are sufficient for most plans with 
no beam angle optimisation. 
In principle gantry angles can be optimised along with the beamlets but the 
computational time becomes excessive. Beam intensity profiles must be optimised for 
every test configuration because the influence of the gantry angles is not known until 
this beamlet optimisation is performed. 
The use of VMAT technologies removes the need to decide on set gantry angles 
up-front. The start and stop positions for the delivery are specified and the algorithm 
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optimises the fluence delivery at each point on the gantry rotation. IMRT plans that 
are sensitive to number of beams and gantry angles used can benefit from this type of 
treatment. 
 
Beam start-up 
IMRT treatments delivered with step-and-shoot techniques tend to have a large 
number of segments, mostly with low MU (e.g. <10). For low MU delivery it is 
important for the beam to stabilise as quickly as possible after start-up as during 
start-up the beam energy, dose per MU and beam profiles can be unstable and vary 
from there intended characteristics. For VMAT delivery the quality of the delivery is 
also dependant on the rapid stabilisation of the beam as the gantry rotates. 
 
Uncertainties in small field dosimetry 
The doses associated with the small, off-axis, elongated fields associated with IMRT 
are difficult to predict. Most treatment planning systems have a limited ability to 
model changes in head scatter for complex situations, and variations in energy 
spectrum across the flattening filter and through treatment aids (such as the couch-
top). This uncertainty requires the use of pre-treatment/patient-specific QA for IMRT 
plans. 
 
Patient-specific QA 
The intention of patient specific QA is to ensure that the correct dose and dose 
distribution are delivered to the patient. It is often difficult to determine if differences 
between measured and planned dose distributions are due to the TPS, data transfer, 
linac delivery, the measuring device or the analysis of the data. Detailed knowledge of 
each part is required to identify the cause of any discrepancies. 
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Patient specific QA is very time consuming and requires the use of specific 
equipment (figure A.7). 
 
Leakage radiation 
IMRT as an inefficient way to deliver dose, increasing MU demand by 2-3 times over 
conventional delivery. Leakage radiation scales directly with MU so out-of-field doses 
to the patient will increase. This raises the whole-body dose to the patient and may 
lead to increased demands on bunker shielding if IMRT is used for a significant 
proportion of treatments. 
 
(a)        (b)  
 
Figure A.7. Examples of equipment used for patient specific QA forIMRT. (a) The MatriXX (IBA, 
Germany) and (b) Delta4 (ScandiDos, Uppsala, Sweden) devices. 
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APPENDIX B 
 
DEFINITION OF PLANNING 
VOLUMES 
 
Improvements and advances in radiotherapy must be measured by patient outcome 
in terms survival and quality of life, which relies heavily on the follow-up of patients. 
This in turn relies on the accurate prescribing, recording and reporting of 
radiotherapy doses. To do this it is necessary to have consistency in the way targets 
and organs are specified and to report these in a consistent way. The way in which 
tumours are outlined can vary, as do the prescription points, doses delivered and 
tolerance doses for organs. The sharing of data between different institutions and 
countries relies on this. 
A dose difference as small as 5% may lead to a change in tumour response, or 
more likely, a change in normal tissue complication rate. This level of uncertainty in 
dose can easily be introduced by different reporting methods, and inadequate 
reporting can lead to the false interpretation of a study and its wrongful application. 
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ICRU volumes 
The definition and delineation of treatment volumes has been defined by the 
International Commission on Radiation Units and Measurements (ICRU) and 
evolved with radiotherapy technology from Report 29 in 1978, through Report 50 
(ICRU 1993) and a subsequent supplement to this, Report 62 (ICRU 1999) (figure 
B.1). These reports provide recommendations on the volumes and absorbed doses 
important to prescribing, recording and reporting radiotherapy treatments. These 
volumes are: 
 
 Gross Tumour Volume (GTV) 
 Clinical Target Volume (CTV) 
 Planning Target Volume (PTV) 
 Treated Volume 
 Irradiated Volume 
 Organ at Risk (OR or OAR) 
 Planning Organ at Risk Volume (PRV) 
 
Gross Tumour Volume (GTV) 
The GTV represents the gross palpable or visible extent and location of the tumour. 
The extent can be determined by palpation or direct visualisation, or indirectly 
through different imaging modalities (CT, MRI etc), and may appear different 
depending on the examination technique used. If the tumour has been surgically 
removed before radiotherapy then no GTV can be defined. 
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Figure B.1. Changes in the ICRU definition of volumes from report 29 to 62. 
 
Clinical Target Volume (CTV) 
Pathology studies of tumours removed surgically confirms that the GTV is generally 
surrounded by a region of ‘normal’ tissue, which may be invaded by subclinical 
microscopic extensions of the tumour. The CTV is an anatomical concept 
representing the volume of known or suspected tumour as it must be assumed that 
there may be cancer cells present even if they can’t be detected.  
If the cancer has spread to other regions of the body then there may be more than 
one CTV. Delineation therefore requires careful consideration of the capacity for local 
invasion to different regions and spread to the lymph nodes 
The largest component of the GTV to CTV margin may be the delineation error in 
drawing the GTV. Consideration should be made for this in the margin used. 
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Internal Target Volume (ITV) 
ICRU Report 62 recommends that an internal margin (IM) be added to the CTV to 
compensate for internal physiological movements and variations in the size, shape, 
and position of the CTV during treatment. The volume that includes the CTV with 
these margins is called the internal target volume (ITV) and therefore the ITV =  CTV 
+ IM. 
 
Set-up Margin (SM) 
To account for uncertainties in mechanical and human alignment a Set-up Margin 
(SM) is needed.  These uncertainties depend on many factors, such as: 
 
– variations in patient positioning, 
– mechanical uncertainties of the equipment (e.g., sagging of gantry, 
collimators, and couch), 
– dosimetric uncertainties, 
– transfer errors from CT and simulator to the treatment unit, 
– human factors. 
 
Planning Target Volume (PTV) 
The PTV is a geometrical concept to ensure prescribed dose is actually delivered to 
the CTV throughout the course of treatment and therefore consists of the Internal 
Margin (IM) and the Set-up Margin (SM). In practice the IM and SM are not added 
linearly but are combined together through the use of a ‘margin recipe’. 
These formulae are based on imaging studies identifying the random and 
systematic errors for a set treatment, and will be particular to each treatment centre. 
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The combination of each source of uncertainty, and therefore the margins required 
for each type of treatment can be calculated from population based studies. Many 
‘margin’ formulae exist and the reader is referred to the publication ‘Geometric 
Uncertainties in Radiotherapy’ (BIR 2003) for further information. 
 
Organs at Risk (OR/OAR) 
Organs at Risk are normal tissues (e.g., spinal cord) whose radiation sensitivity may 
significantly influence the treatment planning process of prescribed dose. Knowledge 
about the sensitivity of normal tissues is derived mainly from clinical observations. 
 
Planning Organ at Risk Volume (PRV) 
As with the PTV, any movements of the Organ(s) at Risk during treatment, as well as 
uncertainties in the set-up during the whole treatment course, must be considered. 
The PRV is a geometrical concept used to ensure adequate OAR sparing will actually 
be achieved. 
Note that a PTV and a PRV may overlap and a ranking needs to be established as 
to which takes priority, and the prescribed dose, or clinical intent altered to allow for 
this. 
 
Treated Volume 
The PTV should be enclosed by a minimum isodose surface which is adequate to treat 
the target. The volume enclosed by this isodose surface (usually 95%) is called the 
treated volume, and is generally larger than the planning target volume. 
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Irradiated Volume 
The volume of tissue receiving a significant dose (e.g., 50% of the specified target 
dose) is called the irradiated volume. Again, this will depend on the treatment 
technique used, but will be larger than the treated volume. Figure B.2 illustrates the 
layering of these ICRU volumes. 
 
 
 
Figure B.2. ICRU volumes. 
 
Dose Reporting 
For simple plans it is adequate to report the dose the ‘ICRU reference point’. This is a 
point within the plan that is: 
 
 Clinically relevant and representative of the dose throughout the PTV 
 Easy to define 
 In a region where dose can be accurately determined 
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A suitable place would be within the central part of the tumour, ideally at the 
isocentre, and it is a basic requirement of ICRU to report the dose at the ICRU point 
and maximum and minimum doses to the PTV. The dose delivered to the tumour 
should be as uniform as possible, but kept within +7% and -5% of the prescribed 
dose. 
ICRU Report 83 (ICRU 2010) extends these reports further to include the 
specific challenges of IMRT. In essence dose reporting should not to a fixed point, but 
to a volume because of the sharp dose gradients involved. The most stable way to 
prescribe the dose is the median dose (D50%), and maximum and minimum doses are 
reported at D2% and D98%. The use of biological evaluation is also encouraged via the 
use of TCP, NTCP and EUD. 
 
Reducing margins 
A clear goal for radiotherapy is the reduction of treatment margins. In this way the 
volume of normal tissue irradiated can be minimised, resulting in fewer and less toxic 
complications. Improvements in imaging have led to the potential for more accurate 
target definition, but the accurate delineation of tumours is still of great concern. 
Outlining exercises performed on standardised cases have demonstrated the 
variation in the outlining of target volume both between hospitals and between 
professions (ICRU 50, ICRU 60, Weiss et al 2003). The standardisation of outlining 
is a critical step in reducing margins and is being tackled through training and 
participation in clinical trials etc. 
Once the GTV and CTV are outlined, the radiation dose that can safely be 
delivered to the target is restricted by the damage caused to surrounding structures. 
If the PTV margin can be reduced then side effects can be minimised, or there is the 
possibility of dose escalation to improve tumour control (maintaining side effects). 
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The goal of IGRT is to improve the accuracy of the dose delivery by routinely 
imaging the patient in the treatment position during the course of treatment. By 
having a detailed knowledge of the actual position of the target and critical structures 
it is possible to reduce treatment margins, thereby reducing the amount of normal 
tissue irradiated. There are numerous approaches to IGRT which are beyond the 
scope of this report. Readers are referred to the publication ‘On Target: ensuring 
geometric accuracy in radiotherapy’ (RCR, 2008) for more information. 
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APPENDIX C 
 
PUBLICATIONS 
 
 
This article was published in the journal Physics in Medicine and Biology in 2008 
and reports on the initial research performed to characterise the operation and 
dosimetric properties of an Elekta linear accelerator running without the flattening 
filter. This article forms the basis of most of chapter 2. 
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Abstract
Commissioning data have been measured for an Elekta Precise linear
accelerator running at 6 MV without a flattening filter with the aim of
studying the effects of flattening filter removal on machine operation and beam
characterization. Modern radiotherapy practice now routinely relies on the
use of fluence modifying techniques such as IMRT, i.e. the active production
of non-flat beams. For these techniques the flattening filter should not be
necessary. It is also possible that the increased intensity around the central axis
associated with unflattened beams may be useful for conventional treatment
planning by acting as a field-in-field or integrated boost technique. For this
reason open and wedged field data are presented. Whilst problems exist in
running the machine filter free clinically, this paper shows that in many ways
the beam is actually more stable, exhibiting almost half the variation in field
symmetry for changes in steering and bending currents. Dosimetric benefits
are reported here which include a reduction in head scatter by approx. 70%,
decreased penumbra (0.5 mm), lower dose outside of the field edge (11%) and
a doubling in dose rate (2.3 times for open and 1.9 times for wedged fields).
Measurements also show that reduced scatter also reduces leakage radiation by
approx. 60%, significantly lowering whole body doses. The greatest benefit of
filter-free use is perceived to be for IMRT where increased dose rate combined
with reduced head scatter and leakage radiation should lead to improved dose
calculation, giving simpler, faster and more accurate dose delivery with reduced
dose to normal tissues.
1. Introduction
The flattening filter is regarded as an essential component of almost all linear accelerators,
acting to produce a flat beam from the forward-peaked photon fluence produced at the target.
However, despite their longstanding use in medical linear accelerators a number of problems
0031-9155/08/071933+14$30.00 © 2008 Institute of Physics and Engineering in Medicine Printed in the UK 1933
1934 J Cashmore
still remain. Monte Carlo studies have shown that the flattening filter is responsible for
the majority of scatter produced in the treatment head (Petti et al 1983, Zhu and Bjarngard
1995) and is dependent on machine type and energy. Large amounts of head scatter make
the complex, often elongated and off-axis fields shapes used in IMRT very difficult to
calculate, limiting dose calculation accuracy and making this the subject of continuing research
(Lam et al 1996, Hounsell and Wilkinson 1997, Jiang et al 2001, Zhu and Bjarngard 2003,
Redpath 2005, Sikora et al 2007). Its presence also causes changes in beam quality away from
the central axis necessitating the use of off-axis spectra and acts as the main source of electron
contamination (which is also very difficult to model) (Nilsson 1985, Hounsell and Wilkinson
1999, Klein et al 2003). Mechanical positioning and electron beam steering are also crucial
as any misalignments lead to asymmetries in the photon beam.
The problem with unflattened beams of course has always been the forward peak to the
dose distribution. For IMRT however this should not be a problem as the actual beam shape
can be taken into account in the segmentation process and therefore the filter should not be
necessary at all. Also in many conventional planning situations, such as the head, neck and
breast, a flat radiation field leads to radiation hotspots at the periphery of the target with
the central portion of the beam left cold. In these cases a central axis boost is required,
necessitating the use of field-in-field techniques or the addition of further beams from other
directions. The forward peak associated with filter removal gives an inherent central axis
boost, hence open and wedged beam characteristics have been measured with the aim of
assessing any benefits to conventional treatment planning.
Flattening filter removal should greatly reduce the magnitude of head scatter and its
variation with field size, simplifying these calculations and improving dose accuracy. Dose
rate will be greatly increased and the x-ray spectrum should exhibit much less variation across
the beam portal. All of these effects are potentially desirable properties for radiotherapy
beams.
Previous studies have mainly focused on the use of Monte Carlo methods to study beam
characteristics (Fu et al 2004, Titt et al 2006a, 2006b, Vassiliev et al 2006a, Mesbahi 2007),
with the notable exceptions of Vassiliev et al (2006b), Ponisch et al (2006) and Zhu et al
(2006) who have measured open beam properties for a Varian Clinac 21EX. The present study
provides a thorough set of commissioning measurements for both open and wedged beams for
an Elekta Precise linear accelerator with the focus on reduced head scatter for IMRT and beam
shape (open and wedged) for conventional planning. The aim is not only to compare beam
characteristics but to study the operation of the machine ready for clinical use and produce a
functional beam model for unflattened beams for treatment plan comparisons.
2. Materials and methods
A low energy Elekta Precise linear accelerator fitted with a standard 80 leaf MLC producing a
6 MV photon (and 10 MeV electron) beam was used for measurements. The flattening filter is
mounted at the secondary filter stage on a five-position rotatable carrier (carousel) in the head
of the machine. Only two of these ports are used clinically in a low energy machine: one for
the flattening filter and the other for the 10 MeV electron scatter foil, leaving three ports free.
Within the machine’s service mode it is a simple matter to rotate the filter out of the beam line
leaving an open port. As well as utilizing an open port the additional unused ports were also
used to house various thicknesses of copper and aluminium to study the effects of electron
contamination on surface dose and machine operation.
A new, independent machine energy was created to run unflattened beams and kept
inaccessible to the machine’s ‘clinical mode’. All energy-specific beam parameters pertaining
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Table 1. Measurements made. Depth doses and profiles were measured with a Semiflex 0.125 cc
chamber, scatter factors with a Farmer NE2571 chamber and build-up and surface doses with a
NACP chamber in solid water.
Depth doses Open/wedge 5, 10, 15, 20, 30 cm2
Profiles Open/wedge 15, 50, 100, 150, 200 mm depths
For 5, 10, 15, 20, 30 cm2
Open diagonal 40 × 40 cm2
Total scatter factors 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 30, 40 cm2
Head scatter factors 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 30, 40 cm2
Wedge factors 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 30 cm2
Build-up Open 5, 10, 15, 20 cm2 at 0–17 mm depths
Surface dose Open 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 30, 40 cm2 at 3 mm depth
Leakage 50 cm and 100 cm from isocentre, patient plane
Dose rate Open/wedge 10 × 10, dmax (15 mm)
to 6 MV were copied to this new energy and the gun servo, steering currents, beam hump and
uniformity reset to allow the beam to run with all interlocks engaged.
Beam profiles and depth dose measurements were taken using a PTW MP3 Tandem
watertank with Semiflex 0.125 cc chambers and running Mephysto 7.4 water phantom
software. For scatter and wedge factor measurements a NE2571 Farmer chamber was used.
Build-up measurements were made with a NACP parallel plate chamber.
A full set of commissioning data as recommended by CMS (2003) was measured along
with surface and out-of-field doses to compare with concurrently measured 6 MV data
(table 1).
Central axis depth dose measurements were measured for square fields from 5 × 5 to
30 × 30 cm2 at 100 cm SSD for both open and wedged beams and profiles taken at five depths.
A 40 × 40 cm2 open field diagonal profile was also taken for beam modelling purposes.
Penumbra measurements were made from films exposed at 100 cm SSD under 15 mm of solid
water using Kodak X-Omat V film. Analysis was performed using a VIDAR scanner and
ImageJ software (Rasband 2006).
3. Results
The beam essentially remains unaffected up until the point where it would normally strike the
flattening filter; hence the vast majority of accelerator running parameters remain unchanged.
Problems only start to arise when the beam reaches the ionization chamber; not only does this
monitor the dose delivered but also acts to servo the radial and tangential steering currents
(2R and 2T on Elekta machines) to maintain a symmetrical beam. The difference between the
inner and outer plates (hump error) is also used to control the gun current and hence maintain
beam energy. There are therefore three fundamental questions to ask of machine performance
in removing the flattening filter:
(1) How does the increased dose rate/dose per pulse affect dosimetry?
(2) Can the gun servo be reset and still function to control the beam energy?
(3) Can the steering current servos be reset to allow operation around their new values?
3.1. Dosimetry
The first (and most obvious) consequence of taking out the flattening filter is the huge increase
in observed dose rate. Running both beams at peak dose rate and taking measurements at dmax
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Figure 1. Dose-per-pulse dependence of a NE2571 Farmer type chamber.
(15 mm) with a Farmer chamber the dose rate is seen to rise by an average of 2.3 times for an
open beam and by 1.9 times for a wedged beam. The lower value seen for the wedged beams is
due to increased absorption (lower wedge transmission factor) in the physical wedge because
of the change in energy spectrum. This increase in dose rate could clearly be a useful factor in
many treatments (e.g. respiratory-gated breathing and stereotactic radiosurgery [SRS]) but the
dose rate can always be lowered by dropping the pulse repetition frequency to regain normal
dose rates if desired.
Repeat measurements under standard conditions confirm that the internal ion chambers
respond well to the higher dose rate and that doses delivered are accurate (<1% error) down
to 2 mu.
Figure 1 shows the dose-per-pulse dependence of a NE2571 Farmer chamber which is
varied by changing the SSD, the curves are normalized at 100 cm SSD for a 10 × 10 cm2 field.
The dose-per-pulse will affect the response of the chamber, but the two curves overlie each other
indicating that these corrections should hold even at these high dose rates. The characteristics
of ionization chambers to pulsed radiation beams have been well reported (Derikum and Roos
1993, Bruggmoser et al 2007) but further work will be required to ascertain correction factors
for these beams. In the current software version the machine cannot be calibrated to 1 mu =
1 cGy under standard conditions due to a software limitation on the range of ‘dose reference’
values.
3.2. Beam steering
Mechanical positioning of the flattening filter and accurate steering of the electron beam are
crucial to flat beam production as any misalignment will lead to non-flat, asymmetrical beams.
Starting from a symmetrical beam the 2R current (controlling symmetry in gun–target axis)
was varied by ±50 mA and bending fine (Bf) by ±20 mA. Measurements with a Schuster
BMS96 linear array (88 diodes with 5 mm spacing) demonstrate that for variations in beam
steering and bending currents the unflattened beam exhibits almost half the variation in field
asymmetry (ratio of absorbed dose at points ±12 cm about the central axis) compared to the
flattened beam (see table 2).
For flattened beams the dose either side see-saws about the central axis with the actual
shape and magnitude of the shifts depend on a complex interaction of steering and bending
currents that can be difficult to decouple (Karzmark et al 1993). For non-flattened beams,
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Figure 2. Profiles from a Schuster array demonstrating changes in beam symmetry for variations
in 2R bending current of ±50 mA. For the flattened beam the asymmetry (ratio of absorbed doses
±12 cm from the central axis) amounts to 7.4% compared to 4.1% with the filter removed.
Table 2. Beam symmetry measurements recorded with a Schuster array. Values quoted are the
percentage difference of readings ±12 cm off axis compared to the central axis value.
FF in FF out
2R +50 mA +7.3% +3.8%
−50 mA −7.5% −4.4%
Bf +20 mA +4.1% +1.5%
−20 mA −6.5% −2.4%
rather than altering the beam shape these variations simply act to shift the beam asymmetrically
with the profile remaining the same relative shape (figure 2). In fact, the beam is so stable
that the first interlock to be triggered when the steering currents are driven off is usually that
for ‘low dose rate’ which is due to a loss of beam current as the beam is driven away from the
target.
Small changes in energy and beam positioning during start-up are magnified by passing
through the flattening filter. This can be a significant problem for IMRT where segments
may be delivered with low numbers of monitor units (Sharpe et al 2000) and where the
beam is unable to stabilize before the dose has been delivered. Delivered dose distributions
could clearly be adversely affected by this. Since the flattening filter acts as an amplifier for
any changes in beam steering and energy these problems are reduced with its removal. The
Schuster array again was used to study beam start-up characteristics by integrating the dose
over a low dose delivery. Whereas repeat measurements for a conventional beam show a 1.5%
tilt in beam symmetry for a 5 mu beam (symmetry measured as defined previously), for the
unflattened beam this is only 0.3%.
The flattening filter is an energy-sensitive component producing changes in beam profile
as the beam energy varies. Elekta machines take advantage of this to servo the beam energy by
monitoring the differences in the inner and outer plate signals (hump error) of the ionization
chamber. Although the beam runs well under normal conditions the energy sensitivity with
the filter out may not operate correctly under all circumstances and needs further study. In
other accelerators the energy is regulated by other means (such as by controlling the voltage
on the PFN to achieve maximum ion chamber current), so this would not be an issue.
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Figure 3. Specification of points used to measure patient plane leakage. The circles are of radii
50 cm and 100 cm. Readings at these points are taken with the collimators in the closed position
and compared to a central axis reading for a 10 × 10 cm2 field.
Table 3. Patient plane leakage measurements. G and T refer to movements towards the Gun and
Target. A and B refer to movements left and right of centre when standing facing the gantry.
Leakage radiation (% of reference reading)
Position Filter in Filter out % Decrease
50 cm G 0.012 0.0068 42.2
50 cm T 0.005 0.0029 45.9
50 cm A 0.018 0.0079 55.4
50 cm B 0.019 0.0072 62.0
100 cm G 0.013 0.0054 58.5
100 cm T 0.011 0.0032 69.6
100 cm A 0.018 0.0079 55.4
100 cm B 0.025 0.0061 76.0
Average decrease 58.1%
3.3. Leakage radiation
Patient plane leakage measurements were taken as recommended by the Elekta acceptance
documents (Elekta 2005). A Farmer chamber (with 1.5 cm build-up cap) is placed at the
cardinal angles at 50 and 100 cm from the isocentre (see figure 3). With the diaphragms
closed the absorbed doses at these points are compared to a reference dose measured for a
10 × 10 cm2 field at the isocentre. The leakage dose should not exceed 0.1% of the dose at
the isocentre and this is easily achieved during normal use. For IMRT delivery, the number
of monitor units required can be raised significantly compared to open beam delivery and
hence leakage radiation will increase proportionally. Without the flattening filter the dose, on
average, is 58% lower than those recorded for normal use (table 3).
Although the transmission factor through the MLC leaves and collimators remains
essentially the same (ignoring any spectral changes) the new beam shape means that the
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Figure 4. Depth doses for a 10 × 10 cm2 field at 100 cm SSD. Lack of beam hardening is seen as
an energy decrease to approx. 5 MV.
Table 4. Comparison of beam quality parameters.
Nominal Beam PDD at 10 cm deep, Depth of 80% dose, Depth of dose max. QI
energy (MV) description D10 (%) d80 (cm) dmax (cm) (TPR 20/10)
6 FF in 67.6 6.7 15 0.679
6 FF out 65.2 6.3 13.5 0.653
5 BJR 5 MV 65.0 6.2 12.5 0.646
photon fluence naturally falls off with distance from the central axis (falling to 50% at the
beam edge). The magnitude of the leakage radiation through the collimators will scale directly
with that of the photon fluence, so the dose outside the field edge (to normal tissues) will also
be lower. This is a simple consequence of there being less primary radiation present at off-axis
positions.
3.4. Depth doses
The flattening filter significantly hardens the radiation beam on the central axis but due to its
physical shape the beam quality decreases with distance from the central axis. Production of
contaminant electrons also affects depth doses beyond dmax but major effects are mainly seen
in the surface region.
Central axis depth doses were measured at 100 cm SSD and normalized at a depth of
15 mm for open and wedged square field sizes from 5 × 5 to 40 × 40 cm2 (30 × 30 cm2 for
wedge).
The filter attenuates the low-energy component of the spectrum increasing the apparent
energy of the beam. With unflattened beams the addition of these soft x-rays to the beam
spectrum lowers the observed energy and produces a beam with characteristics similar to a
5 MV beam (Jordan 1996) (figure 4). Table 4 shows comparisons for most of the commonly
used beam specification parameters which also demonstrate a good match to 5 MV data. The
flattening filter obviously hardens the beam appreciably but this drop in energy could easily be
compensated for by adjusting accelerator parameters, if so desired. As yet there is very little
published depth dose data for unflattened beams and none for Elekta accelerators or wedged
beams, so if BJR25 were to be updated at some point it would be a good opportunity to include
sample data.
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Figure 5. Build-up curves for a 10 × 10 cm2 field measured in solid water. Filter-free beams show
slightly increased surface dose compared to filtered beams at 6 MV.
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Figure 6. Variation of surface dose (at 3 mm depth) with equivalent square normalized to a 10 ×
10 cm2 field. Maximum to minimum ratio is 1.42 with the flattening filter in and 1.23 without, i.e.
half the variation
3.5. Surface dose
Measurements in the build-up region show that there is a slight increase in surface dose with the
flattening filter removed (figure 5). The reduced head scatter however produces appreciably
less variation in dose near the surface (measured at 3 mm depth) with field size (figure 6) than
is seen for flattened beams. Measurements were also performed with thin sheets of copper
and aluminium (1.1 mm Al, 1.9 mm Cu, 1.9 mm Al) in place of the flattening filter with the
hope of reducing surface dose, but no appreciable reduction is seen. During conventional
use the contamination electrons produce a large position-dependent dose in the ion chamber
servo plates which are then used to control the beam. With the filter removed the number
of electrons reaching the ion chamber is so low that the signal at the servo plates is too low
to operate the servos correctly. A certain amount of build-up is therefore necessary to boost
these signals and the use of metal sheets demonstrates an increase in these signals and in the
servo control of the beam, allowing the machine to run not just in service mode but with all
interlocks engaged.
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Figure 7. Lateral dose profiles of unflattened beams at a depth of 10 cm. Field sizes are 5, 10, 15,
20 and 30 cm2.
Monte Carlo studies have demonstrated that the low-energy components of the beam
spectrum are significantly enhanced (Tsechanski et al 2005, Mesbahi 2007) and these photons
would be expected to deposit energy in the build-up region. The fact that depth dose curves
are not altered significantly therefore indicates that the electron contamination in the beam
must be lowered by a similar amount. This role reversal has a twofold benefit: firstly x-rays
are much easier to model than electrons leading to possible improvements in the modelling
of the build-up region and secondly these low kV photons will act to improve the contrast of
portal images.
3.6. Profiles
Water tank scans show the forward-peaked nature of open beam profiles (figure 7). Small
field scans show only minor differences in beam profile to those recorded normally as the
flattening filter has very little effect over these dimensions; field sizes of 5 × 5 cm2 and below
show almost no change in profile. Larger field sizes show enhanced central axis dose with a
rounding of the profiles; similar results have been shown for open beams with a Clinac 21EX
(Vassiliev et al 2006b). Outside the treatment field the doses are lower for non-flattened beams
due to the reduction in out-of-field scatter. This would effectively act to reduce the dose to
surrounding normal tissues. At 90 cm SSD, 10 cm deep for a 10 × 10 cm2 field, the dose
2 cm outside the field edge is reduced from 7.9% to 7.0% (11.3% relative change).
Beam profiles of the internal motorized wedge (nominal 60◦) again show that there is a
slightly faster drop-off in dose at the beam edge and lower dose outside of the field (figure 8).
The wedge profiles are slightly convex rather than concave but importantly the overall effect
of the wedge is retained. The wedge angle itself drops slightly from 56◦ to 53◦ for a 10 ×
10 cm2 field but these factors can easily be taken into account by the beam model.
3.7. Penumbra
The finite dimensions of ion chambers used for water tank measurements means that a blurring
effect is added to recorded profiles and so any subtle changes in beam penumbra can be missed.
Films were therefore used to assess beam penumbra (defined as the distance from 20% to 80%
isodoses measured at 100 cm SSD at dmax). As expected, removal of the flattening filter
produces a change in beam penumbra due to reduced extra-focal radiation, these effects
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Figure 8. Comparison of measured wedge profiles for a 20 × 20 cm2 field, normalized at dmax.
Profile depths are at 15 and 100 mm.
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Figure 9. Head scatter measured using a perspex mini-phantom (normalized to a 10 × 10 cm2
field).
however are of the order of 0.5 mm and although this is of course a good thing it will probably
be of little practical advantage.
Obviously, as the field size increases the 80% point will lie some distance from the beam
edge and another definition of penumbra is needed to make these values meaningful. The
most likely definition involves redefining the position of the 100% reference point to be at the
inflexion point of the curve rather than at the central axis.
3.8. Head scatter
Figure 9 shows head scatter measurements as a function of field size made using a perspex
mini-phantom (90 cm SSD, 10 cm deep). A significant decrease is seen in the range of
readings compared to the flattened field and a variation of only 3% is seen over the entire
range 4 × 4 to 40 × 40 cm2 compared to 9% with the filter in place. This is a reduction of
approximately two thirds and matches well with other reported data (Zhu et al 2006). This has
obvious consequences for beam dosimetry where errors in the calculation of head scatter lead
to errors in monitor unit calculation, particularly in complicated off-axis (IMRT) situations.
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Figure 11. Variation of total scatter factor measured at 100 cm SSD, dmax, and normalized to a
10 × 10 cm2 field.
One of the other major consequences of head scatter is the variation seen in machine
output for rectangular fields depending on which jaw, upper or lower, defines the larger
dimension. Measurements of this collimator exchange effect were made by sequentially
fixing the X and Y jaws at 4 cm and varying the other jaw dimension from 4 to 40 cm. The
magnitude of the effect is on average 1.6% for standard operation and 0.6% with the filter
removed (figure 10). These figures reflect the two thirds reduction of head scatter observed in
figure 9.
3.9. Total scatter
Total scatter factors measured at 100 cm SSD, dmax, also show a reduced range when plotted
against equivalent square (see figure 11) with significant reduction at large field sizes. The
difference in the two measured curves is due to the reduction of head scatter as the phantom
scatter remains essentially the same and depends on the field dimensions at the surface.
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Figure 12. Wedge factors plotted on the same scale to compare variation with field size. The ratio
of 30 × 30 to 4 × 4 readings is 1.098 with filter in and 1.055 filter out.
The ratio of 40 × 40 to 4 × 4 cm2 readings is 1.15 for the flattened beam and 1.08 for the
filterless beam, i.e. half the variation in total scatter factor. Similar results have been shown
by Ponisch et al (2006).
3.10. Wedge factors
The softer spectrum and associated decrease in beam energy to approx. 5 MV lead to an
increase in x-ray attenuation and hence to lower values of the wedge factor. Reduced head
scatter also leads to less variation with field size; the ratio of 30 × 30 to 3 × 3 cm2 readings for
the flattened beam is 1.098 compared to 1.055 with the flattening filter out, i.e. half the relative
range (figure 12). Again filter removal is seen to reduce the variation in field-size-dependent
parameters.
4. Discussion and conclusions
Linear accelerator design has evolved around the need for flat radiation fields and a certain
number of problems must be expected when the flattening filter is removed. Measurements
reported here show that these problems, however, are fairly minimal and most likely to be
resolved it seems with relatively simple software modifications since the vast majority of all
machine running parameters remain unchanged. The only differences are observed at the
ionization chamber where beam parameters such as flatness, symmetry and uniformity need
to be reset, but this can be performed relatively easily and, with some build-up in place, the
chamber servos operated well during the duration of the experiments. In fact, with the filter
removed the beam symmetry is half as sensitive to changes in beam steering, retains a more
consistent profile with these changes and is more stable during start-up irradiation.
To operate the machine clinically however it would be necessary to modify current IEC
specifications (BS EN 60976 2001) which are based upon having square, flattened radiation
fields. The standards are written to ensure the protection of the operator and patient and
to define a number of parameters by which users can compare accelerator performance.
With unflattened beams terms such as ‘flattened area’ are meaningless. Uniformity, flatness,
symmetry, penumbra and field size definitions may need to be redefined for these beams.
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The major benefit of filter removal is in the reduction of head scatter and leakage radiation,
both of which cause significant problems in radiotherapy and come as a direct consequence of
producing a flat beam, i.e., forcing a large proportion of the beam to interact in the flattening
filter. Removal leads to a decrease in head scatter (potentially improving dose calculations)
and to lower whole body doses (reducing the risk of secondary cancers). Reduced scatter also
leads to a reduction in penumbra, dose outside of the field edge and gives less variation in
field-size-dependent factors; again all useful properties.
The only major problem then is the actual beam shape. This should not be of much
concern for IMRT since the intensity profile can easily be modulated by the MLCs to produce
almost any profile necessary and the actual beam shape essentially becomes immaterial (within
reason). The fundamental physics behind the IMRT optimization process remains the same;
the modified beam profile is simply taken into account during the segmentation process.
Reduced head scatter and increased dose rate should lead to simpler, faster and more accurate
dose delivery with reduced dose to normal tissues.
The main application for unflattened beams is seen to be for IMRT but this should not
be considered as a limitation for this technique. Small field profiles (<6 × 6 cm2) are almost
unaffected so these can be used as normal. This is especially true of the very small fields used
in stereotactic radiosurgery (SRS) where the flattening filter serves no useful purpose.
Further work will focus on treatment planning studies using larger conventional field
sizes. Preliminary results using these larger fields show that the forward peak is actually very
useful for treating areas such as the breast, where the use of flat radiation beams results in
radiation hotspots at the extremes of the target region. Unflattened beams give an inherent
boost to the centre of the breast to even out the dose over the entire region. Further, by mixing
flattened and unflattened beams together a dose distribution can be formed anywhere between
these two extremes and this can be tailored very simply and effectively to even out these dose
gradients.
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LOWERING WHOLE-BODY RADIATION DOSES IN PEDIATRIC
INTENSITY-MODULATED RADIOTHERAPY THROUGH THE USE
OF UNFLATTENED PHOTON BEAMS
JASON CASHMORE, M.SC.,* MARK RAMTOHUL, PH.D.,* AND DAN FORD, F.R.C.R.y
*Radiotherapy Physics and yCancer Centre, Hall-Edwards Radiotherapy Research Group, University Hospital Birmingham,
Edgbaston, Birmingham, UK
Purpose: Intensity modulated radiotherapy (IMRT) has been linked with an increased risk of secondary cancer
induction due to the extra leakage radiation associated with delivery of these techniques. Removal of the flattening
filter offers a simple way of reducing head leakage, and itmay be possible to generate equivalent IMRTplans and to
deliver these on a standard linear accelerator operating in unflattened mode.
Methods and Materials: An Elekta Precise linear accelerator has been commissioned to operate in both conven-
tional and unflattened modes (energy matched at 6 MV) and a direct comparison made between the treatment
planning and delivery of pediatric intracranial treatments using both approaches. These plans have been evaluated
and delivered to an anthropomorphic phantom.
Results: Plans generated in unflattened mode are clinically identical to those for conventional IMRT but can be
deliveredwith greatly reduced leakage radiation. Measurements in an anthropomorphic phantom at clinically rel-
evant positions including the thyroid, lung, ovaries, and testes show an average reduction in peripheral doses of
23.7%, 29.9%, 64.9%, and 70.0%, respectively, for identical plan delivery compared to conventional IMRT.
Conclusions: IMRT delivery in unflattenedmode removes an unwanted and unnecessary source of scatter from the
treatment head and lowers leakage doses by up to 70%, thereby reducing the risk of radiation-induced second can-
cers. Removal of the flattening filter is recommended for IMRT treatments.  2011 Elsevier Inc.
Flattening filter, Pediatric, Intensity-modulated radiotherapy, Second cancers, Radiation-induced malignancies.
INTRODUCTION
Intensity-modulated radiotherapy (IMRT) is now a well-
established technique used to concentrate dose into target re-
gion/s while sparing normal tissues, and is recognized as
superior to three-dimensional (3D) conformal radiotherapy
(CRT) in these respects. However, the increased number of
beam directions used in IMRT compared with 3D-CRT
means that a low-level ‘‘dose-bath’’ is given to a larger vol-
ume of normal tissues. Leakage radiation from the treatment
head is also raised because IMRT delivery is wasteful of
monitor units (MU), which can increase by a factor of 2 to
10 (typically 3–5) depending on the techniques and equip-
ment used. Since leakage radiation is proportional to the
number of MU delivered, IMRT is seen to increase whole-
body doses to the patient.
Several authors have compared the delivery of 3D confor-
mal plans against IMRT and reported that IMRT delivery
may double the incidence of solid cancers in long-term sur-
vivors (1–5). The range of reported values varies
considerably (1.2–8) because the MU demand for IMRT is
largely dependent on both the software and the hardware
used for planning and delivery, and also on the
radiobiologic models used in each study.
Radiation-induced secondary cancers are not a serious
concern until at least 5 years after treatment (6), with
patients surviving longer than 10 years being most at risk.
After successful treatment of the original disease, secondary
cancers are diagnosed, on average, 15 years after treatment
(7). A recent study (8) showed that of 115 pediatric patients
diagnosed with secondary cancers after radiotherapy, 22% of
the cancers were >5 cm from the planning target volume
(PTV), and some were detected up to 1 m away. The
peak frequency was seen to be in tissues receiving 2.5 Gy
or less.
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With treatmentsbecomingmore successful and survival rates
rising, the importance and incidence of second cancerswill also
increase and are likely to be of particular concern in children.
Peripheral doses are influenced by many factors and have
been reported for a range of accelerators and beam energies
(9–13). The dose to tissues close to the target site (within
several centimeters) is dominated by internal scatter and
head scatter (14) and is dependent on field size and energy.
At distances beyond the range of internal scatter, periph-
eral doses are dominated by head leakage and are therefore
proportional to MU, so they are unavoidably higher for
IMRT. Given that pediatric patients are also physically
smaller, geometric factors play an important role. The dis-
tance from the field edge to any organ at risk (OAR) in a child
(and also the depth from surface) will also be reduced, rais-
ing organ doses relative to comparable exposure in an adult.
One of the major sources of head scatter and leakage radi-
ation in the treatment head is the flattening filter, and opera-
tion of an Elekta Precise linear accelerator without the
flattener has been shown to reduce patient–plane leakage
at 1 m by 58% at 6 MV (15). Other benefits are seen to in-
clude increased dose rate and improved beam stability. Sev-
eral groups have investigated the treatment planning aspects
of unflattened IMRT (16–18), and one author has
investigated peripheral doses through Monte Carlo
modeling (19), but to our knowledge, no direct
Fig. 1. Peripheral dose measurements as a function of distance from the central axis (CAX). Measurements are in water-
equivalent material at a depth of 5 cm. (a) Flattening filter in, (b) flattening filter out for field sizes of 3 3, 6 6, and 10
10 cm2. (c) Comparison between filter in and filter out for 3  3 and 6  6 cm2 fields (10  10 cm2 removed for clarity).
Variation in dose for collimator rotations of 0 and 90: (d) filter in, (e) with the filter out.
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measurements have been reported between out-of-field
doses for clinical delivery of comparative plans. If IMRT
can be planned and delivered using a system with no flatten-
ing filter, then peripheral doses could be significantly re-
duced, lowering the incidence of secondary cancers.
This study aimed to investigate the potential of IMRTwith
unflattened photon beams by directly comparing the treat-
ment planning and delivery of unflattened beam IMRT
against the conventional IMRT standard. Since peripheral
doses are so dependent on the software, hardware, and en-
ergy used, these have been kept constant (i.e., the same plan-
ning system, plan quality, beam energy, and accelerator were
used throughout).
METHODS AND MATERIALS
Linear accelerator
An Elekta Precise linear accelerator (Elekta Ltd, Crawley, UK)
was commissioned at 6 MV with the flattening filter rotated out
of the beam-line to operate in both conventional and unflattened
(flattening filter-free) modes. Filter removal is straightforward be-
cause of its location on a rotating carousel, but the filter also pro-
duces secondary electrons that give an enhanced dose (and
position-dependent information) to the ionization chamber to oper-
ate the steering servos. Without the filter, these signal levels drop
and the servos no longer function correctly. A thin metal plate
was therefore used to provide buildup into the chamber to restore
these signals and allow the machine to function correctly.
Some material is also needed to remove contamination electrons
(which do not provide position information but do increase surface
dose) from the target/primary collimator, and to ensure that there is
always some material between target and patient even in the event
of target failure.
The flattening filter also acts as a beam hardener, removing low-
energy x-rays from the beam spectrum, resulting in an unflattened
6-MV beam having depth dose characteristics similar to those of
a 5-MV beam (15). For a Varian Clinac 21EX, this effect is greater,
resulting in depth dose curves that resemble those of a 4-MV beam
(20). When comparing plans, this change in energy may be an im-
portant factor, with any differences in plans or peripheral doses be-
ing due to this change in energy rather than to any inherent property
of unflattened beams.
Critically in this work the beam energy was raised back to the ap-
propriate energy by matching standard beam quality indices (D10
(67.5%) and QI/TPR20/10 [0.675]) of the clinical beam.
Owing to the differential attenuation caused by the flattening fil-
ter, this match exists only on the central axis (CAX), but in this way
any differences can be directly compared without excessive refer-
ence to beam energy.
As the dose rate is roughly doubled by filter removal for unflat-
tened beam delivery. the pulse repetition frequency was lowered to
maintain the same dose rate between delivery techniques. This re-
moved any uncharacterized effects (such as chamber response, ion
recombination) that might exist because of the delivery of IMRT at
higher dose rates. Barring any small changes in MU and segmenta-
tion, the plans therefore took the same time to deliver in each case.
Although the dose per pulsewas approximately doubled by filter re-
moval, the machine had been recalibrated so that 1 MU = 1 cGy un-
der standard conditions (10 10 cm2, 90 cm SSD, Dmax), as for any
other clinical beam.
Peripheral doses in a slab phantom
To establish a reference and provide baseline measurements, pe-
ripheral doses were measured for standard field sizes in a slab phan-
tom consisting of tissue-equivalent material. Peripheral doses are
Table 1. Summary of dosimetric parameters used for plan
evaluation
PTV coverage
V90 Volume of target (%) receiving 90% of prescribed dose
V95 Volume of target (%) receiving 95% of prescribed dose
V100 Volume of target (%) receiving 100% of prescribed dose
V107 Volume of target (%) receiving 107% of prescribed dose
D2 Dose to 2% of target volume
D98 Dose to 98% of target volume
HI Homogeneity index (D2–D98/Prescribed dose)*100
VPTV Volume of the planning target volume
CI Conformity index volume of tissue VNT 95/VPTV
Normal tissue sparing
VNT5 Volume of tissue receiving 5% of prescribed dose
VNT 95 Volume of tissue receiving 95% of prescribed dose
Table 2. Summary of doses (in Gy) recorded for planning target volume (PTV) coverage in each plan for flattening filter in (In) and
filter out (Out) according to the evaluation parameters in Table 1
Case1 Case2 Case3 Case4 Case5
In* Out* In Out In Out In Out In Out
V90 99.4 99.3 99.9 99.9 99.9 99.9 99.1 99 100 100
V95 95.3 94.9 98.1 98.3 99.0 98.9 94.2 95.4 96.2 96.3
V100 50.0 50.0 50.0 50.0 50.0 50.0 50 50 50 50
V107 0.2 0.1 0.1 0.2 0.9 0.3 0.4 0.9 0 0
D2 52.6 52.4 52.4 52.9 53.2 52.5 52.6 53.1 51.6 51.5
D98 46.8 46.6 47.9 47.9 48.2 48.2 46.6 46.7 47.3 47.4
HI 11.5 11.5 8.9 9.9 9.9 8.5 11.9 12.7 8.5 8.1
VPTV 420.5 420.5 497.8 497.8 309.9 309.9 441.6 441.6 60.3 60.3
CI 1.13 1.10 1.09 1.10 1.22 1.16 1.05 1.07 1.26 1.23
VNT 5 1445.3 1433.9 939.1 934.3 1345.2 1313.2 1053.8 1038.1 1331.7 1321.8
VNT 95 475.2 462.0 542.3 547.0 378.9 360.6 463.6 471.9 76.1 74
Volumes are expressed as a percentage, except the PTV volume which is in cc.
* ‘In’ refers to the flattening filter in position (i.e., conventional intensity-modulated radiotherapy [IMRT]) and ‘Out’ refers to unflattened
IMRT (flattening filter out).
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relatively independent of measurement depth, and a depth of 5 cm
was chosen as being representative for the cases studied.
Measurements were taken at regular intervals, from the CAX out
to 70 cm away from the gantry, and recorded for a variety of field
sizes and at collimator rotations of 0 and 90, both with and without
the filter. Readings were performed using a cylindrical ionization
chamber (NE2571) and repeatedwithTLD-100 (HarshawChemical
Company, Solon, OH) LiF thermoluminescent dosimeters (TLDs).
For each position, 10 TLDs were used, and readings were normal-
ized to the dose recorded for delivery under standard conditions
(10  10, 90 cm SSD, Dmax). These were then compared to the
dose measured under the same conditions with the ionization cham-
ber to characterize any differences in the energy response of the
TLDs caused by the altered spectrum of scattered/leakage radiation.
Treatment planning system beam modeling
Commissioning data were measured and used to create a beam
model within the XiO treatment planning system (Elekta CMS,
XiO version 4.34.02). The basic machine parameters for the model
(e.g.,machine limits) obviously remained the same, but a new beam
spectrum, depth doses, and profiles along with total scatter (Sc,p)
and phantom scatter (Sp) factors were required. In practice, total
scatter and head scatter (Sc) were measured (and Sp calculated) be-
cause published Sp data are inaccurate for unflattened beams (21).
The XiO system uses two spectra for beam modeling to account
for changes in beam quality across the flattening filter, one on the
CAX and the other 7 off-axis. Although filter removal reduces
the variation in beam spectrum across the beam, a small change still
exists with the filter removed; however, it was seen that a single
spectrum was sufficient to model the beam accurately, and a sepa-
rate off-axis spectrum was not required. This reduced variation has
also been shown experimentally by Georg et al. (22).
To remove any bias introduced by having a beam model for one
technique ‘‘better’’ than another, all IMRT-specific beam data for
both modes were measured concurrently using the same equipment
and techniques. Both models were generated at the same time and
to the same standard. For the final beam model, all differences be-
tween calculation and measurements were well within acceptable
errors (2%/2 mm).
IMRT treatment planning
Patient selection. For this study we retrospectively selected 5
pediatric patients recently treated for intracranial tumors with con-
ventional 3D-CRT at our institution. Additional outlining was then
performed by a consultant pediatric oncologist to enable IMRT
planning for these patients. Intracranial tumors were chosen be-
cause they offered a challenge for the beam models involved and
the opportunity to measure out-of-field doses over a large distance
through the rest of the body.
Treatment plans were produced both with andwithout the flatten-
ing filter (10 plans in all). The number of beams and their gantry an-
gles remained the same in each case (generally five equally spaced
fields). Dose optimization priorities changed for each case, but the
PTVwas given priority unless a critical structurewas compromised.
In many cases, OARs were contained within the PTV, in which case
care was taken to avoid dose hotspots occurring in these regions.
All plans received50.4Gy in28 fractions prescribed to themeanof
the PTV dose (i.e.,DV50 = 50.4 Gy). In each case, calculations were
performed using the superposition algorithm, a step increment of 5
mm on the multileaf collimators (MLCs) and a 2-mm grid spacing.
For each IMRT case, a plan was produced first using the conven-
tional IMRT beam model. Then, having found a set of dose
Fig. 2. Transverse slice through the center of the target region for Case 3 (an embryonal parameningeal rhabdomyosar-
coma of the nasopharynx and skull base) showing dose distribution comparisons between each technique. Left, conven-
tional intensity-modulated radiotherapy plan. Right, plan reoptimized with the flattening filter removed. The planning
target volume is marked in blue, the pituitary in cyan, and the brainstem in brown. Isodoses lines are as marked.
Fig. 3. Dose–volume histogram comparison between conventional
(dotted lines) and unflattened (solid lines) plans for Case 5.
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constraints to drive the optimizer to meet target and OAR limits,
these same objectives were used to produce an optimized unflat-
tened treatment plan. This process removed any interplanner or in-
terplan bias from the evaluation. Plans were then evaluated
according to standard dose indices to assess PTV coverage, homo-
geneity, and OAR sparing.
Verification measurements were performed by transferring the
plan to a solid water phantom according to standard protocol.
Absolute doses weremeasured at a depth of 5 cm using a 0.6-cm3 cy-
lindrical ionization chamber, and relative doses using a two-
dimensional array (MatriXX, IBADosimetry), also at a depthof5 cm.
Anthropomorphic phantom. Out-of-field doses are difficult to
calculate with any degree of accuracy, and peripheral doses to
OARs cannot be reliably or accurately predicted from large-field
phantom studies (9). With an unflattened beam there may be signif-
icant changes in the number and shape of the beam segments re-
quired and the number of MU needed to deliver the prescribed
dose. Scatter and leakage will also depend on the direction and en-
ergy of the scattered radiation, so they may be affected by the
changes in beam spectrum. It is therefore important to measure
these changes under representative conditions.
Phantom measurements yield dose measurements at the correct
distance from the isocenter, at the correct depth and for clinically
usable plans. For these reasons a commercially available anthropo-
morphic pediatric phantom (ATOM dosimetry model 706) (CIRS
Inc., Norfolk, VA, USA) of a 10-year-old child was used to measure
and compare peripheral doses for IMRT delivery.
The phantom consists of 25-mm-thick contiguous sections pre-
drilled to hold TLDs. For each plan delivery, five LiF TLDs were
placed at each of six points within the phantom corresponding to
clinically relevant anatomic locations outside of the treated volume
representing the thyroid, breast, lung, intestines, ovaries, and testes.
Plans were delivered with the beam isocenter at the center of the
head, and each plan was delivered three times to ensure that ade-
quate dose levels were recorded by the TLDs
RESULTS
Peripheral doses in a slab phantom
As expected, peripheral doses were seen to decrease with
distance from the field edge approximately exponentially,
and to increase with increasing field size. In each case the
readings generally started to converge beyond 40 cm from
the CAX; however, doses measured with the filter removed
dropped more quickly and to a lower level (Fig. 1).
For a 10 10 cm2 field at 40 cm from CAX, the dose was
only 50% that of the standard field, and at 70 cm from CAX,
this fell to 38.5%. For a 3 3 cm2 field the values were even
lower: 34.7% and 27.8%, respectively. There was a signifi-
cant drop in dose with the collimator rotation at 0 caused
by the extra shielding (from the MLC carriage) within the
treatment head, which was seen in both treatment modes
with readings diverging at approximately 10 cm from the
CAX and then reconverging at approximately 40 cm. At
20 cm this accounted for a 45% decrease in dose, and when-
ever possible IMRT plans are produced at collimator 0 to
reduce this leakage dose.
Under the same delivery conditions, the TLDs showed
significant differences compared to the ionization chamber
readings, with the conventional beams under-responding,
on average, by 7.5%, whereas the unflattened beams over-
responded by almost 17%.
It is known that TLD-100 chips show variations in dose re-
sponse at low energy, but they have been used previously to
measure out-of-field doses (20). The differences observed
between conventional and unflattened beams are most likely
due to the changes in beam spectrum for scattered/leakage
radiation between the two delivery modes. To account for
these differences, the ratio between ionization chamber
and TLD readings under the same conditions was taken,
and these factors were used to correct measurements taken
in the ATOM phantom.
IMRT plan evaluation
All 10 plans were assessed using standard evaluation cri-
teria as shown in Table 1. Values are reported in Table 2 for
each of the 10 plans created.
Figure 2 shows slices through the isocenter for Case 3 to
illustrate the similarity of the plans. For all planned cases,
the target coverage, homogeneity, and OAR doses both
with and without the flattening filter were similar, with no
one technique producing better plans than the other. This
Table 3. Organ-at-risk doses (in Gy) for the 10 treatment plans (five cases)
Case1 Case2 Case3 Case4 Case5
OAR In* Out* In Out In Out In Out In Out
Lt eyey 34.3 33.6 13.3 13.1 32.0 32.4 36.9 36.6 3.7 3.4
Rt eyey 33.7 33.8 11.5 11.3 12.9 13.0 36.7 35.9 2.6 2.4
Lt lens 38.3 39.5 9.3 9.3 27.8 28.4 40.4 37.1 4.4 4.2
Rt lens 29.6 29.0 5.4 5.2 5.8 6.1 35.8 36.2 3.3 3.1
Optic chiasm 52.8 52.9 32.7 35.3 50.5 50.4 48.9 49.4 11.8 11.8
Brainstem 50.3 50.6 53.1 52.6 53.2 52.1 49.6 50.6 50.5 50.8
Spinal cord 2.9 2.7 49.8 49.7 2.0 1.8 49.6 48.6 0.6 0.5
Lt cochleay 42.2 42.8 45.9 45.3 50.4 50.2 38.9 39.0 9.0 8.5
Rt cochleay 44.6 43.5 45.8 47.7 31.5 33.6 48.8 48.5 8.1 7.6
Pituitary 51.8 51.6 53.6 52.6 51.6 49.5 50.0 51.3 14.9 15.3
* ‘In’ refers to the flattening filter in position (i.e., conventional intensity-modulated radiotherapy [IMRT]) and ‘Out’ refers to unflattened
IMRT (flattening filter out).
y All doses are the maximum point dose to that organ unless marked with a , in which case the mean dose is listed.
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can be seen diagrammatically in Fig. 3, which shows the
dose–volume histogram for the two plans in Fig. 2. The cor-
relation between plans for each case was tested, and differ-
ences were found to be statistically insignificant.
Table 3 lists the maximum point doses to the OARs for
each case with and without the flattening filter. In many
cases, OARs were within the PTV and so received unavoid-
ably high doses.
Table 4 compares thenumber of segments andMUrequired
to deliver the same dose distribution with the two techniques.
Taking the ratio of (unflattened IMRT/conventional IMRT)
for each of the five cases, the average for the number of seg-
ments required was 1.003 and the MU ratio was 1.067.
IMRT delivery quality assurance
The IMRT plans were delivered to a solid water phantom
for standard IMRT quality assurance (QA) checks. IMRT is
in routine use at our center, and all plans passed regular QA
checks as set for clinical IMRT plans. Gamma index evalu-
ation was performed using commercial software (OmniPro
I’mRT v1.6, IBA dosimetry) with a criterion of 3%/3mm.
The number of points with g <1 should be greater than
95% in order for that beam to pass, and it can be seen
from Fig. 4 that all beams from all plans passed this comfort-
ably. Figure 4c shows that with the filter removed there was
a trend toward greater consistency and a higher percentage
of points passing the gamma evaluation than for
Table 4. Segments and monitor units required to deliver identical plans by the two different delivery methods
Case No. of fields
Conventional IMRT Unflattened IMRT
Ratio of segments* Ratio of MUs*
Segments MUs Segments MUs
Case 1 5 89 18,146 89 19,186 1.000 1.057
Case 2 5 94 18,105 98 20,695 1.043 1.143
Case 3 5 85 17,928 76 17,767 0.894 0.991
Case 4 5 100 22,462 104 24,667 1.040 1.098
Case 5 5 57 10,924 59 11,310 1.035 1.035
Average 1.003  0.063 1.067  0.058
Abbreviations: IMRT = intensity-modulated radiotherapy; MUs = monitor units.
* Ratio is taken as unflattened/conventional IMRT.
Fig. 4. Results from the intensity-modulated radiotherapy quality assurance analysis of Case 3. (a) typical fluence map
(beam 1), (b) gamma analysis (3%/3 mm) two-dimensional array vs. treatment planning system, (c) plot of percentage of
points passing evaluation for each beam.
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conventional delivery. This trend was observed for relative
and absolute doses in all of the plans delivered.
Doses to distant organs
These measurements are summarized in Table 5 for each
of the regions of interest and are shown graphically in Fig. 5.
Even in regions close to the target volume, the doses are seen
to be consistently lower for unflattened delivery. On average,
the thyroid was only 5 cm from the field edge but still shows
a 24% reduction in dose compared to the standard IMRT
delivery.
DISCUSSION
The XiO treatment planning system seems capable of both
the modeling and the optimization of unflattened IMRT
beams. The treatment plans produced are of the same quality
as those for conventional IMRT, with virtually identical PTV
coverage and OAR sparing, and this plan quality is main-
tained while retaining similar numbers of segments. There
is a slight increase in the number of MU needed to deliver
the same dose (6.7% for the cases studied), but this is an ex-
pected consequence of unflattened delivery because of the
shape of the beam profile; delivering any dose off-axis will
require the beam to be on for a longer period of time.
Even taking this increase into account, the rise in MU re-
quired for unflattened delivery is modest compared to the re-
duction in leakage dose seen.
The risk of second cancer induction can be related back to
these values and will scale with the ratio of absorbed doses.
Taking a nominal distance of 50 cm to represent whole-body
dose (13), the doses here are reduced on average by 64% for
unflattened IMRT delivery, and obviously represent a signif-
icant reduction in risk from leakage radiation.
Under both standard and clinical conditions, out-of-field
doses are seen to be lower at all positions relative to conven-
tional delivery. In a recent Monte Carlo study by Kry et al.
(23), however, unflattened beams were seen to increase the
dose in the region from 3 to 15 cm from the field edge for
IMRT delivery on a Varian accelerator. These differences
may be due to variations in head design between the Elekta
and Varian machines, or to the Varian accelerator having
a slightly lower effective energy (4 MV). As the field size in-
creases beyond the range used in this study, it is possible that
there may be similar issues for larger PTVs and in adults, and
further study is required to quantify this.
All IMRTplans passed regular patient-specificQAchecks,
and itwas observed thatwith thefilter removed there is a trend
toward a higher pass ratewithmore points passing the gamma
evaluation than for conventional delivery. Although these re-
sults are not conclusive, this may indicate an increase in cal-
culational accuracy for unflattened beams, most probably
caused by the reduction in head scatter; further work is under
way at our institution to fully evaluate this.
Table 5. Summary of doses at specified points of interest for the five cases treated both with the flattening filter in (In) and out (Out)
Case 1 Case 2 Case 5
Distance (mm) In* Out* Ratio In Out Ratio In Out Ratio Average Ratio
Head 0 100 100 1.00 100 100 1.00 100 100 1.00 1.00
Thyroid 100 1.730 1.288 0.745 2.256 1.778 0.778 0.755 0.570 0.755 0.763
Breast 200 0.202 0.167 0.825 0.248 0.195 0.784 0.010 0.078 0.781 0.797
Lung 250 0.159 0.112 0.701 0.189 0.132 0.701 0.082 0.057 0.700 0.701
Intestines 425 0.082 0.031 0.374 0.090 0.036 0.402 0.057 0.021 0.367 0.381
Ovaries 550 0.059 0.019 0.328 0.064 0.024 0.373 0.042 0.015 0.353 0.351
Testes 650 0.057 0.015 0.268 0.064 0.020 0.312 0.041 0.013 0.321 0.300
All doses are normalized to 100% at the beam isocenter (head), which is equal to 1.8 Gy (50.4 Gy/28#).
* In refers to the flattening filter in position (i.e., conventional intensity-modulated radiotherapy [IMRT]), and Out refers to unflattened
IMRT (flattening filter out). Distances are from the central axis (isocenter).
Fig. 5. Sample data from Case 5 illustrating the drop in peripheral
dose for the unflattened beam delivery in the clinical intensity-
modulated radiotherapy plans (a). (b) Plot of the average dose ratio
(unflattened/flattened) for all of the plans delivered. CAX = central
axis.
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Machines operating without a flattening filter are now
commercially available, such as the TomoTherapy HI-ART
(TomoTherapy, Inc., Madison, WI), CyberKnife (Accuray,
Inc., Sunnyvale, CA), and TrueBeam (Varian Medical Sys-
tems, CA), indicating that in a ‘‘bottom-up’’ design the flat-
tening filter is seen to be unnecessary for some treatments.
Helical delivery systems, however, are inefficient in MU de-
livery because dose is delivered in a slice-by-slice fashion, so
to deliver the same dose in clinical treatment plans requires 5
to 15 times as manyMU (24). The TomoTherapy system has
been designed with this in mind, with 23 cm of attenuation
(tungsten jaws andMLC leaves), meaning that for static field
delivery, leakage doses are reduced by 3 to 11 times com-
pared to a conventional accelerator. When these factors are
combined together, this results in similar, if not lower, leak-
age than for a conventional linac delivering IMRT (24).
Leakage may be reduced by increasing the shielding
around the head, but this is both costly and cumbersome. Re-
moval of the flattening filter is a relatively simple way of
achieving the same effect on a conventional linac, and be-
cause the flattening filter doesn’t actually seem to be required
for IMRT, one can argue that it should be removed for IMRT
treatments. A filter-free conventional linac could combine
the best aspects of both delivery methods—a machine that
has the inherent dose delivery efficiency of a linac combined
with the reduction of scatter from flattening filter removal.
CONCLUSIONS
Flattening filter removal is not a complication but rather
an exercise in simplification. Removal leads to a more stable
beam with reduced head scatter and simplified beam model-
ing. These properties in turn may result in greater accuracy
in dose predictions for IMRT, thereby helping to increase
the accuracy of patient-specific QA.
Removal of the flattening filter for IMRT removes an un-
wanted and unnecessary source of scatter from the treatment
head, significantly reducing whole-body radiation doses. If
IMRT is to be used, then this risk must be balanced by an in-
crease in local control and reduced toxicity. Any increase in
whole-body dose must be justified for pediatric patients,
who have the potential for such long-term survival, and as
much as possible should be done to reduce these doses and
lower the risk of cancer induction.
It is recommended that linac-based IMRTon conventional
accelerators be performed without a flattening filter.
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Purpose: A linac delivering intensity-modulated radiotherapy (IMRT) can benefit from a flattening
filter free (FFF) design which offers higher dose rates and reduced accelerator head scatter than for
conventional (flattened) delivery. This reduction in scatter simplifies beam modeling, and combin-
ing a Monte Carlo dose engine with a FFF accelerator could potentially increase dose calculation
accuracy. The objective of this work was to model a FFF machine using an adapted version of a
previously published virtual source model (VSM) for Monte Carlo calculations and to verify its
accuracy.
Methods: An Elekta Synergy linear accelerator operating at 6 MV has been modified to enable irra-
diation both with and without the flattening filter (FF). The VSM has been incorporated into a com-
mercially available treatment planning system (MonacoTM v 3.1) as VSM 1.6. Dosimetric data
were measured to commission the treatment planning system (TPS) and the VSM adapted to
account for the lack of angular differential absorption and general beam hardening. The model was
then tested using standard water phantom measurements and also by creating IMRT plans for a
range of clinical cases.
Results: The results show that the VSM implementation handles the FFF beams very well, with an
uncertainty between measurement and calculation of <1% which is comparable to conventional
flattened beams. All IMRT beams passed standard quality assurance tests with >95% of all points
passing gamma analysis (c< 1) using a 3%/3 mm tolerance.
Conclusions: The virtual source model for flattened beams was successfully adapted to a flattening
filter free beam production. Water phantom and patient specific QA measurements show excellent
results, and comparisons of IMRT plans generated in conventional and FFF mode are underway to
assess dosimetric uncertainties and possible improvements in dose calculation and delivery.VC 2012
American Association of Physicists in Medicine. [http://dx.doi.org/10.1118/1.4709601]
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I. INTRODUCTION
Therapeutic photon beams are generated by stopping a nar-
row electron beam in a metal target. These bremsstrahlung
x-rays have a relatively constant angular energy spectrum,
but a strongly forward peaked energy fluence which becomes
more peaked as the initial electron energy increases. This
translates into a triangular shaped beam profile.
To provide a more uniform fluence distribution, it is cus-
tomary to insert a conical flattening filter (FF) of a high-Z
material into the beam. The primary function of the filter is
to provide a “nominally” flat radiation beam (e.g., at 10 cm
depth), but in doing this, the filter causes negative side-
effects such as
• changes in the spectrum due to differential photon
absorption
• the need for the introduction of “horns” in the particle flu-
ence to compensate for this angular variation of the
spectrum
• a reduction in dose rate
• the creation of a significant source of extrafocal scattered
radiation.
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Such uniform beams can be advantageous for conven-
tional treatments, but in practice, although a beam can be
within flatness specification under uniform conditions (e.g.,
10 cm depth in a homogeneous phantom with a flat surface),
it may be significantly skewed taking into account realistic
treatment geometries with inhomogeneities, body surface
curvature, and treatment at depths other than the reference
depth. Flattening filters have been regarded as an integral
part of linear accelerators since their first medical use in the
1950s, but for beams with modulated intensity, an initially
“flat” radiation distribution should not be necessary, and
removing the filter will remove these disadvantages.
Several studies have reported flattening filter free (FFF)
characteristics for Elekta,1–3 and Varian4–6 accelerators via
direct measurement, Monte Carlo (MC) simulation, and by
multisource modeling.7 These studies demonstrate that filter
free operation results in reduced leakage, higher dose rates,
and simplified beam modeling. Further studies have also
demonstrated that these properties result in significant reduc-
tions in doses to organs outside of the treated volume for
equivalent delivery of intensity-modulated radiotherapy
(IMRT) and SBRT plans on a prototype FFF Elekta linac.8,9
In theory, FF removal could increase the dosimetric confi-
dence in a plan due to reductions in off-axis beam softening
and by virtue of having less scattered photons and contami-
nation electrons in the beam. The accuracy of the beam
model could therefore be improved since we are reducing
the uncertainty in these components. Coupling this with a
Monte Carlo dose calculation algorithm could eventually
lead to more accurate dose prediction compared to standard
techniques.
The objective of this work was to model a FFF machine
using an adapted version of a previously published virtual
source model (VSM)10–12 for Monte Carlo calculations and
to test this implementation against standard phantom meas-
urements and for delivery of clinically relevant IMRT plans.
Effort has been concentrated on a prototype 6 MV FFF beam
from an Elekta Synergy linear accelerator. This is a research
unit that does not operate in clinical mode. Although the
eventual aim is to demonstrate a difference in calculation ac-
curacy between FFF and conventional beams, the aim of this
work is to demonstrate the adaptability of the VSM for FFF
MC dose calculations.
II. MATERIALS AND METHODS
II.A. VSM—Source densities and particle fluence
distribution
For MC simulations, a beam can be described by the
phase space parameters (position, direction of motion, and
energy) of the constituent photons and electrons. It is possi-
ble to generate these parameters analytically in a phase space
plane in front of the patient and use MC transport for par-
ticles passing through the patient. A virtual source model
allows for efficient generation of particle parameters and can
be commissioned for conventional linear accelerators with
semiautomatic modeling tools. The VSM-based MC com-
putes dose in the following way:
(1) Source type, energy, position, and direction of particles
are sampled from the VSM. The required number of par-
ticles is generated on the fly in an arbitrary plane above
the collimators to achieve a predefined level of statistical
noise in the patient.
(2) The particles are transported through collimators or
transmission probability filters,12 e.g., in the multileaf
collimator (MLC) plane.
(3) The dose deposited in the patient is calculated using the
XVMC code.13,14
The VSM treats particles coming from different parts of
the accelerator as if they were coming from three different
virtual sources. These sources are the primary photon source,
the secondary photon source, and the electron contamination
source, with relative contributions Ppri, Psec, and Pecon,
respectively. The primary source is defined in the plane of
the electron beam target where primary photons originate
from interactions within the target. The secondary source
models all of the photons that result from interactions occur-
ring in places other than the target. The positions of the sec-
ondary source and the electron contamination source are free
parameters which are set according to the machine geome-
try. The secondary source is located at the base of the pri-
mary collimator and the electron contamination source at the
base of the FF (or the build-up plate).
It is assumed that each of the sources has a Gaussian
shape with standard deviations rpri, rsec(E), and recon(E) for
primary photon distribution, energy-dependent secondary
photon distribution, and energy-dependent electron contribu-
tion, respectively, according to the following expressions:
rsecðEÞ ¼ Rsec E
E0
 0:34
if E  0:511 MeV; (1)
rsecðEÞ ¼ Rsec 0:511
E0
 0:34
if E < 0:511 MeV; (2)
where E¼ particle energy, E0¼ 1 MeV, and Rsec¼ free pa-
rameter, the base data standard deviation of the secondary
source, and
reconðEÞ ¼ ReconðE=E0Þ0:18; (3)
where Recon¼ free parameter, the base data standard devia-
tion of the electron source.
Upon generation of a photon in the source location, the
particle fluence in a phase space plane that is located above
the collimators is initially flat. The particle weight is altered
depending on the angle between its direction and the central
axis (CAX) according to a tabulated profile. While it is possi-
ble to measure the energy fluence in air with a small detector
fitted with a build-up cap, it proves more robust to measure a
cross-profile in a water tank at the dose maximum (Dmax) and
determine the table by forming the ratio of the measurement
to a simulation with a pristine, flat energy fluence.
II.B. VSM—Energy spectra
The primary photon spectrum (Spri) on the central axis
before the flattening filter is described by
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SpriðEÞ ¼ x0 if Ebin  E < Emin; (4)
SpriðEÞ ¼ E
Emax
 bpri
1 if E  Emin; (5)
where E¼ photon energy (MeV), Emin and Emax are mini-
mum and maximum photon energies.
For Emin, a fixed value of 0.5 MeV is used. x0¼ low
energy bin parameter. bpri¼ free parameter.
In the implementation of this VSM for flattened beams,
this primary spectrum is attenuated with an appropriate, radi-
ally dependent filter function.11
The secondary photon spectrum SsecðEÞ describes the sec-
ondary photons on the CAX after the flattening filter.
SsecðEÞ ¼ xS if Ebin  E < Emin; (6)
SsecðEÞ ¼ ebsecE  ebsecEmax if E  Emin; (7)
where Ebin, xS¼ low energy bin parameters and bsec¼ free
parameter.
The off-axis energy softening is approximated by using
two parameters (dbpri and dbsec) which define the relative
change of the primary and secondary spectra with respect to
the tangent of angle to the CAX [tan()] at the scoring plane
bpriðÞ ¼ bpri þ dbpri tanðÞ; (8)
bsecðÞ ¼ bsec þ dbsec tanðÞ: (9)
The energy spectrum of the contaminating electrons is
approximated by an exponential function
SconðEÞ ¼ Ne exp  EhEei
 
; (10)
where Ne¼ normalization factor and hEei¼mean electron
energy.
The VSM is defined by fixed and open parameters. Fixed
parameters are derived from a BEAMnrc simulation of the
treatment head which is performed only for a given accelera-
tor type. Open parameters are fitted in the polyenergetic ker-
nel superposition commissioning routine for each individual
linac.13 The free parameters of the VSM are derived from ba-
sic beam data measurements performed in water and by mini-
mizing the differences between calculated and measured data.
For the purpose of verifying the dose calculation accuracy
of this model, the MonacoTM treatment planning system
(TPS) (Elekta CMS software, St. Louis, MO) was used (ver-
sion 3.1), which incorporates a commercial implementation
of this model (VSM v.1.6).
II.C. FFF accelerator and beam properties
An Elekta Precise linear accelerator has been modified to
enable irradiation both with and without the FF. In practice,
the filter cannot simply be removed but needs to be replaced
by a thin metal “enhancer” plate in the same position as the
FF. This plate generates electrons which provide build-up
dose to the ionization chamber to give sufficient signal to the
servo plates so they, in turn, can operate properly to control
the beam quality and steering.8 Several materials and thick-
nesses of materials have been used in previous studies and
these have recently been reviewed by Georg et al.15 This
prototype Elekta unit uses a 2 mm stainless steel plate which
provides sufficient dose to the chamber without adding sig-
nificantly to scatter. The differential attenuation of this plate
can be neglected; in contrast, the overall rather large filter
effect of the FF removes photons below about 1 MV almost
completely on the CAX, and decreasingly toward the field
edge. Dosimetric data for a linac operating with this combi-
nation of plate and energy have not been reported in the liter-
ature. These differences are briefly summarized below.
II.C.1. Depth dose slope
Without the beam hardening effect of the filter, the depth
dose (DD) beyond Dmax for unflattened beams are close to
those of flattened 5 MV beams. For the machine used in this
work, the beam energy has been raised back to 6 MV on the
central axis by matching the quality index QI/TPR20/10
(0.675) to the clinical 6 MV (flattened) beam.
II.C.2. Surface dose
Filter removal leads to an increase in the number of low
energy x-rays (softer beam spectrum) which acts to increase
the surface dose. Counterbalancing this is a reduction in
electron contamination, especially at high electron energies.
Measurements and MC simulations in the build-up region of
unflattened beams indicate that, at 6 MV, this leads to a
slight overall decrease in the surface dose. The variation
with field size is also reduced for these beams compared to
standard flattened beams (by approximately half).
II.C.3. Dose maximum
The softer spectrum moves Dmax closer to the surface,
whereas a lower contribution from photon scatter and elec-
tron contamination moves Dmax deeper. Both effects almost
cancel out in practice.
II.C.4. Lateral profiles
Without angular-dependent differential attenuation, there
is a relatively small off-axis softening for FFF beams. Low
spectral variation across the field (beam quality) results in less
variation in the shape of lateral profiles with depth. Reduced
head scatter (Sc) also results in lower doses outside of the
field, which also falls off faster with distance. Small field sizes
are relatively unaffected by filter removal, but beyond approx-
imately 10 10 cm2, the triangular shape of beam profiles is
apparent, and photon fluence starts to decrease.
II.C.5. Head scatter
The FF is known to be the main component contributing
to variation of head scatter in the treatment head. These
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variations must be accurately modeled if dose calculations
are to be correctly performed. The head scatter factor is seen
to vary by 3% between field sizes of 3 3 and 40 40 cm2
with the FFF machine compared to 9% for the standard 6
MV beam. The collimator exchange effect is also reduced by
filter removal.1
II.C.6. Dose rate
The FF is composed of several centimeters of high Z
materials, and one of the most immediate consequences of
filter removal is the increase in dose rate. Measurements on
the central axis indicate an increase in dose rate by a factor
of 1.7 to 800 MU per min. Dose rates of 1200 MU per min
are expected in the clinical version. If high dose rates are not
required, the linac can simply run at a lower rate by changing
the pulse repetition frequency (PRF). These gains in dose
rate are effectively due to an increase in the dose per pulse,
so regardless of PRF/dose rate, the ion recombination factors
needed for accurate dosimetry should be investigated.
II.D. Model commissioning
Measurements for beam modeling included depth dose
curves and profiles for various field sizes measured in a
water phantom (Blue Phantom2, IBA Dosimetry, Germany).
Measurements were performed at SSD¼ 100 cm with suita-
ble detectors [CC01, CC13 IBA Dosimetry, NE2577 Nuclear
Enterprises Ltd. (now QADOS, UK)]. Monaco is used clini-
cally in our department with conventional flattened beams
and the data set and equipment used for FFF measurements
matched those originally used to commission this beam
energy. In this way, the FFF and FF data can be said to be of
the same standard and can be directly compared against one
another.
The measurement set consisted of the following:
• Depth dose curves for field sizes: 2, 3, 5, 10, 15, 20, 30,
and 40 cm2.
• In-plane and cross-plane profiles for field sizes: 2, 3, 5, 10,
15, 20, and 30 cm2 at depths of 1.5, 5, 10, and 20 cm.
• Diagonal profiles for the largest field size: 40 40 cm2.
• Output factors for square fields: 2, 3, 5, 10, 20, 30, and
40 cm2 at 10 cm depth.
The unique feature of the VSM is that it represents the
primary photon spectrum before it reaches the flattening fil-
ter. Therefore, turning off the flattening filter correction cor-
responds to physically removing the flattening filter from the
accelerator head. The procedure for modeling the FFF
machine is very similar to modeling a standard machine and
as a starting point a previously created model of the FF lin-
ear accelerator from the same vendor was used. The model
parameters were modified as follows:
(1) The radially dependent, differential attenuation of the FF
in the conventional model was turned off. Further varia-
tions in off-axis spectrum were kept constant [Eq. (8)].
(2) The relative contribution from primary photons Ppri was
increased.
(3) Emax was increased along with bpri to provide a better
agreement of the depth dose, especially in the Dmax
region. This accounts for the retuning of the machine to
produce a typical 6 MV quality index.
(4) The secondary source Gaussian sigma was made wider
by a factor of 2 due to the fact that in the absence of
the flattening filter, the primary collimator contributes
most of the scatter.
(5) To correct the fluence profile for FFF beams, the tabu-
lated parameters for radial energy fluence variation were
adjusted to the diagonal cross-profiles at Dmax.
The results of the VSM phase space reconstruction are in-
dependent of the dose calculation engine used; therefore, it
can be coupled with other MC dose engines. MC simulation
and treatment planning were performed in the Monaco TPS
using a water phantom of size 50 50 35 cm3. The voxel
size was set at 2 mm for the smallest 2 2 cm2 field and 3
mm for the rest of the fields with statistical uncertainties set
to 0.5%.
II.E. Treatment planning
In order to expose the FFF model to a range of conditions
and test the beam model and the accuracy of the dose calcu-
lation (and delivery), a series of treatments with increasing
complexity and treatment volume were planned. These sites
consisted of skull base, esophagus, prostate, and head and
neck cases.
FIG. 1. (a) Absolute output factors as a function of field size for FFF and conventional 6 MV beams as predicted by the TPS compared to measurement. (b)
Difference in output factors, calculated minus measured.
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To test the model under the extreme influence of the unflat-
tened beams, the isocenter for the prostate and head and neck
plans were placed asymmetrically so that large parts of the
fields were exposed to the off-axis region of the beam.
For each plan, a set of constraints were found to give the
optimal distribution. The plans were then reoptimized using
the FFF beam model and adapted as necessary to fulfill the
dose constraints.
These beams were then recalculated on a phantom (2%, 2
mm) for delivery to a Delta4PT (ScandiDos, Inc., Sweden)
IMRT verification device. All deliveries were made with the
gantry at 0 to remove any influence from the treatment couch.
III. RESULTS
III.A. Water phantom data verification
Figure 1(a) shows a plot of output factor variation with
field size for FFF and conventional beams, and Fig. 1(b) the
difference in calculated relative output factor curve against
measurement. These are absolute values as predicted by the
planning system and not scaled to measured data. The abso-
lute outputs can be predicted within 1.5% of measurements
over the entire range of field sizes.
Figure 2(a) shows a sample DD curve for a 2 2 cm2 field
size and Fig. 2(b) shows profiles at depths of Dmax, 5, 10, and
20 cm for a 30 30 cm2 field. Figure 3 shows, for various
depths and fields sizes, the percentage difference between
measured and calculated depth dose curves. The spread in val-
ues is approximately 1.5% (þ0.5 to 1.0) in both cases indi-
cating that the beam model is of similar quality for both FFF
[Fig. 3(a)] and conventional [Fig. 3(b)] beams, and within the
measurement uncertainty for these fields. Figure 4 shows
comparisons of FFF beam profile measurements against TPS
predictions for field sizes from 2 2 to 30 30 cm2 with their
respective 1D c-analysis for acceptance criteria of 2%/2 mm.
It can be seen that all points had c< 0.8. For set criteria of
1%/1 mm, 93% of all points had c< 1.
III.B. Treatment plans
As the volume of the tumor (treatment length) and com-
plexity of the plan increase, there is a tendency to see an
underdosage in regions far from the central axis, which is
seen as a sloping shoulder on the DVH curve. It is possible
to compensate for this by further penalizing cold spots
within the tumor, and in the Monaco TPS, this can be
achieved by increasing the cell sensitivity (a) of the tumor or
adding a quadratic underdose penalty. This acts to maintain
plan quality but brings about an increase in both the number
of segments and monitor units needed to deliver the plan. It
FIG. 2. Sample beam data: (a) PDD curve for 2 2 cm2 field, (b) cross-profiles for a 30 30 cm2 field for the FFF model.
FIG. 3. Absolute dose difference between measured and calculated depth doses curves (100 cm source-surface distance) for the field sizes indicated for
(a) FFF and (b) FF beams. Monte Carlo variance is set at 0.5%.
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can be seen from Table I that as the treatment volume and
plan complexity increase there is a corresponding increase in
the number of segments and MU needed to deliver the FFF
plans. Figure 5 shows a color-wash dose distribution on sag-
ittal and coronal CT slices through the tumor for a head and
neck FFF IMRT plan. The dose volume histogram indicates
that the plans are equivalent in terms of both PTV coverage
and organ at risk sparing.
FIG. 4. Comparison of calculated vs measured beam profiles for sample field sizes of (a) 2 2 cm2, (b) 5 5 cm2, (c) 10 10 cm2, (d) 15 15 cm2, (e)
20 20 cm2, and (f) 30 30 cm2 at 100 cm SSD and a depth of 5 cm. Criteria for gamma analysis are 2%/2 mm.
TABLE I. Number of segments and monitor units needed for each treatment plan and the relative increase in each necessary to deliver the FFF plans.
Segments Monitor units
PTV volume (cm3) 6 MV FFF % Difference 6 MV FFF % Difference
Skull base 23.2 20 21 þ5.0 416 446 þ7.2
Esophagus 555.4 64 67 þ4.7 785 931 þ18.6
Prostate 804.5 66 68 þ3.0 828 951 þ14.9
Head and neck 918.7 168 183 þ8.9 1343 1682 þ25.2
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III.C. Verification of IMRT beams
Table II shows the absolute dose differences and statistics
for the gamma analysis of the sample plans analyzed at both
3%/3 mm and 2%/2 mm acceptance criteria. It can be seen
that as the volume of tumor and the complexity of the plan
increase the pass rate begins to fall (as expected), but all
plans pass the standard IMRT acceptance criteria of 95% of
points <1 using a 3%/3 mm tolerance.
IV. DICSUSSION AND CONCLUSION
Removal of the flattening filter invalidates the assumption
of energy fluence and phantom scatter homogeneity in the
incident beam so a TPS must be able to model an arbitrary
shape of the energy fluence. It is therefore important to be
able to handle the incident particle fluence by means of a
sufficiently general calculation algorithm.
The virtual source model for flattened beams was success-
fully adapted to a flattening filter free beam production by
particle fluence warping with tabulated parameters and mod-
ifying the energy spectrum to account for the lack of angular
differential absorption and general beam hardening. Since
the VSM was initially derived from studies of phase spaces
created by BEAMnrc,16 it captures the salient features of the
various sources of radiation in a linear accelerator without
overly limiting assumptions, and thereby provides enough
latitude to model flattening filter removal.
Beam modeling of the 6 MV FFF beam within Monaco is
seen to be as accurate as that used clinically. Depth dose pre-
dictions are generally within 0.5% for the FFF beam, with
only a few outliers up to 1% which is more consistent than for
the conventional beam model. 1D gamma analysis of beam
profiles for selected criteria (2%/2 mm) also show an excellent
FIG. 5. Beam setup for IMRT planning of a head and neck case showing
sagittal and coronal color-wash maps (a) and dose volume histogram (b).
The FFF beam is displayed as the dotted line, 6 MV solid.
TABLE II. Gamma analysis and absolute dose difference of individual beams for the IMRT plans. Percentage of points passing gamma analysis (c< 1) at 3%/3
mm and 2%/2 mm for the individual beams of each plan.
Gamma analysis 3%/3 mm Gamma analysis 2%/2 mm Absolute dose difference (%)
Treatment site Beam 6 MV FFF 6 MV FFF 6 MV FFF
Skull base 1 100.0 100.0 99.5 100.0 0.8 0.2
2 99.8 100.0 93.5 92.4 0.2 0.5
3 100.0 99.8 90.6 89.4 0.9 0.1
4 99.8 99.3 92.9 92.3 0.1 0.0
5 99.8 100.0 92.4 91.2 0.6 0.1
Esophagus 1 100.0 99.0 98.3 89.9 0.6 1.2
2 100.0 99.8 99.1 95.9 0.0 1.0
3 100.0 100.0 100.0 99.8 0.1 0.3
4 100.0 100.0 100.0 99.1 0.7 0.5
5 100.0 99.8 98.8 97.2 0.2 1.0
Prostateþ nodes 1 99.4 97.2 93.5 86.2 0.8 1.4
2 99.8 100.0 97.6 98.4 0.2 0.7
3 100.0 99.8 97.7 92.8 0.1 0.9
4 100.0 100.0 98.8 98.8 0.0 0.7
5 100.0 99.9 98.0 94.9 0.0 0.6
Head and neck 1 97.7 98.3 87.8 84.8 0.9 1.4
2 100.0 98.8 97.6 94.6 0.4 1.1
3 99.7 99.5 97.5 94.3 0.3 1.1
4 99.5 100.0 95.7 96.9 0.3 0.9
5 99.4 99.2 92.0 84.0 0.4 1.2
6 99.1 98.3 94.4 87.6 0.6 1.3
7 99.7 99.8 97.5 95.8 0.3 0.9
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agreement. This matches well with commissioning results
reported by Hrbacek et al.17 and Kragl et al.18 for FFF beams
from Varian and Elekta linacs, respectively. Any differences
between prediction and measurement where c exceeded 1
occurred mainly within the out-of-field regions of the beam
profiles and only for the larger (>15 15 cm2) field sizes.
It has been observed that as the field sizes needed for
planning increase then so do the number of MU required to
deliver these plans; this is a natural consequence of the FFF
beam profile since it will require longer beam on times to
deliver doses off-axis. The complexity of the plan is also
seen to increase the number of segments required to treat the
FFF plans compared to the conventional IMRT plans if plan
quality is to be maintained. This may be more specifically
related to the fact that segmentation algorithms used are
optimized for flattened rather than unflattened beam profiles.
Commercial planning systems do not currently consider the
nonflat beam profile during optimization.
The optimization of nonuniform beam profiles has been
discussed by Kim et al.19 who reported that segment num-
bers required for FFF beams can be significantly reduced
once this is taken into account in the optimization process.
Such an addition is likely to reduce the number of segments
required to deliver modulated FFF plans.
In general, the clinical implementation of this filter free
design into a commercially available treatment planning sys-
tem (Monaco) shows excellent results. Commissioning of
the model can be performed by the same set of standard
water phantom data as for the flattened beam models. These
measurements need not be overly sophisticated and hence
help to avoid errors in the commissioning process.
All beams for the planning exercises passed the defined
acceptance criteria used for standard IMRT patient specific
quality assurance tests. Once the test criteria are tightened to
2%/2 mm, slight differences can be seen between the flat-
tened and FFF deliveries, with the conventional beams gen-
erally receiving slightly higher pass rates. There may be
several reasons for this including the increased number of
segments delivered and also the fact that the linac is still a
prototype (nonclinical) release. Once the Elekta FFF linac is
released for clinical use with fully optimized hardware and
dosimetry, these tests should be repeated to assess any possi-
ble improvements in dose calculation and delivery.
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Surface dose variations in 6 and 10MV flattening filter free (FFF) 
photon beams 
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Purpose: As the use of linear accelerators operating in flattening filter free (FFF) modes 
becomes more wide-spread it is important to have an understanding of the surface 
doses delivered to patients with these beams. Flattening filter removal alters the beam 
quality and relative contributions of low energy x-rays and contamination electrons in 
the beam. Having dosimetric data to describe the surface dose and buildup regions 
under a range of conditions for FFF beams is important if clinical decisions are to be 
made. 
Methods: An Elekta Synergy linac with standard MLCi head has been commissioned to 
run at 6MV and 10MV running with the flattening filter in or out. In this linac the 6MV 
FFF beam has been energy-matched to the clinical beam on the central axis (D10). The 
10MV beam energy has not been adjusted. The flattening filter in both cases is replaced 
by a thin (2mm) stainless steel plate. A thin window parallel plate chamber has been 
used to measure a comprehensive set of surface dose data in these beams for variations 
in field size and SSD, and for the presence of attenuators (wedge, shadow tray and 
treatment couch). 
Results: Surface doses are generally higher for small field sizes and lower for large field 
sizes with a cross-over at 15x15cm
2
 at 6MV and 25x25cm
2
 at 10MV. This trend is also 
seen in the presence of the wedge, shadow tray and treatment couch. Only small 
differences (<0.5%) are seen between the beams on varying SSD. At both 6 and 10MV 
the filter free beams show far less variation with field size than conventional beams. 
Conclusions: By removing the flattening filter a source of contamination electrons is 
exchanged for a source of low energy photons (as these are no longer attenuated). In 
practice these two components almost balance out. 
No significant effects on surface dose are expected by the introduction of FFF delivery. 
 
Keywords: skin dose, filter free, unflattened, surface dose 
 
 
I. Introduction 
 
It is well known that megavoltage (MV) photon beams provide a skin-sparing effect, but the actual 
magnitude of this can depend on a number of treatment parameters. Changes in field size, source-
to-surface distance (SSD) and beam energy all cause changes in surface dose. In particular the 
introduction of materials into the beam line such as shadow trays and patient support devices can 
cause large increases in dose to the skin. At the same time it is also important that doses to targets 
close to the surface (such as for head & neck and breast treatments) are accurately known so that 
under-dosage does not occur. 
Doses received by the basal skin layer can result in a range of problems from minor (such as 
erythema/epilation) to serious (desquamation/necrosis) depending on the doses received. A full 
knowledge and understanding of these doses is therefore necessary if clinical decisions are to be 
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made, and these effects have been studied by a number of authors 
1-4
 for conventional ‘flattened’ 
beams. 
Until recently the flattening filter was generally considered to be a standard component in C-arm 
linear accelerators, but with the introduction of the TrueBeam (Varian Medical Systems, 
Palo Alto, CA) and Versa HD (Elekta AB, Stockholm, Sweden) accelerators the clinical use and 
literature surrounding FFF radiotherapy is increasing. Unflattened photon beams offer the 
possibility of increased dose rate and reduced scatter/leakage radiation and have been shown to 
be unnecessary for the production and delivery of IMRT and small field treatments 
5-9
. 
Several authors have reported surface dose variations with field size in FFF beams 
10-13
, but data 
for changes in SSD, tray, wedge, couch etc. are unavailable. With this in mind measurements of 
surface doses for FFF beams are required to assess any potential changes in dose that may 
damage the skin. 
The purpose of this investigation was to evaluate and compare trends in surface dose for 6 and 10 
MV flattened and FFF beams under conditions routinely experienced in radiotherapy treatments. 
These conditions were for: 
 
• variations in field sizes (square fields, sizes 3x3 to 40x40 cm
2
); 
• variation in source-surface-distance (SSD) (55 to 140cm); 
• the presence of 
o motorized wedge (0–60°); 
o blocking tray 
o carbon fiber couch 
 
 
II. Background 
II. A. Skin doses 
 
Skin doses arise from a combination of effects and will depend on the magnitude and relative 
contributions from contamination electrons, low-energy photons and backscattered radiation. 
Contamination electrons in particular can give rise to significant doses in the skin and will be 
influenced by several factors including head design, beam energy, SSD, field size or introduction of 
materials into the beam close to the patient. Skin dose can therefore vary significantly from one 
setup to another and can be a limiting factor in some treatments 
1
.  
Since the flattening filter is responsible for the majority of contamination electrons reaching the 
patient surface 
14
 its removal is therefore likely to reduce this contribution. However, the filter also 
acts as a beam hardener, removing low-energy photons from the spectrum. With the filter 
removed the low-energy component is allowed to pass through to the patient and act to increase 
the surface dose. 
The use of motorized wedges and perspex shadow trays (blocking trays) in conjunction with filter 
removal could also change these characteristics significantly. Since conventional planning with 
unflattened beams has been shown to be of use 
15, 16
 data has also been measured for the 
motorized wedge and shadow tray. Dose measured under different conditions (wedge, SSD, tray 
etc.) can also be a good indicator of the relative levels of dose from low energy photons and from 
contamination electrons (although no attempt has been made to separate these two components 
here). 
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II. B. Dose measurement 
 
In the buildup region of high energy photon beams electronic equilibrium does not exist, therefore 
percentage depth ionization (PDI) and percentage depth dose (PDD) are not equal. Under these 
conditions electronic fluence perturbations in the air-sensitive volume of the cavity cause 
ionization chambers to exhibit an ‘over-response’, and determining PDD from PDI measurements 
is difficult. This will occur for measurements carried out in the dose build-up region (and in the 
transition zones between different media), with a magnitude depending on the geometrical 
characteristics of the chamber. The over-response will be greatest at the surface and decrease as 
dose maximum (dmax) is approached, and electronic equilibrium restored. 
In these circumstances it is generally accepted that extrapolation chambers provide the most 
accurate means of measurement. These chambers, however, are unavailable in most departments 
and are also very time consuming to use, therefore parallel plate chambers are routinely used to 
measure surface and buildup doses, and corrections must be applied to convert ionization to dose. 
The over-response of the chamber has been shown to be mainly due to electron in-scattering from 
the side walls, which is determined by the width of the guard ring 
17, 18
. Perturbation factors will 
therefore depend on the dimensions of the chamber. 
Several methods have been introduced to correct for the perturbation effects seen when using 
parallel plate chambers in the build-up region of high-energy photon beams. These are based 
either on correction based methods from extrapolation chamber measurements, or by direct 
derivation of individual perturbation factors. 
In the first method the chamber reading is corrected by a subtractive factor that depends on the 
beam energy, chamber geometry and depth of measurement 
17-20
. These factors are essentially 
independent of field size but increase with decreasing energy. 
In the second method perturbation factors are derived explicitly. For parallel-plate chambers the 
PDD at depth d can be expressed as 
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Where ( )med
airL ρ∆ is the mean restricted collision stopping power from medium to air and Pfl, Pwall 
and Pcel are perturbation factors for the fluence, wall and central electrode respectively. When 
d>dmax these factors do not change and can be considered as invariant and the dose ratio is then 
equal to the ionization ratio (PDD = PDI) 
21
. In the buildup region however, perturbations in the 
electron fluence cause these chambers to over-respond so that PDI>PDD. Since perturbation 
factors are known to have a strong dependence on chamber design, depth of measurement and 
beam energy,  Pfl, Pwall, Pcel and ( )medairL ρ∆ must be independently evaluated. 
Recent studies have shown that the product PflPwallPcel changes by less than 1% from the surface to 
dmax 
22, 23
 and that ( )med
airL ρ∆  changes by less than 4% for beams up to 18MV. The maximum 
deviation occurs at the phantom surface and will be less than 5%, reducing to 0% at dmax. 
For certain ion chambers and beam energies some of these factors have been evaluated (e.g. Ref 
24). The presence of beam modifiers such as the wedge can change the photon beam spectrum 
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appreciably, so removal of the flattening filter and associated changes in the beam spectrum are 
therefore likely to cause significant changes to this. For FFF beams in general these are unknown 
and an independent set of over-response factors would be required for more accurate prediction. 
For these reasons the effective point of measurement method as described McEwen et al. 
23
 was 
employed to calculate dose in the buildup region, accepting limitations. 
 
 
III. Materials and methods 
III. A. Linear accelerator 
 
An Elekta Synergy linear accelerator (Elekta AB, Stockholm, Sweden) with a standard 80 leaf MLCi 
head has been used for measurements. The linac is fitted with a motorized wedge (nominal 60° 
wedge angle) and an iBEAM evo carbon fiber couchtop, both of which were assessed. 
The flattening filter is replaced with a 2mm stainless steel plate that is used to shield out 
contamination electrons from the primary collimator, and to provide build-up into the ionization 
chamber. Without this plate the signals in the chamber are too low to accurately control the beam 
energy and steering servos. 
Removing the flattening filter changes the energy spectrum of the beam since lower energy 
photons are no longer removed from the beam. This results in unflattened beam having ‘softer’ 
beam spectra than their beam hardened counterparts. The 6MV beam can be energy matched to 
the conventional beam by adjusting the beam running parameters. In this way the depth doses at 
10cm depth, TPR20/10 QI/TPR20/10 [0.675] for a 10x10cm
2
 field are the same. FF removal also affects 
the variation in the energy spectrum across the beam (making it much more uniform) but energy 
matching across the beam is not possible. In contrast, and in following with other work 
12, 25
 the 
10MV beam has not been adjusted. The TPR20/10 for the 10MV and 10MV FFF beams are 0.737 and 
0.716, respectively. 
 
 
III. B. Experimental setup 
 
Measurements were taken in a phantom composed of 30x30cm
2
 WT1 Solid Water slabs (Radiation 
Physics, St Bartholomew’s Hospital, London) of varying thickness, with 15 cm of backscatter 
material to ensure full phantom scatter conditions. Further sheets of Solid water were added to 
take readings in the buildup region (maintaining SSD) (FIG 1a). Doses were measured with an 
NACP-02 (Scanditronix, IBA Dosimetry) parallel plate ionization chamber. The NACP chamber has a 
‘coin-shaped’ sensitive volume with a diameter of 10mm, a height of 2mm and a guard ring of 
3mm in width 
26
. In the literature a guard ring of at least 5mm is recommended for measuring skin 
doses 
18
, but both Carl 
1
 and McEwen 
23
 have investigated its use and found it to be suitable. 
The chamber was embedded in the phantom such that the entrance window of the chamber was 
flush with the surface with the central axis perpendicular to this. The doses at depth were 
measured by adding layers of phantom material while maintaining the SSD at 100cm to the top of 
the phantom (FIG 1a). The effective point of measurement itself was taken as the inside of the 
entrance window which, for the NACP-02 chamber (with a composite window of 0.1 mm Mylar 
and 0.5 mm graphite) is equivalent to 1 mm of water. Surface dose measurements therefore 
represent a measurement depth of 1mm, and all results are plotted relative to the dose measured 
at dmax (15mm 6MV, 22mm 10MV) for the same field size. 
Surface dose readings are therefore reported as relative surface dose (RSD) where: 
 
maxddRSD surface=
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Buildup curves through the carbon fiber couch we measured according to the setup shown in FIG 
1b, with the gantry rotated to 180° to deliver radiation through the couch. Couch transmission 
factors were measured using a Farmer type chamber (NE2577 Nuclear Enterprises Ltd. (now 
QADOS, UK)) set at isocentre within 10cm of WT1 (FIG 1c). Couch factors are expressed as the 
ratio of the posterior to anterior electrometer readings. 
Polarity corrections in x-ray beams are generally small, but can become significant for parallel 
plate chambers, especially in the buildup region 
27
. It is expected that the largest differences will 
occur at the surface, and that this will reduce as dmax is approached. To estimate polarity effects 
buildup curves were measured at ±200V over the buildup region, representing the full range of 
contamination conditions at 6 and 10 MV. 
 
 
  
 
 
 
 
FIG 1. Experimental setup for (a) surface dose and buildup, (b) surface dose and buildup through the couch, 
(c) couch transmission factors. 
 
 
IV. Results 
 
IV. A. Bias effects 
 
Surface doses were measured at positive and negative polarity (±200V) under representative high 
and low conditions (surface and dmax). Figure 2 shows these buildup curves for both 6 and 10MV 
FFF beams (for a 10x10cm
2
 field), and the ratio of these readings (+ve/-ve) vs. depth. 
As expected, the correction becomes larger as the measurement point moves closer to the surface 
and was found to differ by <1.3% (1.3% at 6MV, 1.1% at 10MV) and fall to unity at dmax. This was 
considered to be of small enough magnitude to disregard as the main purpose of this paper is to 
compare surface doses and evaluate trends. Readings were therefore taken at -200V only for the 
remainder of the study. 
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Page 6 of 14 
  
 
 
FIG 2. Fractional surface dose as a function of depth for +ve and –ve polarization voltages for (a) 6MV and 
(b) 10MV photons. The +ve/-ve ratio shows the increasing disequilibrium towards the surface. 
 
 
IV. B. Field size variation 
 
Surface doses are seen to increase fairly linearly with increasing field size, albeit at a shallower 
incline for FFF beams than for the conventional. At 6MV the unflattened beam shows a slight 
increase in RSD at smaller field sizes (+3.4% at 3x3cm
2
) and decrease at larger (-7.1% at 40x40cm
2
) 
with equivalency at 15x15cm
2
.  
 
  
 
 
 
FIG 3. Variation of surface dose with field size for Flattened and FFF beams for jaw settings of 3x3 to 
40x40cm
2
. (a) 6MV and (b) 10MV. 
 
At 10MV there is again far less variation in the RSD with field size for the FFF beams, but the 
conventional beam generally exhibits lower surface doses. At small field sizes the unmatched 
10MV FFF shows an increase of 10% in absolute terms over the conventional 10MV beam; in 
contrast, the largest field size the FFF beam then shows a 5% decrease. The surface doses are 
equivalent for a field size of 25x25cm
2
. 
For the 6MV beam there is a variation in RSD of 26.7% (absolute) in changing from a 3x3 to 
40x40cm
2
 field (0.353 to 0.620) compared to 16.2% (0.387 to 0.549) for the FFF equivalent. At 
10MV these values are 31.0% for 10MV (0.242 to 0.552) and 16.0% for 10MVFFF (0.344 to 0.504). 
The variation of surface dose with FS is very similar for the 6 and 10MV FFF beams showing only 
minor differences with field size (0.44%cm
-1
 FFF at 6MV and 0.43%cm
-1
 at 10MV. For conventional 
operation these gradients are 0.72%cm
-1
 at 6MV and 0.84%cm
-1
 at 10MV. 
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IV. C. Wedge 
 
The skin dose for wedged field increases as field size is increased in a similar manner to the skin 
dose for open fields. 
With the wedge in place surface doses at both 6 and 10MV are seen to be generally lower for FFF 
beams. This is true at all field sizes for 6MV (FIG 4a) and those beyond 12x12cm for 10MV (FIG 4b). 
The slope of the curves is also much shallower for the unflattened beams. This is demonstrated 
clearly in FIG 4c where wedge only data is plotted for each beam. 
 
 
 
 
FIG 4. Variation of RSD with field size for wedged beams. (a) 6MV FFF and conventional open and wedged 
beams, (b) variation at 10MV, (c) wedge only data for 6 and 10MV. 
 
 
 
FIG 5. RSD variation with wedge angle for motorized wedge, 6MV. Field size is 15x15cm
2
. 
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The gradient of these lines is 0.66%cm
-1
 vs. 0.99%cm
-1
 at 6MV and 0.65%cm
-1
 and 1.09%cm
-1
 at 
10MV, again demonstrating much less variation with field size for filter free. 
Skin doses for wedge angles of 15°, 30°, 45°, and 60° were also measured for the motorized wedge 
at 6MV only (figure 5). Since the wedge is shown to reduce RSD the greatest difference is observed 
when the field is fully wedged. 
 
 
IV. D. SSD variation 
 
At 6MV there is little difference between the FFF and conventional beams, except near the 
treatment head where the FFF beams show a reduction in surface dose of up to 5%. Increasing the 
beam energy to 10MV shows the typical reduction in surface dose. The FFF beam again shows 
reduced doses at the shortest SSD’s, but this quickly reverses with the conventional 10MV beams 
exhibiting a marked reduction in dose beyond 60cm SSD. 
RSD is very stable between 90 and 140cm SSD then shows a sharp rise for measurements closer to 
the treatment head. Again, there is a reduction seen in the variation in FFF beams than for 
conventional beams. 
SSD variations were also investigated with the wedge in place. At both 6 and 10MV a larger dose 
difference is seen between FFF wedge and open data than is seen for the conventional beams. The 
highest RSD is seen for 10MV FFF beams, and lowest for the 10MV wedge. A 10% reduction in RSD 
is seen for 10MV FFF compared to only 4% for 10MV. At 6MV these figure are 11% vs. 7%. 
 
 
 
 
FIG 6. Effect of changes in source to surface distance on surface dose for 6MV and 10MV beams for open 
and wedged beams (15x15cm
2
). 
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IV. E. Shadow tray 
 
Inevitably the insertion of an acrylic shadow tray (10mm thick acrylic [polymethyl methacrylate]) 
into the beam causes an increase in the observed surface dose. At 6MV the smallest field sizes 
exhibit very similar readings, but these rapidly diverge as field size increases with the FFF beam 
having a much shallower slope. For a 40x40cm
2
 field the difference rises to 12% for the FFF beam. 
For the 10MV beams the slope is once again much shallower for the FFF energy. There is a switch 
over from higher to lower surface doses at around 20x20cm
2
 with doses being approximately 10% 
higher for 3x3cm
2
 and 15% lower for 40x40cm
2
. 
 
 
FIG 7. Variation of RSD when passing through Perspex shadow tray for (a) 6MV and (b) 10MV. 
 
At 10MV a reduced variation with field size is again prevalent with a gradient reduction for FFF. 
The slope of FFF curves is calculated to be 0.85%cm
-1
 FFF vs. 1.33%cm
-1
 at 6MV and 0.85%cm
-1
 vs. 
1.52%cm
-1
 at 10MV. 
 
 
IV. F. Carbon fiber couch 
 
FIG 8 (a, b) show the buildup characteristics when passing through the couch. The curves for both 
6 and 10MV show very little difference between FFF and conventional beams. At 6MV there is a 
slight decease for FFF (~3%) at the surface, but nothing large enough to be of clinical significance. 
As the field size is varied from 5x5 to 40x40cm
2
 the difference is slightly exaggerated (up to 6%) 
(FIG 8 c, d). 
Couch transmission factors follow a similar pattern between FFF and conventional energies with 
the FFF beams showing a greater factor at both energies, 0.976 vs. 0.982 for 6MV and 0.982 vs. 
0.988 for 10MV. 
 
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
0 10 20 30 40
R
e
la
ti
v
e
 S
u
rf
a
ce
 D
o
se
Field Size (cm)
6MV FFF Tray
6MV FFF
6MV Tray
6MV
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
0 10 20 30 40
R
e
la
ti
v
e
 S
u
rf
a
ce
 D
o
se
Field Size (cm)
10MV FFF Tray
10MV FFF
10MV Tray
10MV
(a) (b) 
Page 10 of 14 
 
 
 
 
FIG 8. Buildup curves for (a) 6MV and (b) 10MVwith and without the treatment couch intersecting the 
beam. Relative surface dose vs. field size for (c) 6MV and (d) 10MV. Couch transmission factors vs. gantry 
angle (e, f). 
 
The variation of couch transmission factor with changing gantry angle and with field size are 
shown in figures 8e and 8f. 
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V. Discussion & Conclusions 
 
By passing through the flattening filter conventional beams exhibit a hardened beam spectrum so 
tend to contain a low amount of low-energy x-rays which will lead to lower surface doses, but high 
amounts of contamination electrons, raising surface doses. FFF beams on the other hand contain 
larger amounts of low-energy photons since these are no longer filtered out by the flattening 
filter, but lower amounts of contamination electrons, reversing the situation seen in the 
conventional filtered beam. In practice it seems that these effects almost cancel each other out so 
that the overall magnitude of surface doses from FFF beams are not too dissimilar to those seen in 
the original beams. 
The increase in surface dose with increasing field size is a well known effect and it is electron 
contamination that gives rise to most of this variation 
28
, so the overriding effect of filter removal 
is a reduction in the variation of surface doses with field size. Here, the reduction in electron 
contamination means that the FFF beams show much less variation with changes in field size 
compared to filtered beams. In general surface doses in FFF are higher for small field sizes and 
lower for larger field sizes with the cross-over at 15x15cm
2
 for 6MV and at 25x25cm
2
 for 10MV. 
Kragl 
12
 observed a similar variation in surface dose with field size for an energy-matched Elekta 
linac (42.3% at 5x5cm
2
, 56.5% at 30x30cm
2
 compared to 39.7% and 53.1% seen here). These 
readings are 2-3% higher than those seen in this study but can be explained by the use of a 6mm 
Cu plate in earlier versions of the filter plate, instead of a 2mm stainless steel as in final 
configuration. Kragl also reported data for a non energy-matched Elekta linac at 6MV reporting 
surface doses of 47.1% at 5x5cm
2
 and 61.6% at 30x30cm
2
, and increase of approx. 5% over 
operation in the energy matched linac. In the un-matched machine the average energy is reduced 
to around 5MV by filter removal so this increase in surface doses (by approx. 5%) can be explained 
by the change in beam quality. 
A similar situation is seen for the Varian TrueBeam accelerator where the beam energy is not 
adjusted and FFF doses are seen to be higher at all field sizes for both 6 and 10MV compared to 
operation with the filter in place 
10, 13
. Surface doses are strongly dependent on beam energy, so 
by altering the beam energy to match, maintaining TPR20/10 on the central axis, surface doses can 
be reduced. 
Materials in the path of the beam can both generate electrons and absorb them from further 
upstream. Since it is relatively thin and of low-Z material the tray generates more electrons than it 
stops, and these pass through to reach the patient, raising skin doses. As the field size increases 
more electrons are emitted from the shadow tray, therefore higher doses are expected for larger 
field sizes compared to open fields. 
Fontenla et al 
29
 showed an increase in the skin dose of approximately 16% when a tray was added 
into a 25x25cm
2
 field at 6 MV.  Our data shows an increase of 13% for the conventional beams and 
9.5% for the 6MV FFF. At 10MV these figures are 14.2 and 10% respectively. 
Electrons generated by the shadow tray are likely to be similar in both beams indicating that the 
initial contamination from upstream must be higher in the conventional beam. 
The wedge is of sufficient thickness to absorb all of the contamination electrons rising from the 
head of the linac 
30
, but surface doses will be influenced by electrons generated within the wedge. 
These are produced in a thin layer close to the exit surface, equivalent in thickness to the range of 
the secondary electrons. 
Regardless of beam energy the presence of the wedge is seen to reduce surface doses, by up to 
10% for larger field sizes. Compared to conventional fields the FFF beams again show a reduction 
in RSD across all field sizes with the slope of the curve being much shallower for FFF operation, 
and filter removal is seen to have a much larger effect on the 10MV FFF beam than the 10MV (10% 
at 10MV FFF compared to 4% for 10MV). Considering the blocking tray, wedged fields and open 
Page 12 of 14 
fields together the overall reduction in the slope of the curves with field size is seen to be reduced 
by 36.1% at 6MV and 44.4% at 10MV. 
Considering the variation of RSD with SSD at 6MV it seems that this remains very stable at SSD’s 
beyond 90cm. At shorter SSD’s there is a significant rise in surface dose for both beams, but to a 
greater extent for the conventional 6MV. This again indicates the presence of greater number of 
contamination electrons in the filtered beam, which are gradually absorbed by the air column as 
SSD increases. At 10MV the surface dose is generally higher for the FFF beams at all but the 
shortest SSD’s, but the variation is much reduced for FFF operation. Again an approximate 10% 
reduction in RSD is seen on filter removal at both beam energies with the wedge in place, and this 
is consistent across all SSD’s. 
Increasing the beam energy is known to reduce surface dose so even though 10MV FFF doses are 
seen to be slightly higher than for standard 10MV operation, they are still lower than those seen 
at 6MV. At 10MV differences in surface dose may be due to the lower effective energy of the 
beam compared to the standard as in this study the 10MV FFF beam has not been energy 
matched. The small variation seen between 6MV FFF and 10MV FFF over a range of conditions 
indicates that a change in beam energy to match the 10MV might have little overall effect. 
Several authors have studied the effects of carbon fiber couchtops on surface dose (e.g. Refs 31-
33). The proximity of the patient to the couch means that the skin sparing effect is almost 
completely lost and surface doses increase to 85-95% of that seen at dmax, and for FFF beams a 
similar pattern is observed. At 6MV a very slight reduction in %DD is seen for FFF operation, and at 
10MV the buildup curves are almost identical. The variation of RSD with field size is again seen to 
be reduced for FFF use being universally lower for 6MV over all field sizes, and lower at 10MV 
beyond 15x15cm
2
. 
Since the unflattened beams contain more low-energy photons than conventional beams the 
transmission factor of the couch is greater for both FFF energies (by approx. 0.5%), showing a 
similar variation with gantry angle to that observed for normal use. 
Removal of the flattening filter has been shown to have many benefits over conventionally filtered 
beams for the delivery of treatments techniques such as (but not limited to) SRT, SBRT and IMRT. 
The present study indicates that the surface doses from these beams are very similar to those 
experienced for conventional flattened beams, and are therefore unlikely to cause concern in a 
clinical setting. However, as variations in electron contamination with SSD, or from the 
introduction of wedges, trays and couches are not taken into account in most treatment planning 
systems 
28
, it is possible that the use of FFF beams may help to reduce the uncertainty of dose 
calculations in the buildup region. 
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SURFACE DOSE
CHARACTERISTICS OF 6 & 10MV 
UNFLATTENED PHOTON BEAMS
Jason Cashmore, Hall-Edwards Radiotherapy Research Group, University Hospital Birmingham, UK jason.cashmore@uhb.nhs.uk
Introduction Method
Linear accelerators operating in flattening-filter-free (FFF, or 
unflattened) modes are becoming more widely used. The 
changing beam spectrum and relative amounts of low-energy 
photon and electrons make it important to have an 
understanding of changes in surface doses in this mode, 
especially if clinical decisions are to be made. Trends in surface 
dose for 6 and 10 MV flattened and unflattened beams are 
reported for a range of clinically relevant parameters.
Skin doses arise from a combination of effects and will depend on the magnitude and relative contributions from contamination 
electrons, low-energy photons and backscatter. Contamination electrons in particular can give rise to significant doses in the skin and 
will be influenced by several factors including head design, reduced SSD, increased field size or introduction of material into the beam 
close to the patient. Skin dose can therefore vary significantly from one setup to another and can be a limiting factor in some treatments.
The flattening filter simultaneously acts as a source of contamination electrons and as a beam hardener, removing low-energy photons 
from the spectrum. Its removal could therefore affect this greatly. The use of motorised wedges and Perspex shadow trays in conjunction 
with filter removal will also change these characteristics and will depend on their relative contributions.
An Elekta Precise linac has been commissioned to run at 6MV and 
10MV with the flattening filter in or out. The 6MV beam has been
matched to the clinical beam on the central axis (TPR20/10). The 
10MV beam energy has not been adjusted. The flattening filter is
replaced by a thin metal filter to provide sufficient build-up into 
the ionisation chamber. A thin window parallel plate chamber 
(NACP-02) has been used to measure data in the buildup region 
(corrected for polarity and recombination).
Skin Doses
Results
At 6MV surface dose measurements (measured as fractional surface dose relative to Dmax [FSD]) are universally lower for unflattened 
beams (by up to 10% for fields >30cm). This is repeated in the presence of the wedge, shadow tray and treatment couch. Only small 
differences (<0.5%) are seen on varying SSD. For the 10MV beam the situation is more complicated with a cross-over in dose at mid to 
large field sizes. At this energy FSDs are generally higher (up to 10%) for the unflattened beam at smaller field sizes (<30cm open, <10cm 
wedged).
By removing the flattening filter a source of contamination electrons is swapped 
for a source of low energy photons (as these are no longer attenuated). In practice 
these two components almost balance out. At both 6 and 10MV the filter free 
beams show far less variation in surface doses than conventional beams. No 
significant effects on surface dose are expected by the introduction of flattening 
filter free delivery at 6MV.
Conclusions
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Results
Conclusions
Accurate calibration of the field defining jaws and MLCs is essential for the delivery of photon beams in radiotherapy, especially for IMRT. Standard
software packages are available to perform these calibrations using images captured by the EPID. There is an increasing use of flattening filter free
machines for IMRT delivery, and with the changes in beam profile and transmission for these beams it is essential that calibration procedures for un-
flattened beams are developed to provide an equivalent calibration.
The AutoCal calibration software provides an accurate method for calibrating both the jaws and
MLCs for a filter free Elekta Precise linac. The EPID calibration effects the MLC calibration
obtained, however as the gradients of the penumbra are much sharper than the gradients
across the beam, the effects are small. By choosing appropriate measures to find the field
edges, a single MLC calibration suitable for both flat and un-flat beams is possible.
Actual beam calibration of EPID:
Even gain calibration of EPID: Equipment:
•Elekta Precise linac.
•6MV flattened and un-flattened 
energy matched beam
•IViewGT EPID
•AutoCal software V2.0 
(Scanditronix Wellhofer)
Edge Detection:
•Local maximum uses a percentage 
of the greatest value on a profile to 
define the field edge.
•Steepest gradient uses second 
differential to determine the field 
edge.
Item Part Values (IPVs):
• 7 IPV ≈ 1mm.
Calibrate panel 
with flattened 
beam.
Use ACAL to 
perform calibration.
Switch to un-flattened linac
calibration  keeping original 
MLC calibration.
Use ACAL to 
perform 
calibration.
Calibrate panel 
with un-flattened 
beam.
Calibrate panel 
with flattened beam 
and 10 cm solid 
water at 90SSD.
Use ACAL to 
perform 
calibration.
Switch to un-flattened linac
calibration  keeping 
original MLC calibration.
Use ACAL to 
perform 
calibration.
Field sizes:
MLC minor offsets and gains:
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Field sizes agree well when using flattened and 
un-flattened beams with either even gain or actual 
beam calibrations. A worst case difference of 1.2 
mm was found for a 240mm field size. Steepest 
gradient edge detection produced the least 
differences.
Comparisons of consecutive analyses of minor 
gains and offsets using an even gain calibration 
produce consistent results with differences 
averaging about 0 IPV within errors. Calibrations 
produced by flattened and un-flattened beams are 
also consistent. Local maximum edge detection 
produces the most consistent results. 
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Introduction and methods 
 Medical accelerators utilising a flattening filter free (FFF) design can of-
fer significant advantages over those operating in a conventional 
‘flattened’ mode, such as increased dose rate.  Due to changes in the 
beam spectrum, beam profile, and levels of scatter radiation originat-
ing from the treatment head, dose rates and cumulative doses meas-
ured inside and outside of the treatment vault will be altered.  Previous 
studies [1] have indicated that FFF IMRT significantly reduces  whole-
body doses to patients.  In addition, FFF IMRT is expected to allow for 
reductions in shielding requirements or in occupational exposures. 
   
 Measurements in 40x40cm open field 
 An Elekta Precise linear accelerator has been modified to operate in 
conventional and unflattened modes (6MV mode matched in terms 
of depth dose and quality index; in 10MV operation, the unflat-
tened beam is unmodified, and thus has a lower average energy 
than the clinical beam).  Instantaneous dose rates were measured 
outside a linac bunker at 6MV and 10MV for flattened and unflat-
tened beams, using a standard compensated GM tube.  Field sizes 
from 40x40cm to 2x2cm were used; only the 40x40cm fields deliv-
ered a measurable dose rate.   FFF dose rates were normalised to 
the clinical dose rate for the same MV to make the results directly 
comparable. 
 
Measurements using a  6MV IMRT plan 
Cumulative doses were measured for delivery of a 6MV head and neck 
IMRT plan (67.2Gy equivalent) at several points inside and outside the 
bunker using calibrated Harshaw lithium fluoride TLD-100s.  For both 
plans, all fractions were delivered consecutively with a 20cm thick solid 
water phantom positioned in the beam to simulate clinical attenuation 
conditions.  
 
Instantaneous dose rates and cumulative doses 
 
Conclusions and discussion 
All measurable external dose rates for large fields were found to be lower 
in the unflattened case; in particular unflattened dose rates at both MV 
settings in the control area were half the flattened values. 
 
Cumulative dose measurements using TLDs were lower for FFF operation 
at the edges of the treatment vault and in the maze for equivalent head-
and-neck IMRT plans; this is despite the FFF plan requiring 33% more 
monitor units to deliver than the conventional IMRT plan. 
For beams of similar dose rate FFF beams produce both lower instanta-
neous and cumulative dose rates, leading to potential savings in shield-
ing requirements or occupational exposure. 
  
However, if the higher dose rates achievable with FFF beams were to 
be used clinically, instantaneous dose rates would increase, which 
might reduce the savings predicted here. 
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Additional measurements 
In addition to the results presented above, the normalised instantaneous dose rates on the vault roof directly above 
isocentre, with the linac at a gantry angle of 180º, were measured at 6MV to be 150µ Svh-1  (flattened) and 124µ Svh-1 
(unflattened), and at 10MV to be 300µ Svh-1  (flattened) and 113µ Svh-1 (unflattened). Dose rates were also measured 
at the outside wall closest to the machine isocentre, and in an adjacent storage room; dose rates measured in these 
locations were found to be indistinguishable from background. 
 
Cumulative doses were also measured at the gate, the edge of the controlled area, in an adjacent store room, on the 
roof directly above the isocentre, and on an outside wall; these doses were found to be similar to background levels. 
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[1] Lowering Whole-Body Radiation Doses in Pediatric Intensity-Modulated Radiotherapy Through the Use of Unflattened Photon Beams, Jason Cashmore, Mark Ramtohul and Dan 
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Methods 
Field sizes (FWHM) are unaffected for the Unflattened (UF) beams, but exhibit a sharper 
beam penumbra (80-20%) with a reduction of up to 0.5mm and lower dose outside of the 
field (graph below right).  
Results 
Conclusions 
References 
Stereotactic radiosurgery (SRS) treatments are defined by single fraction, high dose treatments with sharp dose fall-off. The flattening filter 
serves no useful purpose for these small fields and its removal simultaneously reduces leakage radiation and increases dose rate. Benefits 
to the patient may include tighter beam penumbra and lower out-of-field doses. 
Small field dosimetry data has been measured for an Elekta Precise linear accelerator 
adapted to run at 6MV either with or without the flattening filter fitted. Six BrainLab conical 
collimators (10, 12.5, 15, 17.5, 20 and 22.5mm diameter) have been commissioned in both 
modes and data entered into the BrainScan (v 5.31) SRS treatment planning system. 
Printed by 
Method 
Treatment Plans 
Plans have been produced for 3 intracranial cases. 
Each case was planned with conventional beams 
then recalculated with the unflattened beam model. 
The plan opposite (Acoustic neuroma, chart, right) 
required 2 isocentres to cover the PTV, one using 4 
arcs and a 20mm collimator, the second 3 arcs with a 
10mm collimator, each arc covering  100 degrees. 
The dose to the lesion, brainstem and normal brain 
have been assessed. 
The dose volume histogram to the lesion remains 
unchanged, however tissue sparing was seen for  
brainstem and normal brain. The most significant 
differences were observed for the low isodoses. For a 
prescribed dose of 12Gy, the V10 for normal brain 
and brainstem were reduced by nearly 60% and 10% 
respectively by using the unflattened beam model. 
(table, below). 
    V10 (cc) V20 (cc) V50 (cc) V100 (cc) 
Normal  Unflattened beam 249.3 61.9 11.7 2.9 
tissue With Flattening Filter 396.6 80.5 12.6 3.0 
(3005.6cc) % Reduction using UF -59.1 -30.1 -7.7 -3.8 
Lesion Unflattened beam 2.4 2.4 2.4 2.4 
(2.42cc) With Flattening Filter 2.4 2.4 2.4 2.4 
% Reduction using UF 0.0 0.0 0.0 0.0 
Brainstem Unflattened beam 12.5 7.5 1.7 0.2 
(14.31cc) With Flattening Filter 13.6 8.7 1.8 0.2 
% Reduction using UF -8.7 -15.7 -8.5 0.0 
Conclusions 
Removal of the flattening filter removes an unnecessary source of scattered 
radiation from the linac head. Identical lesion coverage can be achieved but 
with greater critical and normal tissue sparing. At large (50 cm) distances from 
the treatment field, leakage doses are reduced by up to 50%. Whist this will 
reduce the extracranial dose to a patient, we have shown intracranial dose 
sparing can also be achieved. It is therefore recommended that stereotactic 
radiosurgery without the flattening filter in place should be developed clinically. 
This work has been partially funded by Elekta UK ltd. 
Comparison of Unflattened (UF) and Flattening Filter (FF) profiles 
using 6 conical stereotactic collimators (10-22.5mm diameters)
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Results 
Profiles and depth doses were measured with a CC01 chamber in a BluePhantom2 watertank (iBA dosimetry) at 92.5cm SSD. Clinical 
SRS plans for a number of intracranial patients have been re-calculated using the unflattened beam, and compared to plans achievable 
with the flattening filter in place. 
Doses measured at 25mm from the central axis were lower for the unflattened beam than for the flattened beam for all the collimators 
(graph above left), due to the reduction in the linac head leakage observed when the flattening filter is removed. This reduction in the 
dose outside the central axis provides normal tissue sparing. The effect of normal tissue sparing is magnified for stereotactic radiosurgery 
over conventional radiotherapy due to the fact that the stereotactic plan involves multiple small field arced (typically 100 degree) beams, 
each with a high number of monitor units. 
Comparison of dose between unflattened and flattened 
beams through an axial slice of an acoustic neuroma
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Dose intensity as a function of distance from central axis from a 20mm 
stereotactic conical colliamtor with and without a flattening filter using EBT1 
gafchromic film
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